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Abstract 
The focus of this research is to determine the magnitude and moderators of placebo 
and nocebo effects on sport performance and to explore the impact of a placebo intervention 
on athletes’ beliefs and intentions towards sport supplements. Recent research suggests that 
supplement users may be more likely to use banned substances (i.e. doping) and that beliefs 
and intentions towards supplements may influence future supplement use. As such, this 
research also explores the effects of a placebo intervention on athletes’ attitudes to doping. 
Study 1 focuses on the development and validation of the Sports Supplements Beliefs Scale. 
This measure is used to assess athletes’ beliefs about sport supplements and the impact of the 
placebo intervention conducted in Study 2 on these beliefs. Study 2 uses a placebo 
intervention to examine the magnitude and moderators of the placebo and nocebo effect on 
repeat sprint performance, and Study 3 examines the impact of this intervention on 
participants’ beliefs and intentions to use sport supplements and attitudes to doping. In Study 
2, no significant mean placebo effect on sport performance was evident, however, a 
significant mean nocebo effect compared to no-treatment controls was observed. Further 
analyses indicated that participants’ intentions to use sport supplements influenced the 
direction and magnitude of the placebo effect. Study 3 showed that participants’ beliefs and 
intentions towards sport supplements and attitudes to doping changed after the intervention. 
Although it appeared to reduce the likelihood of athletes using sport supplements and banned 
substances overall, participants that were not intending to use sport supplements before the 
intervention were more likely to use them after. In conclusion, data from this research suggest 
that an athlete’s intention to use sport supplements moderates the direction and magnitude of 
placebo effects on sport performance and that a placebo intervention significantly influences 
athletes’ beliefs and intentions towards sport supplements and attitudes to doping. These 
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results have important implications for how international and national anti-doping 
organisations develop their anti-doping education interventions. Interventions aimed at 
educating athletes about the placebo effect and targeting their use of sport supplements, may 
prevent future doping behaviours.  
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INTRODUCTION  
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1.1 Introduction to the research programme 
Historically, the placebo effect has been regarded as a nuisance and methodological 
artefact that should be controlled using the placebo control trial. However, recent studies in 
clinical medicine, neuroscience and psychology suggest that this effect is a biological 
response to psychosocial cues surrounding the administration of a treatment (Benedetti, 2013; 
Hall, Loscalzo and Kaptchuk, 2015). Studies have shown that the placebo effect can mimic 
effects associated with actual drugs (Benedetti, 2013, 2014; Benedetti & Dogue, 2015; 
Kessner et al., 2014; Weimer, Colloca, & Enck, 2015). Research has also shown that these 
effects are not always positive in direction. Negative responses are often referred to as 
nocebo effects, which can offset some or all of the benefits of a treatment. 
An extensive body of evidence now suggests that placebo and nocebo effects can 
significantly influence sports performance (Beedie & Foad, 2009; Broatch, Petersen, & 
Bishop, 2014; de la Vega, Alberti, Ruiz-Barquin, Soos, & Szabo, 2017; Ross, Gray, & Gill, 
2015; Saunders et al., 2017). This research has presented interesting data relating to the 
direction and magnitude of placebo and nocebo effects, with implications for both research 
and practice. However, investigations into placebo effects on sports performance often lack a 
no-treatment control, which make it difficult to accurately estimate the relative magnitude. 
Similarly, the sample size in the majority of placebo effect studies in sport is too small to 
facilitate identification of variables that moderate this effect. If knowledge of placebo and 
nocebo effects is to develop, an understanding of the relevant moderators and mechanisms is 
needed through larger sample sizes and robust methodologies that include a no-treatment 
control.  
Data from sports science suggest that athletes using sport supplements may be more 
likely to progress to banned substances (i.e. doping; Backhouse, Whitaker, & Petroczi, 2013; 
Barkoukis, Lazuras, Lucidi, & Tsorbatzoudis, 2015; Hildebrandt, Harty, & Langenbucher, 
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2012; Ntoumanis, Ng, Barkoukis, & Backhouse, 2014; Petróczi, 2013), a phenomena often 
termed the gateway hypothesis (Kandel, 1975). Researchers have suggested that anti-doping 
organisations could inform athletes about the placebo effect and in doing so, support them to 
make more informed choices about the use of sport supplements and banned substances 
(Beedie & Foad, 2009; Kalasountas, Reed, & Fitzpatrick, 2007; Maganaris, Collins, & Sharp, 
2000; McClung & Collins, 2007). Maganarais et al. (2007) reported anecdotal evidence in 
which athletes were less inclined to use banned substances after experiencing a placebo 
effect. Similarly, data from Beedie (2007) suggest that if athletes are informed about the 
placebo effect, they might realise that a proportion of the benefit of banned substances comes 
from their belief in it and as a result may be less likely to use banned substances. 
Hypothetically, therefore, if it is demonstrated to athletes that placebo effects can affect their 
performance to a similar degree to a sport supplement, it is reasonable to suggest that athletes 
with this experience and/or knowledge may be less likely to use sport supplements in the 
future. While this link has been made by several authors anecdotally (Kalasountas et al., 
2007; Maganaris et al., 2000; McClung & Collins, 2007), the idea remains untested.  
In light of this context, the aim of this research programme is to extend the current 
body of knowledge in placebo effect research using a large sample to investigate the 
magnitude and moderators of placebo and nocebo effects in sports performance. In addition, 
this research aims to assess the effect of a placebo intervention on athletes’ beliefs and 
intentions towards sport supplements and attitudes to doping.  
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1.2 Definition of key terms 
Despite an extensive body of placebo effect literature, the term ‘placebo effect’ often 
causes considerable confusion among researchers. For example, by searching placebo in the 
online resource PubMed, approximately 200,000 papers can be found, the word placebo 
frequently associated with the term response or effect (Benedetti, 2008). Many of these 
papers use the term placebo effect inappropriately, suggesting that it is, for example, an 
“outcome that is found in a group of participants who receive a placebo.” It is also common 
to discover titles of studies such as “High rate of placebo effects in clinical trials on…” or 
“Analysis of the placebo effect in clinical trials on…” These papers do not analyse the 
placebo effect per se, but the time course of symptoms in placebo control groups, which 
could be due to factors unrelated to the placebo effect such as regression to the mean, natural 
history of the condition or spontaneous improvements in symptoms. Further, and given that 
this research aims to distinguish what moderates the placebo effect of sport supplements, 
definitions surrounding sport supplements are often inaccurate and researchers often confuse 
moderation with mediation. For these reasons, and to add clarity to the terminology used 
throughout this research, sport supplements, moderation and mediation are defined. 
Placebo 
Historically, placebos are often used as a control treatment that is indistinguishable 
from the experimental treatment, but without the essential component. From a medical 
perspective, the term placebo is referred to as an inert substance devoid of any specific 
properties (Colloca & Miller, 2011b; Kirsch, Wampold, & Kelley, 2016). However, placebos 
are not all equal. Placebos can be, for example, a sugar pill, saline injection or fake surgery. 
A placebo must match the experimental treatment in terms of its name, description, 
appearance and mode of administration. A placebo is therefore identical to an active 
treatment but differs only with respect to the essential component.  
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The placebo effect  
In its broadest sense, the placebo effect is an improvement in a person’s symptoms 
following the administration of a placebo, which cannot be attributed to the properties of the 
placebo itself (Arnold, Finniss, & Kerridge, 2014). However, the placebo effect is a 
misnomer because in some cases there is no need to use a placebo to induce a placebo effect. 
Placebo effects can be induced after administration of an actual treatment and can be induced 
by factors that include the treatment context, expectations on behalf of the person receiving 
the treatment and the person administering it, previous experiences and symbols (Carlino, 
Piedimonte, & Benedetti, 2016). Thus, researchers examining the placebo effect are studying 
the psychosocial context surrounding the person and the effect that this context has on the 
persons experience, brain and body (Price, Finniss, & Benedetti, 2008).  
The nocebo effect 
The nocebo effect is a negative response following the administration of a placebo. It 
is essentially the opposite of the placebo effect and relates to the negative aspects of the 
psychosocial environment (Benedetti, Carlino, & Piedimonte, 2016). 
Sport supplements 
Although there have been many attempts, there is no universal definition of what 
constitutes a sport supplement (Maughan et al., 2018). Where definitions are attempted, they 
are largely unhelpful and confusing. The Oxford English Dictionary (2017) defines a 
supplement as “something added to supply a deficiency.” However, this definition is 
inconsistent with the use of such products, with many supplements including nutrients and 
food chemicals for which the body does not have an estimated or theoretical requirement 
(Castell, Stear, & Burke, 2015). The US congress defines dietary supplements as a “product, 
other than tobacco, which is used in conjunction with a healthy diet” (Maughan, Depiesse, & 
Geyer, 2007, p. 104). Based on this definition, a product is a sport supplement if it is 
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consumed by an athlete who has a “healthy diet,” whereas that same product is not a sport 
supplement if it is consumed by an athlete who has an “unhealthy diet.” The Dietary 
Supplement Health and Education Act of 1994 provides a more comprehensive definition of 
non-banned substances. However, this document includes 13 separate sections and is over 
4,000 words. In terms of practical application, the Australian Institute of Sport (AIS) define 
sport supplements as products comprising one or more of the following categories: 
- Sports foods: Specialised products used to provide a practical source of nutrients 
when it is impractical to consume everyday foods (e.g. beetroot juice, sport drinks and 
sport gels) 
- Medical supplements: Used to treat clinical issues, including diagnosed nutrient 
deficiencies (e.g. calcium, iron and vitamin D) 
- Performance supplements: Used to directly contribute to optimal performance (e.g. 
caffeine, sodium bicarbonate, and creatine) 
In line with the AIS definition, the term sport supplement is presented throughout this 
research programme as relating to sport foods, medical supplements and performance 
supplements.  
Moderation 
A moderator affects the direction and/or strength of the relationship between an 
independent variable and dependent variable (Baron & Kenny, 1986). Therefore, moderation 
implies that relationships of interest differ significantly in two or more subpopulations. 
Specifically, in a correlational analysis, moderation affects the zero-order correlation between 
two other variables. In placebo effect research, Holroyd, Labus, and Carlson (2009) reported 
that anxiety moderated the relationship between a placebo pill and chronic headaches. That 
is, participants who reported low scores of anxiety, were more likely to report a reduction in 
headache pain following the administration of a placebo pill than those who reported high 
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scores of anxiety. Moderation is also reported when the direction of the correlation changes 
(Hayes, 2009). Such an effect would have occurred in the Holroyd et al. study if those with 
higher anxiety levels reported an increase in headaches following the administration of the 
placebo pill.  
Mediation  
Similar to moderation, mediation involves detecting an interaction between an 
independent and dependent variable. However, while moderation affects the direction and/or 
strength of the relationship between two variables, mediation explains the relationship 
between the two. Thus, researchers examining mediation are interested in determining under 
which conditions an independent variable can be considered a possible cause of the 
dependent variable (MacKinnon, Fairchild, & Fritz, 2007). For example, Benedetti, Amanzio, 
Rosato, and Blanchard (2011) reported that placebo analgesia was reversed following the 
administration of the cannabinoid receptor antagonist rimonabant. This indicates that placebo 
analgesia is mediated by the release of endogenous cannabinoids.  
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Chapter Two  
 
REVIEW OF THE LITERATURE  
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 This research programme examines the magnitude and moderators of the placebo and 
nocebo effect in repeat sprint performance. It also examines the impact of a placebo 
intervention on an athlete’s beliefs and intentions towards sport supplements and attitudes to 
doping. The first part of this review aims to familiarise the reader with literature around the 
placebo effect, the associated psychological and neuropsychological mechanisms, and 
empirical studies that have addressed this phenomenon in sport. The second part of the 
review aims to provide an overview of doping in sport. The literature concerning the history 
of doping is briefly addressed, the policy and methods in place to prevent doping in sport are 
explained, and the psychosocial predictors of current and future doping behaviours are 
reviewed.  
2.1.1 Introduction to the placebo effect 
While use of the term placebo dates back to biblical periods (Psalm 114:9), use of the 
term placebo effect gained significant scientific interest and attention since Beecher’s (1955) 
seminal paper which reported that around one third of people respond to a placebo. Beecher’s 
paper marked a new era for placebo effect research, whereby new concepts and ideas were 
put forward. Although his methods and conclusions have been heavily criticised 
(Hróbjartsson & Gøtzsche, 2001; Kienle & Kiene, 1997), Beecher’s paper paved the way for 
researchers investigating the placebo effect across a range of medical conditions (e.g. blood 
pressure, depression, Parkinson’s disease; Benedetti, 2016), ultimately leading to a 
neurobiological understanding of the phenomenon twenty years later (Levine, Gordon, & 
Fields, 1978).  
As far back as the 18th century, researchers have acknowledged that placebo effects 
(although not explicitly labelled as such) can have significant effects on a range of 
conditions. In 1784, Louis XVI instructed Benjamin Franklin to perform a series of 
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experiments to see if the psychic force of mesmerism had “any real force” or whether it was 
the result of “imagination” (Lopez, 1993, p. 329). After World War II, placebos were widely 
adopted as concurrent controls in randomised control trials. From these trials, scientific 
interest into the placebo effect emerged out of the observation that patients in the placebo 
control would often demonstrate significant improvement (Finniss, Kaptchuk, Miller, & 
Benedetti, 2010). Shortly after, Beecher’s seminal 1955 paper “The Powerful Placebo” 
suggested that 35% of participants respond positively to a placebo. Two decades after this 
publication, Levine et al. (1978) provided the first mechanistic explanation of the placebo 
effect, reporting that it could be blocked by naloxone (i.e. an opioid antagonist), thus 
implicating a role for the endogenous opioid system.  
Psychological theories posit that learning and classical conditioning play key roles in 
the formation of placebo effects (Benedetti et al., 2003; Montgomery & Kirsch, 1997; 
Voudouris, Peck, & Coleman, 1990), alongside a variety of cognitive and psychosocial 
variables (e.g. expectations, beliefs and desires; Amanzio et al., 2001; Kirsch, 1985; Kirsch & 
Weixel, 1988). Various neurobiological mechanisms of the placebo effect have been 
reported, most notably the endogenous opioids (Levine et al., 1978; Zubieta et al., 2005) and 
neurotransmitter pathways (e.g. dopamine; de la Fuente-Fernández et al., 2001; Fulda & 
Wetter, 2007).  
 While placebo effects are generally reported to be beneficial for the recipient, they can 
also be harmful. Negative effects of a placebo treatment are usually labelled nocebo effects 
and are essentially the opposite of placebo effects. They were first observed in clinical trials 
whereby participants in the placebo control reported similar side effects to those of the actual 
drug (Mitsikostas, Mantonakis, & Chalarakis, 2011). In fact, participants assigned to the 
placebo control may discontinue because of the adverse side effects attributed to the 
treatment (Enck et al., 2013; Rief, Bingel, Schedlowski, & Enck, 2011). Beecher (1955) was 
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one of the first to report that placebos can lead to side effects such as headaches, fatigue and 
nausea (i.e. nocebo effects). More recently, investigations have reported that just one 
occasion of a nocebo effect can induce long-lasting effects that influence the efficacy of a 
future treatment (Colloca & Miller, 2011a). For these reasons it has been suggested that if a 
placebo treatment were submitted to the Food and Drug Agency for approval, although the 
agency might be impressed with its efficacy, it would probably be rejected based on the high 
incidence of side effects (Glasser & Frishman, 2008).  
With increasing advancements in scientific methodology (e.g. balanced placebo 
design; Rohsenow & Marlatt, 1981) and technology (e.g. positron emission technology), 
researchers now have the tools to identify several of the psychological (e.g. expectations) and 
neurobiological (e.g. dopamine) mechanisms of placebo effects. This research has enabled 
the identification of not one but many placebo effects operating across different pathways and 
receptors of the brain and driven by different psychological and neurobiological mechanisms 
depending on the context in which a placebo is administered (Price et al., 2008). However, 
while knowledge and understanding of placebo effects have progressed significantly in the 
last 15 years, further research is required to foster a better understanding of its mechanisms 
and the ability to control and capitalise on these in clinical and applied practice. 
2.1.2 Psychological mechanisms 
Theoretical and experimental research over the past 30 years has centred upon two 
psychological mechanisms of the placebo effect phenomenon: expectancy and classical 
conditioning. Expectancy theory is underpinned by a person’s belief that an effect will occur 
(Shaibani, Frisaldi, & Benedetti, 2017). Expectations can be generated by verbal 
instructions/suggestions (Michael, Garry, & Kirsch, 2012), environmental cues (Christiansen, 
Townsend, Knibb, & Field, 2017), emotional arousal (Zhang, Guo, Zhang, & Luo, 2013), 
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previous experiences (Reicherts, Gerdes, Pauli, & Wieser, 2013) and interaction with others 
(Benedetti, Durando, & Vighetti, 2014). Positive expectations about a treatment can result in 
positive feelings that increase reward mechanisms in the brain (e.g. dopamine) and negative 
expectations about a treatment can create negative feelings that increase threat related areas 
of the brain (e.g. Cholecystokinin; Benedetti, 2013). In short, when a person expects a 
particular outcome, a chain of cognitions is set in motion that can influence psychological 
and neurobiological pathways.  
Classical conditioning theory posits that a conditioned stimulus (e.g. placebo pill) 
elicits a conditioned response (e.g. placebo effect) by virtue of its previous coupling with an 
unconditioned stimulus (e.g. the drug purported to be inside the pill). When an active 
treatment (e.g. anti-depressants, caffeine, paracetamol) is administered repeatedly and 
replaced with a placebo, similar neurobiological drug effects can occur (Meissner, Kohls, & 
Colloca, 2011). For example, repeat coupling of a placebo capsule with caffeine can lead to a 
conditioned response (e.g. increase in heart rate), whereby the placebo on its own can create a 
response that is similar to caffeine. The placebo is thus the conditioned stimulus and the 
placebo effect is the conditioned response (Stewart-Williams & Podd, 2004). This is often 
framed as a learning phenomenon, where previous experiences of a treatment can lead to 
placebo responses. 
Expectancy and classical conditioning are often pitted against one another as the main 
theory to explain the placebo effect (e.g. Colloca & Miller, 2011b; Kirsch et al., 2014; 
Montgomery & Kirsch, 1997; Price et al., 1999). While authors have noted that the focus on 
only two mechanisms is limiting (Geers & Miller, 2014), placebo experiments often share a 
basic framework in which variations of these two psychological mechanisms are manipulated 
and many of the findings reported in the placebo effect literature can be explained by both 
expectations and conditioning. Take for example the finding that placebo injections are more 
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effective than placebo capsules (Kaptchuk, Goldman, Stone, & Stason, 2000). Depending on 
the stance of the researcher, these findings can be interpreted differently. Within the classical 
conditioning framework, the researcher may argue that injections often contain a more potent 
dose than capsules, so the placebo effects elicited are based on prior learning and experience. 
However, an expectancy theorist may suggest that people expect injections to have stronger 
effects than capsules, and that it is this expectation that produces the enhanced effect.  
An alternative suggestion is that classical conditioning results in the formation of a 
generalised expectation. In fact, it is worth noting that some authors argue that classical 
conditioning is an expectation of the occurrence or non-occurrence of an unconditioned 
stimulus (Benedetti et al., 2003; Kirsch, 2004). For example, expectations created by verbal 
information, social observation and learning, are hypothesised to mediate conditioning and 
ultimately the placebo effect (Kirsch et al., 2014). Studies have shown that expectations 
induced by verbal suggestions can reverse the placebo effect of pharmacological 
preconditioning (Benedetti et al., 2003; Carlino & Benedetti, 2016) suggesting that placebo 
effects might be induced by expectations and not conditioning. However, further evidence 
has shown that expectations about hormonal increases and decreases after the administration 
of a placebo had no effect on growth hormone plasma concentrations, whereas 
preconditioning mimicked the effect of a hormonal drug in the absence of expectations 
(Benedetti et al., 2003). Thus, expectations did not influence hormonal levels, but 
conditioning did. This suggests that learning and previous experiences can contribute to the 
placebo effect even in the absence of conscious awareness. While placebo effects are often 
the result of beliefs and expectations, these beliefs and expectations are complex and only 
partially dependent on conscious cognitive processes.  
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2.1.3 Neurobiological mechanisms 
In a landmark study, Levine et al. (1978) demonstrated that the placebo effect could 
be reversed by administration of the opiate antagonist naloxone. Amanzio and Benedetti 
(1999) reported that this paper marked the date that “the neurobiology of placebo was born” 
(p. 484). Since this publication, an extensive body of research has shown how expectations 
and conditioning mediate specific mechanisms of the placebo effect. In fact, this research has 
shown that there is not just one mechanism of the placebo effect but several operating across 
different neurobiological pathways. While many mechanisms are posited, a significant 
number of studies have investigated the mediating role of the endogenous opioid and 
dopaminergic pathways. 
Since Levine and colleagues’ (1978) study, research investigating placebo analgesia 
(i.e. the placebo effect of pain) has been corroborated by functional magnetic resonance 
imaging (fMRI) and positron emission tomography (PET) technology. Using ischemic arm 
pain as the main outcome measure, a series of experiments between 1999 and 2003 identified 
the role of the endogenous opioid system as a mediator of placebo analgesia. In one study, 
participants exposed to a conditioning procedure of the opioid drug buprenorphine, reported 
placebo analgesia when the drug was surreptitiously replaced with saline. However, when 
replaced with naloxone, placebo analgesia was reversed, highlighting the mediating role of 
the endogenous opioid system (Amanzio & Benedetti, 1999). In a follow up study, Benedetti 
et al. (2003) provided further evidence that placebo analgesia could be induced via 
preconditioning, but could also be reversed by the nocebo effect. After a conditioning 
procedure similar to Amanzio and Benedetti (1999), participants were administered a placebo 
but informed that it was a hyperalgesic agent (i.e. would increase pain). Authors reported that 
verbal instructions blocked placebo analgesia and induced hyperalgesia (i.e. an increase in 
pain). These findings demonstrate that nocebo effects can act on the endogenous opioid 
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system through negative expectations and block placebo analgesia induced via 
preconditioning procedures. 
Mechanisms of placebo analgesia are also suggested to be mediated by cannabinoid 
receptors. Amanzio and Benedetti (1999) demonstrated that placebo analgesia is mediated by 
expectations and conditioning, with the latter activating the opioid system and the former 
activating cannabinoid receptors. These authors reported that naloxone blocked placebo 
analgesia induced by means of expectations of morphine, whereas placebo analgesia induced 
by means of prior conditioning with the cannabinoid receptor agonist ketorolac, was 
insensitive to naloxone. Similarly, the cannabinoid receptor antagonist rimonabant had no 
effect on opioid-induced placebo analgesia of morphine, but completely reversed placebo 
analgesia following nonopioid conditioning of ketorolac (Benedetti et al., 2011). Further, 
specific placebo analgesic responses can be obtained on different parts of the body, and can 
be further reversed by naloxone (Benedetti, Arduino, & Amanzio, 1999). Benedetti et al. 
(1999) reported that after applying a harmful cream to participants’ hands and feet and 
applying a placebo cream on one hand, placebo analgesia was only reported on the hand 
receiving the placebo cream. This effect was further blocked by naloxone, suggesting that the 
placebo activated opioid systems can involve highly specific areas of the central nervous 
system. The results of these studies, and elsewhere (Lee et al., 2015; Petrovic, Kalso, 
Petersson, & Ingvar, 2002; Price et al., 1999; Rütgen et al., 2015), suggest that placebo 
analgesia can be mediated by both opioid and cannabinoid receptors that often depend on 
participants’ previous exposure to pharmacological drugs (Benedetti, 2013).  
Several dopaminergic pathways have also shown to be influenced via expectancy and 
conditioning procedures. Using PET imaging, de la Fuente-Fernández et al. (2001) 
demonstrated that administration of a placebo, described as an active drug, increased 
dopamine in the striatum for Parkinson disease patients who expected the drug to be 
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effective. The increase in dopamine concentration corresponded to a change of 200%, which 
is comparable to the response of amphetamines in people with an intact dopamine system 
(Benedetti, 2014). In a further study with Parkinson disease patients (Pollo et al., 2002), 
electrodes were implanted to the basal ganglia (an area of the brain highly modulated by 
dopamine) and patients were administered deep brain stimulation. Hand movement was 
monitored via a movement analyser and each patient was tested twice on different days under 
two different treatments. In the first treatment, patients were informed that the stimulation 
would impair motor performance, whereas in the second they were informed that it would 
improve motor performance. However, unbeknown to patients, the stimulation was identical 
for each treatment. Authors reported that patients’ hand movement was faster when they 
expected good hand movement and slower when they expected impaired movement. Scott et 
al. (2008) also demonstrated that while placebo effects increased activation of dopamine 
neurotransmitters, nocebo effects significantly decreased it. These findings demonstrate the 
significant influence placebo and nocebo effects can have on motor performance and the 
dopaminergic system. 
 Neurobiological mechanisms of placebo effects are evident in pain (Amanzio & 
Benedetti, 1999; Petrovic et al., 2002), Parkinson’s disease (de la Fuente-Fernández et al., 
2001; Jarcho et al., 2016), immune diseases (Albring et al., 2014; Vits et al., 2011), anxiety 
(Furmark et al., 2008) and depression (Kong et al., 2006; Kong et al., 2009). These responses 
are often induced by prior conditioning of a treatment and/or the expectation of treatment 
outcome. Placebo effects often share similar neurobiological pathways to those activated by 
pharmacologically active treatments. Expectations of analgesia for example, can activate the 
same receptors and pathways, and elicit similar biological effects as those produced by verum 
treatments (Benedetti, 2013). Furthermore, Amanzio et al. (2001) have shown that even when 
a verum treatment is administered, the placebo effect component of that treatment can have a 
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significant influence on its outcome. Authors demonstrated that administering a drug (i.e. 
tramadol, buprenorphine and ketorolac) openly to the participant is far more effective than 
when participants are unaware of its administration (closed administration). These data 
suggest that the expectation of drug administration is a crucial component of its effectiveness. 
2.1.4 Responders and non-responders  
As noted in previous sections, the administration of a placebo treatment can influence 
a wide variety of conditions. Nevertheless, the proportion of people responding to a placebo 
treatment varies considerably from study to study. Administration of a placebo treatment will 
not always elicit a placebo effect, and identifying those who respond (i.e. placebo responders) 
and those who do not (i.e. placebo non-responders) has been a focus of placebo effect 
research for over 60 years.  
Historically, authors have identified placebo responders through self-report 
instruments. For example, Knowles and Lucas (1960) reported that participants identified as 
extroverted on the Maudsley Personality Inventory (Eysenck, 1959) were significantly more 
likely to report placebo analgesia (r = .89, p < .01). More recently, Geers, Wellman, Fowler, 
Helfer, and France (2010) reported that participants identified as optimistic on the Life 
Orientation Test-Revised psychometric scale (Scheier, Carver, & Bridges, 1994) were more 
likely to report placebo analgesia than pessimists (p = .007). De Pascalis, Chiaradia, and 
Carotenuto (2002) suggested that participants with high scores on the sensory suggestibility 
scale (Gheorghiu & Reyher, 1982) were more likely to report placebo analgesia than those 
scoring lower on the scale (p = .039). 
Personality traits have also been shown to influence activity in the brain after 
administration of a placebo. In a review of mechanisms associated with placebo analgesia, 
Medoff and Colloca (2015) reported that ego-resiliency, altruism, straightforwardness and 
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low angry hostility predicted 25% of placebo analgesia and 27% of endogenous opioid 
system activation. Additionally, Huber, Lui, and Porro (2013) reported that for participants 
with high suggestibility, placebo analgesia was associated with increased activity of the 
dorsolateral prefrontal cortex. These results suggest that certain personality traits may be 
linked with placebo analgesia and the ability to release endogenous opioids after 
administration of a placebo. 
Researchers have also suggested that certain genetic traits moderate responses to a 
placebo. Participants with catechol-O-methyltransferase (COMT) polymorphism Met/Met 
alleles have been shown to demonstrate larger placebo analgesic effects than those with 
Val/Val and Val/Met alleles (Hall et al., 2012), whereas those with the Val/Val alleles are 
associated with higher frequency of nocebo effects (Wendt et al., 2014). Similarly, Pecina, 
Stohler, and Zubieta (2014) reported that gene variants in the fatty acid amide hydrolase 
predicted placebo analgesia and regulated the release of endogenous cannabinoids. While it is 
unlikely that a single genetic trait will predict who will respond to a placebo treatment, a 
small body of data provide evidence that certain genetic traits may moderate a person’s 
response to a placebo. 
 Placebo effects are also suggested to be triggered by situational determinants generated 
from outside (e.g. context in which the treatment is administered) or inside the person (e.g. 
mood of the participant). Accumulated evidence suggests placebo effects are often created 
within a psychosocial context that influences a person’s response to a placebo. These include 
the interaction between the person receiving the treatment and the person administering it 
(e.g. patient and doctor), the environment in which the treatment is delivered (e.g. laboratory) 
and the sensory processes involved (e.g. colours, shapes, tastes and smells). For instance, 
coloured pills have shown to be more effective than white pills (de Craen, Tijssen, de Gans, 
& Kleijnen, 2000), injections are reported to be more effective than capsules (Moerman & 
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Jonas, 2002) and branded drugs are suggested to be more effective than generics (Kam-
Hansen et al., 2014). In the context of medical practice, placebo effects are more likely to be 
induced if the doctor administers the treatment with empathy, attention and confidence 
(Kaptchuk, Kelley, Conboy, et al., 2008). These findings emphasise the importance of 
context in the generation of placebo effects and suggest that even when a legitimate treatment 
is administered, its effectiveness can be mediated and moderated within the context in which 
it is delivered. 
 To illustrate the previous point, Amanzio et al. (2001) examined the effect of four 
widely used painkilling drugs (buprenorphine, tramadol, ketorolac and metamizol) and their 
effectiveness on the analgesic dose needed to obtain a 50% pain reduction in open and hidden 
administration settings. The open setting consisted of a doctor administering the drug in full 
view of the patient coupled with the information that it was a powerful analgesic. The hidden 
setting consisted of an automatic infusion machine delivering an injection of the same drug 
unknowingly to the patient. Authors reported that the analgesic dose needed to reduce pain by 
50% was much higher in hidden settings compared to open settings (Figure 2.1). Similar 
results have been shown in Parkinson’s disease symptoms, where brain stimulation is shown 
to be more effective when participants are aware they are receiving the treatment than when 
they are not (Pollo et al., 2002). These studies highlight that the overall effectiveness of a 
treatment is heavily influenced via the psychosocial context in which it is delivered. If a 
placebo treatment is administered and the psychosocial context is absent, it is less likely that 
a placebo effect will be induced.  
Given the available evidence, placebo effects appear to be manifest in an interaction 
between individual traits and the social context in which the placebo is delivered. Individual 
characteristics (e.g. learning, personality and genotype), the type of placebo treatment (e.g. 
pills, capsules and injections) and the verbal instructions used (e.g. “the treatment is a potent  
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Figure 2.1. Hidden vs. open administration of treatments. Note. Differences in the 
analgesic dose needed to obtain a pain reduction of 50% between open and hidden 
settings (Amanzio, Pollo, Maggi, & Benedetti, 2001). 
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analgesic”) are just some of the mediators and moderators of the placebo effect. In light of 
this understanding, it is emphasised that people will respond differently to treatments 
administered in different situations. A participant does not arrive to a study as a “blank slate” 
but with a history of experiences and memories that are evoked by signals related to the 
idiosyncrasies of the treatment and the environment. In other words, a treatment is not 
administered in a vacuum, but rather in a complex set of psychological states that varies from 
person to person and from situation to situation (Benedetti, 2013). Arguably, therefore, 
almost every aspect of the administration of a treatment, placebo or verum, moderates the 
placebo components of that treatment. While there may not be a single setting that everyone 
will respond to or in, this does suggest that under the correct circumstances, everybody has 
the potential to be a placebo responder. In this model, the placebo responder is ubiquitous and 
activated by an interaction of individual traits and the situational determinants in which a 
placebo is administered. 
2.1.5 No-treatment controls in placebo effect research 
While there is extensive evidence to suggest that placebo effects are influenced by 
individual and situational variables, there are a number of methodological problems 
associated with a large proportion of these studies. Aside from basic problems such as self-
report instruments with poor validity and reliability and a lack of randomisation of 
participants to treatments (Geers, Helfer, Kosbab, Weiland, & Landry, 2005), mechanisms 
associated with the placebo effect are often observed in studies that are not designed to 
investigate individual differences in responses to a placebo. Instead, they are often designed 
to investigate a medical treatment within a randomised controlled trial. During this trial, the 
placebo treatment is often relegated to a passive baseline against which to control the 
effectiveness of the active treatment. Rarely do researchers include a no-treatment control to 
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compare both the placebo and the verum treatment (Benedetti, 2013). If researchers use this 
type of design, any attempt to analyse the mechanisms influencing the response to the 
placebo treatment is limited. 
 To highlight this point, take for example a randomised controlled trial investigating the 
efficacy of a drug for chronic lower back pain. Participants with chronic lower back pain are 
sampled and randomised to either drug or placebo. Results demonstrate that both the drug 
and placebo significantly improved lower back pain after one hour of administration. From 
these results, it could be inferred that the placebo improved lower back pain and is indicative 
of a placebo effect. However, without a no-treatment control, we are unable to truly assess if 
changes in lower back pain are due to the psychosocial context in which the treatment was 
administered or the natural course of the condition. Symptoms may fluctuate on a daily, even 
hourly basis and what may be identified as a placebo effect may be fluctuation of symptoms. 
Likewise, if the participants sampled report extremely high pain scores at the onset of the 
study, any follow up trial would tend to show lower scores. In this instance, changes in 
symptoms are often interpreted as placebo effects, but are instead the result of a statistical 
phenomenon referred to as regression to the mean. Furthermore, participants in a study may 
change aspects of their lifestyle over the course of a trial (e.g. diet, sleep and exercise) that 
can go unnoticed and affect the outcome of treatment. For these reasons, without a no-
treatment control in study design, natural history, fluctuation of symptoms, regression to the 
mean and lifestyle changes cannot be discounted. For future research investigating the 
placebo effect and its mechanisms, researchers must include a no-treatment control, or 
control for potential confounders, to ensure changes observed in the placebo treatment are in 
fact due to the psychosocial environment surrounding the administration of treatment and not 
non-specific factors associated with methodological and/or statistical artefacts. 
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2.1.6 The placebo effect: control or capitalise? 
Researchers often aim to control for the placebo effect using the randomised 
controlled trial. Participants in these trials are often administered a placebo that is, in theory, 
indistinguishable from the treatment under examination. The ultimate aim of these trials is to 
measure the magnitude of the placebo effect in order to make an accurate estimation of the 
“true” effect of a treatment and hence prevent overestimation of the treatment by accounting 
for the contribution of placebo effects or non-specific effects that may occur during 
administration (Garcia, 2015). However, in applied practice it is reasonable to suggest that 
the placebo effect is something that could be capitalised on and enhanced. Once a treatment 
has shown efficacy in randomised controlled trials, the ultimate aim is to maximise a person’s 
response to the treatment. It is therefore important for researchers to understand that 
controlling for the placebo effect in randomised controlled trials can optimise placebo-
treatment differences and that capitalising on it in applied practice can augment the benefits 
of a treatment. 
 Randomised controlled trials are recognised as the gold standard for assessing the 
efficacy of a treatment (Kaptchuk, Kelley, Conboy, et al., 2008) and are intended to prevent 
overestimation of a treatment under examination due to other effects that can occur during 
administration (e.g. placebo effects; Enck et al., 2013). Many variants of the randomised 
controlled trial have developed since its inception. For example, researchers have used 
treatment-naive participants to control for expectations (la Fuente‐Fernández, 2012), replaced 
inert placebos with active placebos to mimic the side effects of a treatment (Jensen, 
Bielefeldt, & Hróbjartsson, 2017), and extended trial duration to decrease the occurrence of 
placebo effects (Potkin et al., 2011). One of the most controversial variations of the 
randomised controlled trial is the placebo run-in trial, where researchers identify and exclude 
placebo responders at an early stage in the trial (e.g. Lavalle-González et al., 2013). Although 
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some evidence suggests this does not prevent the occurrence of placebo effects in the latter 
stages of a trial (Quigley et al., 2013), it is generally accepted that placebo run-in trials are 
more effective at controlling for the placebo effect and optimising placebo-treatment 
differences than standard randomised controlled trials (Enck et al., 2013).  
While researchers attempt to control for the placebo effect in randomised controlled 
trials, a basic assumption during these trials is that placebo effects shown in the placebo arm 
are identical to placebo effects shown in the treatment arm (Colloca, Klinger, Flor, & Bingel, 
2013; Kirsch, 2013; Meissner, Bingel, et al., 2011). However, recent studies have shown that 
this may not be true under all conditions (Lund, Vase, Petersen, Jensen, & Finnerup, 2014; 
Muthén & Brown, 2009) and that placebo effects may fluctuate between participants and 
contexts (Benedetti, 2013). A consideration for future research is therefore to explore whether 
placebo effects are additive or interactive during the administration of a verum treatment 
(Figure 2.2). If the latter is correct, then caution should be applied by researchers using the 
standard randomised controlled trial to estimate the difference between placebo and treatment 
effects  
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Figure 2.2. Additive vs. interactive effects of treatments. Note. A: Additive model, 
which assumes placebo effects are equal in the placebo and treatment groups. B: 
Interactive model, which assumes that treatment effects may interact with placebo 
effects (adapted from; Enck, Bingel, Schedlowski, & Rief, 2013). 
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On the other hand, if the placebo effect interacts positively with the pharmacological 
effects of a treatment, applied practitioners could theoretically be able to augment the 
pharmacological effects of a treatment by manipulating a person’s belief about that treatment 
(Foad, Beedie, & Coleman, 2008). It is reasonable to suggest that the ultimate aim of an 
applied practitioner should be to enhance the pharmacological effect of a treatment 
irrespective of whether the effects are attributed to the treatment, the placebo, or a 
combination of both (Figure 2.2; Enck et al., 2013). For practitioners to capitalise on the 
placebo effect of a treatment, expectations prior to its administration should be monitored to 
ensure that the person receiving the treatment expects that it will benefit them. If the person 
does not expect the treatment to be beneficial, then they may not fully benefit from it. 
Research has shown that patients’ expectations about the severity of illness significantly 
influence recovery from a surgical treatment (Barefoot et al., 2011) and that expectations 
about the effectiveness of an analgesic influence how well it works (Ružić, Ivanec, & Stanke, 
2017). Thus, the words a practitioner uses and the information provided to the participants 
can significantly affect the outcome of treatment. Influencing a participant’s expectations by 
the careful use of words and provision of appropriate information about the expected effects 
of the treatment are important characteristics of administration (Enck et al., 2013).  
To address whether researchers or practitioners should control or capitalise on the 
placebo effect is, however, difficult. Placebo research is still in an embryonic stage and 
although research in disciplines such as medicine, neuroscience and psychology has shed 
light on potential mechanisms, a major challenge still exists in both controlling, and 
capitalising on the placebo effect. Current evidence suggests that we can “tap into” certain 
mechanisms when a certain set of trait and situational variables are met, but we are still far 
from fully predicting and controlling these mechanisms and associated responses. Future 
research is therefore needed to provide greater understanding of the placebo effect and its 
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underlying mechanisms. Doing so has the potential to not only enhance our understanding of 
the placebo effect, but also to improve how researchers and applied practitioners can control 
and capitalise it. 
2.1.7 Placebo effects on sports performance 
In recent years, numerous studies have examined the placebo effect in sport and 
exercise science. While placebo effects have been shown to influence sports performance for 
a variety of ergogenic aids (e.g. ice baths, respiratory training devices and shoes), the aim of 
this review is to focus on sport supplements and banned performance enhancing substances. 
Empirical evidence has demonstrated that placebo effects can influence performance by on 
average 6.5% (range = -7.8% to 22.1%; see Table 2.1), with qualitative data suggesting that 
effects may be associated with pain sensation, arousal regulation (Beedie, Stuart, Coleman, & 
Foad, 2006) and increases in motivation (Ross et al., 2015). Others have suggested that 
personality traits, specifically extroversion, agreeableness, openness and neuroticism, may 
also influence the response to a placebo (Beedie, Foad, & Coleman, 2008). While research 
continues to explore this phenomenon, the extant literature suggests that placebo effects can 
have a significant impact on sports performance. 
The first published study to investigate the placebo effect in sport was by Ariel and 
Saville (1972). After baseline strength testing for bench press, military press, sitting press and 
squat, six sub-elite weightlifters were deceptively administered placebo pills described as 
Dianabol (i.e. an anabolic steroid). Participants received the pills each day for four weeks, 
before strength data were collected once more. Participants improved by 9.6, 8.5, 6.2 and 
13.8% for bench press, military press, sitting press and squat, respectively. The authors 
concluded that the strength improvements shown were the result of participants believing 
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Tale 2.1 
 
Research studies investigating placebo effects on sports performance 
 
# Author Year n  Sample characteristics Design Performance Measure 
Treatment % Change Informed Received 
1 Ariel and Saville 1972 6 Sub-elite 
weightlifters 
Within-
participants 
design 
Strength (bench press, 
military press, seated 
press, squat) 
Anabolic steroids Placebo 9.5 
2 Maganaris et al. 2000 11 Sub-elite 
weightlifters 
Between-
participants 
design 
Strength (Bench press, 
dead life, squat) 
Anabolic steroids Placebo 3.8 
Anabolic steroid then 
placebo 
Placebo 1.7 
3 Clark, Hopkins, 
Hawley, and 
Burke 
2000 42 Sub-elite endurance 
cyclists 
Between 
participants 
Latin square 
design 
Endurance (40 km 
cycling power) 
Carbohydrate Placebo (50% of 
participants) Carbohydrate 
(50% of participants) 
1.7 
Placebo Placebo (50% of 
participants) Carbohydrate 
(50% of participants) 
4.3 
50/50 chance of 
receiving carbohydrate 
Placebo (50% of 
participants) Carbohydrate 
(50% of participants) 
-1.1 
Overall placebo effect 3.8 
4 Beedie et al.  2006 6 Sub-elite cyclists Within-
participants 
design 
Endurance (10 km 
cycling power) 
0 mg·kg-1 caffeine Placebo -1.4 
4.5 mg·kg-1 caffeine Placebo 1.3 
9.0 mg·kg-1 caffeine Placebo 3.1 
Continued on next page 
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Table 2.1 cont. 
# Author Year n Sample characteristics Design Performance Measure 
Treatment % Change Informed  Received 
5 McClung and 
Collins 
2007 16 Sub-elite 
endurance athletes 
Within-
participants 
Balanced placebo 
design 
Endurance (1000 m 
running time) 
Sodium bicarbonate Sodium 
Bicarbonate 
1.7 
Sodium bicarbonate Placebo 1.5 
No treatment Sodium 
bicarbonate 
-0.3 
6 Beedie et al.  2007 42 Sub-elite athletes Between-
participants design 
Anaerobic (30 m 
running speed) 
Positive supplement Placebo 0.0 
Negative supplement Placebo -1.6 
7 Kalasountas et al. 2007 42 Untrained students Between-
participants design 
Strength (Bench press, 
seated leg press) 
Amino acids Placebo 19.6 
Amino acids then placebo Placebo 6.3 
8 Pollo, Carlino, & 
Benedetti  
2008 44 Sub-elite athletes Mixed design Strength (leg 
extension) 
Caffeine Placebo 11.8 
Caffeine (after conditioning 
procedure) 
Placebo 22.1 
Perceived fatigue Caffeine Placebo -0.3 
Caffeine (after conditioning 
procedure) 
Placebo -7.8 
9 Foad et al.  2008 14 Sub-elite cyclists Within-
participants 
Balanced placebo 
design 
Endurance (40km 
cycling power) 
Caffeine Caffeine 2.3 
Caffeine Placebo 0.1 
No treatment Caffeine 2.9 
No treatment No treatment -1.9 
Continued on next page 
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Table 2.1 cont. 
# Author Year n  Sample characteristics Design Performance Measure 
Treatment % Change 
Informed  Received 
10 Duncan, Lyons, 
and Hawkey  
2009 12 Untrained athletes Within-participants 
design 
Total weight lifted (Leg 
extension) 
Caffeine Placebo 19.0 
Placebo Placebo 12.0 
11 Hulston and 
Jeukendrup 
2009 10 Sub-elite athletes Within-participants 
design 
Endurance (60 minute cycling 
power) 
Carbohydrate  Placebo 0.4 
12 Wright et al. 2009 32 Sub-elite runners Within-participants 
design 
Endurance (5 km running time) superoxygenated 
water 
Placebo 6.5 
13 Wright et al. 2009 18 Untrained students Within-participants 
design 
Anaerobic (Wingate power) Alpha-
hydroxydreatine 
Placebo 0.6 
14 Wright et al. 2009 10 Cardiovascular 
disease patients 
Within-participants 
design 
Endurance (6 minute walk 
distance) 
Pellegrino Spa 
Water 
Placebo 1.4 
15 Duncan  2010 14 University athletes Within-participants 
design 
Anaerobic (Wingate power 
output) 
Caffeine Placebo 9.7 
Placebo Placebo 7.1 
16 Bottoms, 
Buscombe, and 
Nicholettos 
2014 12 Untrained athletes Within-participants 
design 
Endurance (incremental arm 
crank peak power) 
Positive 
supplement  
Placebo 5.4 
Negative 
supplement 
Placebo -0.8 
Continued on next page 
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Table 2.1 cont. 
# Author Year n  Sample characteristics Design Performance measure Treatment % Change Informed  Received 
17 Carlino, 
Piedimonte, 
and Frisaldi  
2014 110 Untrained students Between-participants 
design 
Endurance (Work performed KJ) Caffeine (100% chance) Placebo 11.4 
Caffeine (50% chance) Placebo 13.7 
Caffeine (25% chance) Placebo 9.7 
Caffeine (0% chance) Placebo 6.3 
Caffeine (100% chance 
after conditioning 
procedure) 
Placebo 22.0 
Caffeine (50% chance 
after conditioning 
procedure) 
Placebo 19.5 
Caffeine (25% chance 
after conditioning 
procedure) 
Placebo 21.3 
Caffeine (0% chance 
after conditioning 
procedure) 
Placebo 12.6 
18 Bellinger 
and 
Minahan 
2015 8 Sub-elite athletes Within-participants 
Balanced placebo 
design 
Anaerobic (1 km cycling power) β-alanine β-alanine 2.4 
β-alanine Placebo 0.6 
Placebo β-alanine 1.8 
No treatment No treatment -1.0 
Continued on next page 
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Table 2.1 cont. 
# Author Year n Sample characteristics Design Performance Measure 
Treatment % Change 
Informed Received 
19 Tolusso, Laurent, 
Fullenkamp, and 
Tobar  
2015 10 Untrained athletes Within participants 
design 
Anaerobic (Running sprint 
power) 
New sport supplement Placebo 6.7 
20 Ross et al. 2015 15 Sub-elite athletes Between-participants 
design 
Endurance (3 km running time) OxyRBX Placebo 1.5 
21 Tallis, 
Muhammad, Islam, 
and Duncan  
2016 14 Untrained athletes Within-participants 
Balanced placebo 
design 
Strength (leg extension) Caffeine Caffeine 15.8 
Caffeine Placebo 9.8 
Placebo Caffeine 12.8 
22 Saunders et al.  2017 42 Sub-elite athletes Within-subject design Endurance (25 min time-trial) 50/50 chance of 
receiving caffeine  
Placebo 1.5 
23 de la Vega, 
Alberti, Ruiz-
Barquin, Soos, and 
Szabo  
2017 60 Sub-elite athletes Between-participants 
design 
Anaerobic (200 m running 
speed) 
100% change of 
supplement 
Placebo 5.9 
50% chance of 
supplement 
Placebo 2.2 
Placebo Placebo 1.9 
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they were ingesting an anabolic steroid. These results were the first to suggest that the 
placebo effect can significantly improve sports performance among sub-elite athletes. 
 Maganaris et al. (2000) investigated the deceptive administration of a placebo tablet on 
weightlifting performance. One week after baseline testing for bench press, deadlift and 
squat, eleven elite weightlifters were administered a tablet and informed they had received a 
potent anabolic steroid. Participants performed experimental trials and showed improvements 
of 3.5, 4.2 and 5.2%, for bench press, deadlift and squat, respectively. One week later, 
participants received a further tablet but this time, six participants were informed that the 
tablets were in fact a placebo while the other five were given no new information. Compared 
to the first experimental trial, performance was maintained for those who believed they had 
received anabolic steroids (3.2, 4.0 and 4.4%, respectively). However, the performance of 
participants informed they were receiving a placebo reduced significantly (1.7, -0.4 and 
0.4%, respectively). Maganaris et al. concluded that the expectation of receiving a potent 
anabolic steroid significantly improved participants’ performance. Authors also highlighted 
that almost all participants would have achieved international level status as a result of the 
intervention. The results of both Ariel and Saville and Maganaris et al. suggest that certain 
drugs expected to improve performance may in part be influenced by the placebo effect.  
While the results of Ariel and Saville (1972) and Maganaris et al. (2000) provide 
evidence of the magnitude of placebo effects in sports performance, they do little to elucidate 
the potential psychological mechanisms underpinning the phenomenon. Beedie et al. (2006) 
used quantitative and qualitative methods to explore the possibility of a dose-response 
relationship to placebos and the mechanisms underpinning changes in performance. Six sub-
elite cyclists performed two baseline and three experimental 10 km time-trials. In 
experimental trials, participants were administered placebo capsules and informed that they 
would receive a placebo, 4.5 mg·kg-1 caffeine and 9.0 mg·kg-1 caffeine randomly assigned. 
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Compared to baseline, performance in experimental trials showed a dose-response 
relationship, with participants producing -1.4% less power when they believed they had 
received a placebo, 1.3% more power when they believed they had received 4.5 mg·kg-1 
caffeine and 3.1% more power when they believed they had received 9.0 mg·kg-1 caffeine. 
To further explore these changes in performance, semi-structured interviews were conducted 
after the intervention. Participants reported heightened arousal, pain reduction and a change 
in pacing strategy when they believed they had ingested caffeine. One participant however, 
believed that caffeine would have a negative effect on his performance and reported that he 
“felt terrible” during the caffeine trials (i.e. a nocebo effect). The results of this study 
suggested a dose-response relationship between expectation and effect. 
Having observed a potential nocebo effect (Beedie et al., 2006), Beedie et al. (2007) 
designed a study to investigate the impact of positive and negative expectations on sports 
performance. After baseline 3 x 30 m repeat sprints, 42 sub-elite team-sport athletes were 
randomised to one of two treatments. In the first treatment, participants were given a red and 
white capsule and informed that it would have a positive effect on speed and endurance, 
whereas in the second treatment, participants were given the same capsules and informed that 
it would have a positive effect on endurance but a negative effect on speed. Participants 
performed the experimental condition in an identical manner to baseline 20 minutes later. 
Authors reported that speed decreased significantly during baseline for both treatments. 
However, during the experimental condition, while speed continued to decrease in the 
negative treatment, speed in the positive treatment increased. No differences in speed were 
shown between baseline and the positive treatment (p = .96), demonstrating that expectation 
of receipt of a beneficial supplement offset fatigue and facilitated performance (Figure 2.3). 
However, the expectation of receiving a negative supplement appears to have impaired 
performance and influenced the ability to maintain speed over consecutive sprints. Results 
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demonstrate that negative expectation could offset the effectiveness and potential benefits of 
an intervention. Although it is unlikely that an athlete would ever knowingly ingest a 
supplement they expect was harmful to their performance, the results suggest that if athletes 
do not expect that the treatment is beneficial, they may not fully realise the benefits of that 
treatment. 
In a further study, Foad et al. (2008) investigated the placebo effect of caffeine on 
sport performance using the balanced placebo design (Rohsenow & Marlatt, 1981). Fourteen 
sub-elite cyclists performed 14 x 40 km time-trials consisting of eight experimental trials 
interspersed with six baseline trials. Experimental trials consisted of: 1) informed 
caffeine/given caffeine; 2) informed caffeine/given placebo; 3) informed placebo/given 
caffeine; 4) informed placebo/given placebo. Caffeine was found to improve performance 
compared to baseline whether participants expected to receive it or not (informed 
caffeine/given caffeine = 2.9 ± 3.4%; informed placebo/given caffeine = 2.3 ± 3.3%). In   
Figure 2.3. Results from Beedie, Coleman and Foad (2007). Mean times for trials 1-6 
expressed as percentages of Trial 1. Note: a denotes significant difference from Trial 1 (p < 
.05), and b denotes significant difference from Trials 3 and 4 in the positive belief trials (p 
< .05).  
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contrast to previous research, no mean placebo effect was observed compared to baseline 
when participants were informed caffeine/given placebo (0.1 ± 3.2%). In summarising the 
findings of their study, the authors suggested that placebo effects may operate differently 
depending on whether a verum treatment is present. Arguably, when participants receive a 
verum treatment (e.g. caffeine), they are consciously or unconsciously responding to the 
subtle cues of its presence (e.g. heightened arousal, increase in heart rate or increase in 
alertness). Thus, in a study when no active treatment is administered, no comparison of the 
presence or cues of that substance can be made and researchers cannot be confident that the 
participant’s expectation about the treatment is the significant factor in performance 
improvement.  
Other studies exploring the impact of placebo effects on sports performance include 
McClung and Collins (2007), who reported that expectation of receipt of sodium bicarbonate 
improved performance to the same magnitude as actually receiving sodium bicarbonate, and 
Ross et al. (2015), who reported that participants self-injecting saline water believed to be a 
new performance enhancing substance significantly improved their time to run 3000 m. 
Collectively, 23 published investigations in sport and exercise science have shown that the 
belief that a treatment has been received can influence performance by on average 6.5% 
(Table 2.1). However, the idea that placebo effects are reliable and predictable is questioned 
by the results of Foad et al. (2008). The placebo effect is a complex psychosocial 
phenomenon consisting of an interaction between cognition, previous experiences and the 
context in which the treatment is administered. Accordingly, people will respond differently 
to different placebo interventions. Understanding and determining potential moderators is 
required to help explain why some people respond to a placebo intervention and others do 
not. Furthermore, while the body of research suggests that receiving a placebo is beneficial to 
performance, a handful of researchers (e.g. Beedie et al., 2007; Bottoms, Buscombe, & 
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Nicholettos, 2014) suggest that the performance outcome may not always be positive. Pre-
existing beliefs and/or experiences about a treatment can offset some, or all of the therapeutic 
benefits of that treatment. Further research is required to understand the nocebo effect on 
sports performance and the implications this could have in the effectiveness of a treatment.  
2.1.8 Limitations of placebo effect studies in sport 
The available research suggests that placebo effects can have a significant impact on 
sports performance. However, the sample size is small in almost all studies investigating the 
placebo effect of performance enhancing substances. In studies conducted between 1972 and 
2013, samples sizes ranged from 6 to 44, with only 319 participants sampled in total. While 
these studies may be sufficiently powered to reject a false null hypothesis, the sample sizes 
are too small to facilitate the reliable identification of variables that may moderate the 
placebo effect. The variance of the performance measure in most studies is often greater in 
experimental trials than baseline, suggesting that even if a placebo effect is observed, there is 
considerable inter-individual variability in the response to placebo.  
Placebo effect studies often fail to demonstrate unequivocally that observed changes 
in performance are placebo effects, and not the result of methodological and/or statistical 
artefacts. For example, Beedie et al. (2007) reported both placebo and nocebo effects during 
repeat sprint performance, but did not include a no-treatment control alongside experimental 
treatments. What was labelled a placebo or nocebo effect could have been regression to the 
mean and/or spontaneous changes in performance. The studies by McClung and Collins 
(2007) and Foad et al. (2008) for example, used participant’s own baseline as a no-treatment 
comparison. Without a separate no-treatment control, observed placebo effects could be 
attributed to methodological artefacts such as carry-over effects and/or behavioural 
conditioning (Horing, Weimer, Muth, & Enck, 2014). In fact, 19 of the 23 studies (83%) 
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outlined in Table 2.1 do not include a no-treatment control in study design. Without a natural 
history control treatment, authors cannot be confident that simple measurement repetition 
would result in the same changes in performance. In light of the above, research investigating 
placebo effects should include a large enough sample size to facilitate the reliable 
identification of the mechanisms of the placebo effect. In addition, the inclusion of a natural 
history control treatment ensures that observed changes in performance are the result of 
placebo effects and not the result of methodological artefacts.  
2.1.9 Translating placebo effect research into applied practice 
In laboratory studies, the aim of the research is usually to explore the biological basis 
of the placebo effect. However, it is also important to develop knowledge that can support 
applied practice. To achieve this, translational placebo effect research emphasising the real 
world impact of the placebo effect on sports performance is required.  
Over the last 40 years, empirical research into the placebo effect in sport and exercise 
has remained relatively static, with focus placed on examining the existence of the placebo 
effect in controlled environments. Seldom have authors attempted to translate the knowledge 
gained from placebo effect research into applied settings. This is important, as translating the 
results from empirical research can enhance best practices in the community (Rubio et al., 
2010). For example, in vitro and in vivo empirical biomedicine research develops knowledge 
that helps improve the diagnosis, treatment and prevention of human diseases (Barbieri et al., 
2015) and data from controlled experimental trials of physical activity help to shape national 
and international policy guidelines (Estabrooks, 2017). In light of this, researchers in sport 
and exercise science should aim to translate knowledge gained from empirical placebo effect 
research into applied practice.  
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Translating placebo effect research into applied practice is, however, fraught with 
ethical dilemmas. Typically, placebo effect research involves deception, with a placebo 
presented as a potent performance enhancing substance. While this type of research can, for 
example, generate knowledge about the impact of beliefs on performance, applying this in 
practice is arguably unethical (Beedie, Foad, & Hurst, 2015; Beedie et al., 2017). The 
benevolent and paternalistic use of a deceptive treatment is arguably contrary to the respect of 
individual autonomy. Pre-existing beliefs or experiences of a treatment may also result in 
nocebo effects that could eliminate or negate the therapeutic benefits. Therefore any attempts 
to translate placebo effect research should be done in accordance with professional norms and 
ethical principles (Beedie et al., 2017).  
With this in mind, using a deceptive placebo treatment in isolation in applied practice 
is perhaps unethical. However, research has suggested that a significant proportion of the 
efficacy of a performance enhancing substance may be due to the placebo effect. This 
suggests that athletes using sport supplements may not benefit entirely from the 
pharmacological properties of that substance, but from their beliefs (e.g. it will be effective 
for improving performance). Athletes that are aware of this, and that their beliefs about the 
effectiveness of a substance could make as much difference to their performance as the actual 
pharmacological properties, may be less likely to use these substances in the future. 
Anecdotal evidence by Maganaris et al. (2000) suggests that participants were less likely to 
use anabolic steroids once they were informed about the placebo effect. McClung and Collins 
(2007) also highlighted the importance of educating athletes about the placebo effect as an 
educational intervention and suggested that athletes aware of this phenomenon could make 
more informed decisions about their use of sport supplements. Other researchers have made 
this explicit link (Kalasountas et al., 2007) but this suggestion remains untested. It is 
reasonable to conclude that translating the findings of placebo effect research into applied 
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practice and emphasising the significant impact the placebo phenomenon may have on sports 
performance could help athletes make more informed decisions about their use of sport 
supplements and banned performance enhancing substances. This has the potential to reduce 
the potential health risks of athletes using performance enhancing substances. 
2.1.10 Summary of placebo effect research in sport  
Since Ariel and Saville’s (1972) study, a plethora of researchers have presented data 
relating to the magnitude of the placebo effect on sports performance. Despite 
methodological limitations (e.g. sample size and no-treatment controls), there is evidence that 
the placebo effect has a significant influence on sports performance. Although not everyone 
will respond to a placebo under the same conditions, numerous questions arise as to how 
sport practitioners and researchers capitalise and control for this response in sport and 
exercise scenarios. This is even more important when considering that an athlete’s pre-
existing beliefs and experiences of a treatment may be negative. Only a handful of authors 
(Beedie et al., 2007; Bottoms et al., 2014) have investigated the nocebo effect on sports 
performance, and further research addressing the magnitude and moderators of this effect is 
required. In addition, a lack of translational placebo effect research is evident, with authors 
seldom utilising knowledge gained from placebo effect research in applied settings. While 
careful consideration of ethical guidelines is of paramount importance, applying and utilising 
the placebo effect could act as a vehicle to educate athletes and provide them with the 
information to make better more informed decisions regarding supplement and banned 
substance use. Extant evidence suggests that a significant proportion of the efficacy of a 
substance could be the result of the participant’s beliefs and expectations about it. However, 
data supporting this is anecdotal. A hypothesis therefore remains untested that aims to 
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determine how awareness of placebo effects influences an athlete’s decision to use sport 
supplements and banned performance enhancing substances. 
2.2 Anti-Doping Literature Review  
The second aim of this literature review is to describe and explain the anti-doping 
literature. The origins of doping are reviewed in order to establish the context in which anti-
doping policy was shaped. While it is not the purpose of this research programme to examine 
the structures in place aimed at preventing doping, it is impossible to discuss the use of sport 
supplements and performance enhancement in sport without doping policy being a significant 
feature. Debates about whether doping should be banned or not are outside the scope of this 
research, the focus of which is the athletes’ use of sport supplements and doping substances. 
The social science literature is mostly referred to, which consists of the psychosocial 
variables associated with doping behaviours.  
 It has been suggested that researcher bias can influence interpretation of the literature 
and methodological design (Finlay & Gough, 2008). In the anti-doping literature this is no 
different. For these reasons, some authors have suggested that the researcher acknowledges 
their position on doping to provide the context by which implicit biases may have shaped the 
research design and outcomes (Mazanov, 2016). In this research programme, the researcher 
holds the position that values preventative approaches as opposed to post-hoc detection and 
sanctioning, one that provides athletes with education, information, strategies and tools that 
inform and support their decisions. The aim of this research is to understand the impact of a 
placebo intervention on an athlete’s beliefs and intentions towards sport supplements and 
their attitudes to banned substances. 
Anti-doping policy is necessary to both protect the integrity of sports, which are 
defined by their rules, and even more importantly, to ensure the health and wellbeing of 
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athletes. Yet, while anti-doping policy is essential, it can be draconian, unfair and ineffective 
(Dimeo, 2016). Anti-doping policy was created in the early 20th century within a context of 
distorted and inaccurate information (about both the drugs it was trying to control and the 
user; Coomber, 2014; Dimeo, 2016; Henne, 2015). Linked to immorality and to prejudice, 
anti-doping policy was shaped to “protect” the values of sport (Dimeo, 2008), which 
included, for example, ethics, health and courage. Dimeo (2016) argues that anti-doping 
policy emerged with the vision to separate the virtuous “self” from the “dirty” other. The 
implication arising from this is the judgement about the moral status of an athlete. In the 
media, for example, athletes are often stigmatised and ostracised for doping and are often 
judged as “clean” or “dirty.” To label athletes this way can invoke stereotyping and prejudice, 
equivalent to “good vs. evil” or “hero vs. villain.” For example, in response to Usain Bolt 
winning the Olympic 100 metres against Justin Gatlin (who has failed two drug tests), the 
Guardian newspaper printed the headline “Usain Bolt stars in old-fashioned battle between 
‘good and evil’ at Rio 2016” (i.e. Bolt being “good” and Gatlin “evil”; The Guardian, 2016). 
Such language may be common within the media, but within academia, such prejudice can 
distract the reader from potentially important messages underpinning the researcher’s aims. 
Mazanov (2016) argued that using such language could invoke a sense of racism that 
suggests athletes described as dirty need to be rehabilitated and modified and are not as 
valuable as those labelled clean. Although researchers using such words may simply be 
reflecting the language of the layperson, labelling and judging athletes this way only serves to 
reinforce prejudice. For this reason, moralistic language, such as labelling athletes as clean or 
dirty, is avoided throughout this research. 
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2.2.1 Introduction to doping in sport 
The use of substances to improve performance has permeated sport since the 
beginning of competition. Athletes in the ancient Olympics (776 – 394 AD) ate raw animal 
testicles to improve performance, hearts to increase bravery and brains to enhance 
intelligence (Willick, Miller, & Eichner, 2016; Yesalis & Bahrke, 2002). In the late 1800’s, 
swimmers and runners combined alcohol, strychnine, heroin and cocaine to improve 
performance and cyclists drank coffee spiked with cocaine and strychnine during races. 
Likewise, ultramarathon runners experimented with dosages of morphine, brandy and 
strychnine during events lasting six days (Hoberman, 2001; Yesalis & Bahrke, 2002). The 
first death associated with substance use in sport was attributed to the English cyclist, Arthur 
Linton, who reportedly overdosed on trimethyl during the Bordeaux-Paris race in 1886 
(López, 2014). While the actual cause of his death is debated (Dimeo, 2008), the apparent use 
of substances at this time represents the significant health risks athletes exposed themselves 
to.  
Prior to the inter-war period, substance use in sport was arguably viewed as standard 
practice (Hoberman, 2001; Waddington, 2001). However, in the late 1920’s debates on 
“natural athleticism” and what could be perceived as “normal” in sport ensued (de Hon, 
2016). Such debates led to the term “doping,” which was first described as an artificial means 
to improve performance (Yesalis & Bahrke, 2002). In 1928 the International Association of 
Athletics Federations (IAAF) made an official statement banning doping substances in 
competition (Gleaves & Hunt, 2016). After the amphetamine-related death of Dutch cyclist 
Knut Jenson in 1960, the Medical Commission of the IOC voted to adopt a policy banning 
doping in sport. In doing so, the IOC published a list of prohibited substances and methods 
outlining what athletes cannot use in competition, while enforcing punishments for those 
found violating these prohibitions (de Hon, 2016). This early anti-doping policy aimed to: 1) 
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uphold and preserve the ethics of sport; 2) safeguard the physical health and mental integrity 
of athletes; and 3) ensure that all competitors have an equal chance of winning (Dvorak, 
Saugy, & Pitsiladis, 2014). To achieve these aims and discourage doping, the IOC introduced 
drug testing and sanctioning at the 1966 FIFA World Cup and 1968 Olympic Games.  
Up until the latter part of the twentieth century, sporting organisations independently 
conducted their own drug tests and sanctioning (Houlihan, 2002). After the 1998 “Festina 
scandal” in which the Festina cycling team were found to have an organised and systematic 
doping regime, stakeholders in sport met at the first World Conference on Doping in Sport 
and agreed on the creation of a separate, independent agency to head efforts in this field. This 
agency is called the World Anti-Doping Agency (WADA; Henne, Koh, & McDermott, 
2013). Today, WADA standardises anti-doping policies across all Olympic sports, which 
include universally applicable sanctions, a list of prohibited substances and management of 
doping controls.  
Half of WADA’s funding comes from public authorities with the remainder coming 
from the IOC. The funding given to WADA has increased from US$18 million in 2002 to 
$30 million in 2016 (WADA, 2003, 2017a). A considerable proportion of this funding is 
spent on implementing the WADC, which includes costs associated with organising, 
conducting and analysing drug testing. In 2002, the United States Anti-Doping Agency 
(USADA) spent approximately US$4 million on drug testing (USADA, 2003), while in 2016, 
it spent over $9 million (USADA., 2017). Likewise, the Australian Sports Anti-Doping 
Authority (ASADA) spent approximately US$0.6 million in 2006 and $3.5 million in 2016 
(ASADA, 2017). The financial costs for WADA analysing drug tests has increased by 50% 
from 2003 to 2016 (WADA, 2004, 2017a). Despite greater emphasis and financial resources 
aimed at preventing doping and the technology to detect more types of banned substances, 
there has not been a statistical increase in the number of tests returning positive since 1985 
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(Pound, Ayotte, Parkinson, Pengilly, & Ryan, 2013). In fact, if the substances marijuana, 
asthma medications and glucocorticosteroids were removed from the analysis, all of which 
can be used with therapeutic use exemption, less than 1% of tests would return positive 
(Pound et al., 2013). While this could suggest that increases in drug testing have discouraged 
athletes from doping, the prevalence of doping is estimated to be far greater than the number 
of positive tests. Recent reports suggest between 14 and 39% of elite athletes are doping (de 
Hon, Kuipers, & van Bottenburg, 2015), which is significantly higher than the 1 to 2% of 
athletes identified with banned substances in their system.  
2.2.2 Anti-doping education 
 Preventing a behaviour from occurring is recognised to be more effective than 
discouraging one that is already established (Backhouse, Patterson, & McKenna, 2012). 
When implemented properly, education can provide athletes with the information to make 
more informed decisions about their doping behaviours. For this reason, educational 
interventions have been a key element in WADA’s policy since the publication of the 2009 
WADC. Article 18 of the latest WADC states: 
 
The basic principle for information and education programs for doping-free sport is 
to preserve the spirit of sport…from being undermined by doping. The primary goal 
of such programs is prevention. The objective shall be to prevent the intentional or 
unintentional Use by Athletes of Prohibited Substances and Prohibited Methods  
          (WADC, 2015, p. 96) 
 
Anti-doping educational interventions are implemented all over the world to athletes 
and the general public. Traditionally, these interventions comprise of value laden “moral 
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education” that aims to instil a commitment to ideological sporting principles such as 
integrity, respect and honesty (e.g. UKAD’s “100% me,” USADA’s “play clean” and the 
IOC’s “Olympic Values Education Programme”). WADA includes copious material on their 
website about the “spirit of sport,” including online games such as “the Play True Quiz” and 
“Youth Quiz” (WADA, 2017b). International federations (e.g. IAAF, IOC and UCI) and 
National Anti-Doping Organisations (e.g. ASADA, UKAD and USADA) also organise 
campaigns to educate athletes and the general public about the values of sport in an effort to 
deter doping behaviours. The British Olympic Association’s (BOA) “Get Set for the Spirit of 
Sport” campaign which “encourages young people to develop a core set of sporting values” 
has engaged over 4.5 million children and young people since 2012 (BOA, 2017). The 
Federation Internationale de Football Association (FIFA) implemented the “11 rules to 
prevent doping in football” campaign to raise awareness among young athletes about the 
“dangers and consequences of doping” in over 20 countries across Africa, Asia, Europe, 
Oceania and South America (FIFA, 2017). UNESCO sponsor a series of projects that deliver 
anti-doping education to “raise awareness of the risks associated with doping” to people all 
over the world, including Lithuania, Botswana, Ethiopia, Malawi and the Philippines 
(UNESCO, 2015).  
While the reach of anti-doping educational interventions is impressive, limited 
evidence is available to support the effectiveness of these interventions. In this context, 
effectiveness refers to the degree in which educational interventions contribute to WADA’s 
objective of preventing doping in sport (WADC, 2015, p. 98). Although it is argued that this 
goal will never be achieved, doping-free sport is what WADA aims to achieve (de Hon, 
2016). Typically, WADA and other anti-doping organisations evaluate the effectiveness of 
anti-doping educational interventions on the outputs delivered (i.e. how many athletes 
received education, how many interventions were delivered; Petróczi & Naughton, 2011), 
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rather than the impact they are having on an athlete’s decision to dope. Hoberman (2013) 
argued that such an approach could “signify a tacit agreement to do nothing beyond issuing 
proclamations, promulgating slogans, and putting online anti-doping games on the Web” (p. 
139). Without any evidence of effectiveness, WADA cannot guarantee that anti-doping 
educational interventions are meeting their objectives of preventing doping. 
A similar paucity of evidence for the effectiveness of interventions characterises the 
scientific literature. In a systematic review funded by WADA that included over 100 studies 
of the social science anti-doping literature, Backhouse, McKenna, Robinson, and Atkin 
(2007) reported that there is little evidence to indicate the effectiveness of anti-doping 
education. This conclusion is similar to a follow up review in 2016 (Backhouse, Whitaker, 
Patterson, Erickson, & McKenna, 2016). In fact, the available evidence suggests that 
interventions have little impact on doping behaviour. For example, the ATLAS (Athletes 
Training and Learning to Avoid Steroids; Goldberg et al., 1996) and ATHENA (Athletes 
Targeting Healthy Exercise and Nutrition Alternatives; Elliot et al., 2004) interventions, 
which both involve conveying knowledge about a range of unhealthy behaviours, including 
doping, showed only a small reduction in doping intentions and no changes in actual reported 
cases of doping (Ntoumanis et al., 2014).  
More recently, Barkoukis, Kartali, Lazuras, and Tsorbatzoudis (2016) educated 
athletes on the health, moral, social and psychological aspects of sports supplements and 
doping and Sagoe et al. (2016) provided athletes with information on fundamental principles 
of exercise and strength training, use of supplements, and resisting peer pressure to dope. In 
both studies, authors reported no differences in doping attitudes pre and post-test. Similar 
results were shown for Lucidi et al. (2017) who educated athletes about the role of media 
messages in promoting dysfunctional beliefs, the side effects of doping substances, nutrition 
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and lifestyle, the way the media may disregard or minimize the moral implications of doping, 
and reframing sport goals to resist doping temptations.  
There is also the risk of interventions increasing doping by intervening to prevent it. 
For example, a knowledge-based information intervention, which provided facts on the 
comparable physiological effects of nitrate rich foods and synthetic EPO, increased the 
reported likelihood of athletes using EPO (James, Naughton, & Petroczi, 2010) and a training 
programme aimed at enhancing athletes’ ethical decision making ability was reported to elicit 
more favourable attitudes to doping (Elbe & Brand, 2016).  
A number of explanations could account for the limited effectiveness of these 
interventions (Box 2.1). Firstly, interventions are often aimed at overall health-related 
behaviours and are not sufficiently focused on doping behaviours. The ATLAS (Goldberg et 
al., 1996) intervention sought to improve participants’ knowledge of a range of variables 
such as nutrition, optimal training, communication skills and anabolic steroids, and the 
ATHENA (Elliot et al., 2004) intervention comprised of eating disorder behaviours, driving 
without a seatbelt, media advertisements and anabolic steroid use. Secondly, questionnaires 
used to detect changes in, for example, attitudes towards doping, are often bespoke 
instruments with questionable validity (Backhouse et al., 2007; Backhouse et al., 2016). 
These measures may not be sufficiently reliable and valid to detect changes in doping 
intentions and behaviours. Thirdly, participants sampled in anti-doping education 
intervention studies often report low initial intentions to dope. Ntoumanis et al. (2014) 
posited that initial low intentions, or “floor effects,” may explain the limited effectiveness of 
current education interventions. If, for example, a research study recruits participants with no 
prior intention to use doping substances, establishing the effectiveness of the intervention is 
extremely difficult. Finally, if an athlete admits to doping, they could be banned from  
competition for up to four years. Even an athlete that is not currently doping but who is  
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tempted to do so might understandably experience some reluctance in disclosing this.  
In light of the above, evaluating the effectiveness of an anti-doping educational 
intervention is challenging. However, over the past ten years a growing body of literature has 
identified a number of psychosocial variables that influence doping behaviours. In a recent 
meta-analysis, Ntoumanis et al. (2014) identified 34 predictors of doping behaviours, 
including task and ego orientation, moral disengagement, perfectionism, sport confidence and 
anticipated regret. The authors also reported that the use of sport supplements was one of the 
strongest predictor of doping behaviours. As such, targeting an athlete’s use of sport 
supplements as opposed to banned substances might therefore be not only a legitimate anti-
doping intervention, but also one that facilitates less problematic evaluation of its 
effectiveness, given that it is predicated on the use of supplements and not banned substances.  
2.2.3 Sport supplements as a risk factor to doping 
 Sports supplements are reported to be widely used by athletes of all ages and abilities 
(Knapik et al., 2016), with the aim of enhancing performance, recovery, and/or other sport 
related factors (Lun, Erdman, Fung, & Reimer, 2012; Maughan, King, & Lea, 2004; Nieper, 
Box 2.1. Limitations of anti-doping education interventions 
1. Intervention focus   
Interventions aiming to improve overall health-related behaviours do not sufficiently 
focus on doping behaviours 
2. Ad hoc instruments   
Interventions using bespoke and ad hoc instruments to identify changes in the behaviour 
may not be valid or reliable 
3. Floor effects    
Recruiting participants with low doping intentions make it difficult to identify any 
changes following the intervention 
4. Admitting to doping   
   Athletes may be reluctant to admit their doping behaviours and/or intention 
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2005). Prevalence is suggested to be anywhere between 40 and 70% (Outram & Stewart, 
2015) with estimates dependent on gender (Nieper, 2005), age (Desbrow et al., 2014; 
Lieberman et al., 2015) sport played (Heikkinen, Alaranta, Helenius, & Vasankari, 2011), 
time of the season (Tscholl, Alonso, Dolle, Junge, & Dvorak, 2010) and the definition of 
supplement used in the study survey (Outram & Stewart, 2015). It should also be noted that 
sport supplement use is reported to be widespread not only among athletes, but among the 
general population. Reasons for use by the general population are attributed to enhancing 
health (Bailey, Gahche, Miller, Thomas, & Dwyer, 2013), diet (Dickinson, Blatman, El-Dash, 
& Franco, 2014) and physical appearance (Pezdirc et al., 2015). While prevalence is high 
among both athletes and the general population, this research programme will focus only on 
athletes.  
Use of sport supplements is suggested to be a risk factor for an athlete’s health and to 
future doping behaviours. A number of recent anecdotal reports and scientific evidence 
suggest that sport supplements can be contaminated with banned substances (Geyer et al., 
2004; Geyer et al., 2008), and that they may act as a “gateway” to doping substances 
(Backhouse et al., 2013; Ntoumanis et al., 2014). 
Cross-contamination of a sport supplement occurs as a result of insufficient 
surveillance and quality control by the sport supplement industry (Geyer et al., 2004). Many 
supplements by-pass the most rudimentary pharmaceutical safeguards and banned substances 
can often be added to the supplement accidentally or deliberately. Geyer et al. (2008) 
analysed 634 sport supplements in 13 countries and reported that 15% of sport supplements 
were contaminated with anabolic steroids and testosterone. Cohen, Bloszies, Yee, and Gerona 
(2016) also reported that of 21 supplements sampled, 52.4% contained stimulants. Thus, for 
athletes using sport supplements, the probability of contamination and potentially failing a 
drug test is high. 
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Contamination of substances can also have serious health implications. A review of 
24 commercially available protein drinks indicated that 31% failed quality assurance tests, 
with 6 to 18 mg of lead discovered in some of the products (Maughan, 2013). Another study 
reported that products sold online did not include any of the active ingredients displayed on 
the label, with low-cost substitutes such as melamine used instead of protein ingredients 
(Champagne & Emmel, 2011). More seriously, the use of a weight-loss supplement 
containing hidden quantities of an untested drug (n-nitrsoso-fenfluramine) resulted in four 
deaths and 800 people falling seriously ill (McVeigh, Evans-Brown, & Bellis, 2012), while 
use of a similar weight-loss supplement (ephedra) has been linked to multiple deaths and 
cardiovascular incidences (McVeigh et al., 2012).  
In addition to the health risks posed by the use of sports supplements, it has been 
proposed that habitual consumption of these supplements can lead athletes to use banned 
performance enhancing substances. Several hypotheses have been put forward to explain this 
association. Thorndike’s (1911) “law of effect” suggests that the probability of a response is 
increased when followed by a reward and decreased when followed by discomfort. 
Accordingly, an athlete using a sport supplement for the first time may attribute any 
improvements (or decrements) in performance to the supplement, with improvements in the 
athlete’s performance increasing the likelihood of future supplement use and decrements 
decreasing the likelihood of future supplement use. Further positive experiences of 
supplementation reinforce the belief that the supplement is effective, while negative 
experiences reinforce the belief that the supplement is ineffective. The response to the 
supplement is thus reinforced by the performance outcome. This is underpinned by classical 
conditioning, where a stimulus (i.e. sport supplement) is associated with a response (i.e. 
improvement in performance), which can reinforce belief in the substance’s effectiveness 
(Everitt & Robbins, 2013). These experiences can also create cues that strengthen the 
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association between the response and the stimuli (Stewart, De Wit, & Eikelboom, 1984). The 
conditioned effects of a substance can activate neural mechanisms that mimic the neural 
activity of the substance, and it is the activation of these states by conditioned stimuli that 
may initiate further substance use behaviour (Everitt & Robbins, 2005; Everitt & Robbins, 
2013). However, with repeated exposure of a substance, the pharmacological effects are often 
markedly reduced over time and the brain systems that are normally involved become 
desensitised to the physiological effects, but more significantly, become hypersensitive to the 
associated stimuli (Hyman & Malenka, 2001). Sensitisation of substances may lead to an 
increased use of the same substance or use of another, stronger, substance; a process termed 
“cross-sensitisation” (Robinson & Berridge, 1993). 
While it is clear that numerous hypotheses might explain the progression to strong 
drugs through the use of weaker ones, the term “gateway hypothesis” has been used as a 
coverall. Originally credited to Kandel (1975), the gateway hypothesis posits that individuals 
become increasingly involved in drugs in stages and in sequences. Kandel (1975) reported 
that if adolescents use marijuana, the likelihood of them using harder drugs, such as cocaine 
and heroin, increases significantly from 2 and 3% to between 16 and 23%. More recent 
epidemiological data report that 56.3% and 84.5% of high school students smoke tobacco or 
drink alcohol before progressing to marijuana and cocaine respectively (Johnston et al., 
2013). Further evidence from the Substance Abuse and Mental Health Services 
Administration (2013) revealed that 65% of marijuana users started smoking or drinking 
before they started using marijuana, while 97% of cocaine users started smoking or drinking 
before progressing to cocaine. Fergusson and Horwood (2000) reported that over 99% of 
illicit drug users in New Zealand used cannabis first before progressing to other illicit drugs 
and Prince van Leeuwen et al. (2014) reported that tobacco use in the Netherlands was 
associated with a higher likelihood of developing a marijuana use disorder. 
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Although the epidemiological evidence presented above has arguably established a 
“weak drug-strong drug” sequence in which different substances are used progressively, it 
has not identified what causes the progression from one drug to the next. For this reason, 
many authors have criticised the validity of the gateway hypothesis and its causal 
mechanisms (Kleinig, 2015; Vanyukov et al., 2012). However, animal studies have shown 
that the intake of a “softer” drug can increase the intake of a “harder” drug; for example, 
animals sensitised to amphetamines have shown an increased intake of cocaine (Ferrario & 
Robinson, 2007), while animals given sugar increase their intake of alcohol (Avena, Carrillo, 
Needham, Leibowitz, & Hoebel, 2004) and cross-sensitise to cocaine (Gosnell, 2005). Levine 
et al. (2011) proposed a molecular explanation for the gateway hypothesis and the sequence 
of drug use, suggesting that exposure to nicotine caused specific changes in the brain that 
made it more vulnerable to cocaine addiction. It was also shown that pre-treatment with 
nicotine altered the response to cocaine in terms of addicted related behaviour and changes in 
brain regions critical for addiction related rewards. Furthermore, and at a molecular level, 
nicotine was found to enhance the effect of cocaine when administered for several days prior 
to the use of cocaine. These results stimulated further analysis of epidemiological data, where 
Kandel and Kandel (2014) reported that cocaine users would often start using cocaine only 
after prolonged smoking of tobacco. Collectively, data suggest that in the general population 
in Western societies, there is a well-defined sequence of progression of drug use. That is, 
hard drug use often starts with a softer drug. The idea of the gateway hypothesis has 
influenced US drug policy since the 1950’s (Morral, McCaffrey, & Paddock, 2002). 
For anti-doping educational interventions, targeting an athlete’s use of sport 
supplements may therefore prevent unintentional (i.e. via cross-contamination) and future 
(i.e. via the gateway hypothesis) use of banned performance enhancing substances.  
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2.2.4 Theories of substance use behaviour in sport 
Research on sport supplement and banned substance use often frames the behaviour 
as one of decision-making (Hauw & McNamee, 2015). Based on this, doping is the outcome 
of a process determined by numerous factors such as an athlete’s beliefs, hopes, attitudes, 
intentions, expectations and perceptions of others. Therefore, researchers using this 
framework often study the explicit or implicit processes involved in the decision to dope (e.g. 
Backhouse et al., 2013; Petróczi, 2013; Ring & Hurst, 2019). Given this, there are several 
existing models posited to explain the reasons why athletes might dope. Social Cognitive 
Theory (SCT; Bandura, 1986), Self-Determination Theory (SDT; Deci & Ryan, 1985), the 
Theory of Reasoned Action (TRA; Ajzen & Fishbein, 1975) and the Theory Planned 
Behaviour (TPB; Ajzen, 1985) have been used extensively in the past decade. In this research 
programme, the TRA and TPB are referred to. However, to provide an insight into the 
evolving anti-doping field and position the theoretical underpinning of this research 
programme more clearly, SCT and SDT will be briefly addressed first. 
Bandura’s (1986, 1989, 1991) SCT of moral thought and action describes how moral 
conduct is influenced by external (e.g. other athletes) and internal (e.g. cognitions) factors. 
This theory posits that behaviour is guided by moral standards and people are responsible for 
their own actions. When behaviour is not in line with moral standards, negative emotions are 
experienced. Thus, for an athlete using a banned performance enhancing substance, it is 
suggested athletes with high moral standards will feel a greater sense of regret and guilt than 
those with lower moral standards. Numerous studies have supported the notion that morality 
influences an athlete’s decision to use performance-enhancing substances (Kavussanu & 
Ring, 2017; Ring & Hurst, 2019; Ring, Kavussanu, Lucidi, & Hurst, 2019).   
Other authors (e.g. Barkoukis, Lazuras, Tsorbatzoudis, & Rodafinos, 2013; Chan, 
Dimmock, et al., 2015; Chan, Donovan, et al., 2015) have applied the constructs of SDT 
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(Deci & Ryan, 1985; Deci & Ryan, 2008) to account for athletes’ motivation to use 
performance enhancing substances. According to SDT, motivation exists along a continuum 
anchored by two broad types: autonomous and controlled. Autonomous motivation represents 
behaviour that is driven by intrinsic interest or because of the value attached to the activity,  
whereas controlled motivation represents behaviour that is driven by extrinsic interest, ego 
enhancement and fame. It has been reported that athletes high in controlled motivational are 
more likely to dope than those with high autonomous motivation (Chan, Dimmock, et al., 
2015; Gucciardi, Jalleh, & Donovan, 2010; Lucidi et al., 2008).  
Several authors have used the TRA (Ajzen & Fishbein, 1975) and TPB (Ajzen, 1985, 
1991) to examine intentions, attitudes and beliefs around doping behaviours. Both theories 
have shown to accurately predict a number of different health behaviours such as physical 
activity participation (Bélanger-Gravel, Godin, & Amireault, 2013), smoking (Cooke, 
Dahdah, Norman, & French, 2016), sexually transmitted disease prevention (Andrew et al., 
2016), nutritional choices (McDermott et al., 2015) and driving while under the influence of 
alcohol (Lheureux, Auzoult, Charlois, Hardy‐Massard, & Minary, 2016). 
The TRA and TPB both assume that a person’s intention is the most proximal and 
immediate predictor of behaviour (Chan, Hardcastle, et al., 2015). Intention is the extent to 
which a person plans to engage in the behaviour in the future (Ajzen, 1991). Barkoukis et al. 
(2013) reported that participants who self-reported using banned substances showed 
significantly stronger intentions to use these substances in the future than self-reported non-
users. These results are supported by Dodge and Jaccard (2007) and Goulet, Valois, Buist, 
and Cote (2010), who report significant relationships between banned substance intention and 
actual use. This relationship is also reported in relation to sport supplement use (Tsochas, 
Lazuras, & Barkoukis, 2013).  
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The TRA and TPB suggest that intention is determined by attitudes (i.e. how a person 
favours the behaviour) and subjective norms (i.e. how a person perceived the social 
appropriateness of the behaviour). The TPB, which is an extension of the TRA, suggests that 
a person’s perceived behavioural control also influences decision making (i.e. how a person 
perceives the controllability of their behaviour). Since athletes admitting to the actual use of 
doping is problematic (see Box 2.1, p. 46), attitudes, subjective norms and perceived 
behavioural control are often used as a proxy for doping behaviours and intentions. Lucidi, 
Grano, Leone, Lombardo, and Pesce (2004) and Lucidi et al. (2008) reported that the Theory 
of Planned Behaviour constructs (i.e. attitudes, subjective norms and perceived behavioural 
control) significantly predict doping intentions and behaviour.  
Attitudes, subjective norms and perceived behavioural control are also suggested to be 
determined by behavioural, normative and control beliefs, respectively (Figure 2.4). For 
instance, attitudes are determined by a person’s beliefs about the outcomes of performing the 
behaviour (i.e. behavioural beliefs). A person who holds strong positive beliefs about the 
effectiveness of anabolic steroids, for example, is proposed to have positive attitudes towards 
them. Similarly, a person who believes it is socially acceptable to use anabolic steroids (i.e. 
normative beliefs), often holds positive subjective norms about the use of anabolic steroids. 
This is then suggested to influence the person’s intention to use anabolic steroids, which 
ultimately influences a person’s likelihood of using them.  
Most empirical research in the doping literature has focused on doping attitudes. 
Typically, attitudes are assessed via open-ended questionnaires or surveys that people from 
the target population are asked to complete. One of the most widely used attitude 
questionnaires in the doping literature is the Performance Enhancement Attitude Scale 
(PEAS; Petróczi, 2006; Petróczi & Aidman, 2009), which represents people’s general 
attitudes to doping. The questionnaire contains 17 items such as “doping is necessary to be 
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competitive” and “doping is not cheating since everyone does it,” which are evaluated on a 6-
point Likert type scale ranging from strongly disagree (1) to strongly agree (6). PEAS scores 
have been shown to be significantly associated with self-reported banned substance use 
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Figure 2.4. Theory of Reasoned Action and Theory of Planned Behaviour. Note. Areas shaded in grey show the Theory of Planned Behaviour constructs.  
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(Whitaker, Long, Petróczi, & Backhouse, 2014; Zabala, Morente-Sánchez, Mateo-March, & 
Sanabria, 2016) and intention to use banned substances (Chan, Dimmock, et al., 2015; 
Lazuras, Barkoukis, Mallia, Lucidi, & Brand, 2017) whereas, users of sports supplements 
have shown to be and intention to use banned substances. However, there is no published 
evidence of a theoretical or conceptual framework underpinning the PEAS. After assessing 
the factor structure of the PEAS amongst 1,054 adults, Nicholls, Madigan, and Levy (2017) 
reported that the 17 item PEAS displays poor model fit. Authors reported that modifications 
of the scale used elsewhere (e.g. Elbe & Brand, 2016; Gucciardi et al., 2010; Gucciardi, 
Jalleh, & Donovan, 2011; Vargo et al., 2014) with fewer items provide better model fit than 
the original. Future research using the PEAS should therefore examine the factor structure 
and model fit before assessing athletes’ attitudes towards doping.  
While doping attitudes are related to other psychosocial predictors of doping (e.g. 
perfectionism, motivational climate, willingness to dope and achievement goal orientations; 
Nicholls et al., 2017), recent meta-analytical data suggest that attitudes have only a small 
effect on actual banned substance use (effect size = 0.08; Ntoumanis et al., 2014). In a 
relatively early study in this field, Petróczi (2007) reported that attitudes were not 
significantly associated with actual banned substance use, but that beliefs about doping were. 
While the Theory of Reasoned Action and Theory of Planned Behaviour suggest that beliefs 
determine attitudes before they affect behaviour, Petróczi’s (2007) findings suggest that 
beliefs might directly influence doping behaviours. Chan, Hardcastle et al. (2015) showed 
that beliefs about the advantages of using banned substances predicted doping attitudes (β 
=0.43, p <.01), subjective norms (β = 0.29, p <.01), perceived behavioural control (β = 0.25, 
p <.01) and intention (β = 0.29, p <.01). Research conducted by Backhouse et al. (2013) and 
Dascombe, Karunaratna, Cartoon, Fergie, and Goodman (2010) suggests that athletes who 
use sport supplements express more favourable beliefs about these types of substances than 
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non-users. Research examining the belief-based constructs of doping is limited, but there is 
sufficient evidence to suggest that future interventions targeting athletes’ beliefs in the 
interests of preventing doping are warranted.  
2.2.5 Summary of anti-doping literature 
 Over the past 50 years, sport organisations have attempted to prevent doping via drug 
testing and sanctioning. In recent years, sport organisations have encouraged a more 
preventive approach that focuses on educating and informing athletes about doping. While 
challenges exist in evaluating the effectiveness of these interventions (Box 2.1, p. 46), 
targeting predictors of doping and the underlying psychological processes might facilitate 
less problematic evaluations. However, any attempt to measure and understand the 
psychological process should use valid and reliable measures to ensure accurate estimations 
of athletes’ actual doping related behaviours. Recent evidence suggests that athletes using 
sport supplements are more likely to use banned performance enhancing substances, and that 
their beliefs, attitudes and intentions about sport supplements influence future behaviours. 
Anti-doping education targeting sport supplements as opposed to doping could be a more 
pragmatic alternative to evaluating the effectiveness of interventions. This type of 
intervention could enable athletes to make more informed decisions about their use of 
supplements and subsequently, banned substances.  
2.3 Summary 
This review aimed to familiarise the reader with the placebo effect and anti-doping 
literatures. These literatures have informed the rationale and aims of this research 
programme, the research questions posed and the methodological choices made. The research 
questions and aims of this research are presented in Chapter Three. 
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Chapter Three  
 
RESEARCH PROGRAMME QUESTIONS AND AIMS 
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3.1 Questions and aims 
The placebo effect has been extensively studied in sport. The nocebo effect has 
received less attention, with a paucity of evidence suggesting that negative beliefs can 
significantly impair performance. In one of the first studies investigating both placebo and 
nocebo effects in sport, Beedie et al. (2007) reported significant improvements and 
decrements in repeat sprint performance when participants ingested a placebo believed to be 
a supplement likely to have either a positive or negative effect, respectively. However, the 
study in question did not include a no-treatment control in study design and, although 
relatively large for a study in sport and exercise science, the number of participants recruited 
was not sufficiently large enough to examine factors that might moderate the placebo effect 
(n = 42). Small sample size and lack of a no-treatment control are common features in 
placebo effect studies on sports performance making it difficult to accurately ascertain the 
magnitude and moderators of observed placebo and/or nocebo effects. Using a similar repeat 
sprint design to Beedie et al. (2007), a major aim of this research programme was to explore 
the magnitude and moderators of the placebo and nocebo effect using a large sample of 
athletes in a fully controlled experimental design (Study 2).  
It has been proposed that athletes aware of the placebo effect, or who have direct 
experience of it, may be less likely to use supplements and banned substances (Kalasountas et 
al., 2007; Maganaris et al., 2000; McClung & Collins, 2007). The idea underpinning this 
proposal is that an athlete aware of the placebo effect might also recognise that this 
significant psychological contribution to the effectiveness of a supplement is something that 
they may be able to achieve through other means, such as mental preparation and 
psychological skills training. If such an athlete is less likely to use supplements, the gateway 
hypothesis also predicts that the athlete is theoretically less likely to progress to banned 
substance use. Therefore, a second aim of this programme was to measure the outcomes of a 
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placebo intervention on athletes’ intentions to use sport supplements and banned substances 
(Study 3) 
Data suggest that beliefs about sport supplements influence future doping behaviours 
(Backhouse et al., 2013; Petróczi, 2007). If a placebo intervention is designed to target 
athletes’ beliefs about the effectiveness of sport supplements, a measure facilitating the 
reliable and valid assessment of beliefs about supplements could represent a useful tool in 
understanding the effectiveness of this type of intervention. To the author’s knowledge, no 
validated measure of athletes’ beliefs about sport supplements has been published. A third 
aim of this programme was to develop and validate a psychometric instrument that could be 
used to help verify the impact of the placebo intervention used in study 3 (Study 1).  
3.2 Summary of aims and research questions  
Aims 
1. Develop and validate a psychometric instrument that can be used to measure the 
outcomes of a deceptive placebo intervention 
2. Assess the magnitude of resultant placebo and nocebo effects on a large sample of 
athletes 
3. Examine potential moderators associated with observed placebo and nocebo effects 
4. Measure the impact of a deceptive placebo intervention on athletes’ beliefs and 
intentions towards sport supplements and attitudes to doping  
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Research questions 
1. What is the magnitude of placebo and nocebo effects on the repeat sprint performance 
of a large sample of athletes associated with the administration of a purported sport 
supplement? 
2. What factors moderate observed placebo and nocebo effects in repeat sprint 
performance? 
3. What is the impact of a placebo intervention on athletes’ beliefs and intentions 
towards sport supplements and attitudes to doping?  
 
This research programme will be conducted in three sequential chapters:  
 
Study 1 – DEVELOPMENT AND VALIDATION OF THE SPORTS SUPPLEMENTS 
BELIEFS SCALE 
Aim: To develop and validate a psychometric instrument that measures athletes’ 
beliefs about sport supplements. Development and validation of the measure was conducted 
in five parts using both qualitative and quantitative methods to develop and validate a list of 
items that could be used to evaluate the impact of the placebo intervention used in Study 2. 
 
Study 2 – INVESTIGATING THE MAGNITUDE AND MODERATORS OF THE 
PLACEBO AND NOCEBO EFFECT ON REPEAT SPRINT PERFORMANCE  
Aim: To assess the magnitude and moderators of placebo and nocebo effects on a 
large sample of athletes. This experimental study used a randomised controlled design to 
assess the effects of placebo and nocebo treatments on repeat sprint performance.  
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Study 3 – EFFECT OF A POSIITVE AND NEGATIVE BELIEF INTERVENITON ON 
ATHLETES’ BELIEFS AND INTENTION TOWARDS SPORT SUPPLEMENTS 
AND ATTITUDES TOWARDS DOPING 
Aim: To test whether a deceptive placebo and nocebo intervention influences athletes’ 
beliefs and intentions towards sport supplements and attitudes to doping. Participants 
completed a series of psychometric measures including the Performance Enhancement 
Attitude Scale (PEAS; Petróczi, 2006), and the Sports Supplements Beliefs Scale (SSBS), 
developed and validated in Study 1. Pre-post intervention scores were calculated and 
corroborated with post-intervention qualitative responses.  
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Chapter Four  
 
DEVELOPMENT AND VALIDATION OF THE SPORTS SUPPLEMENTS 
BELIEFS SCALE   
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4.1 Introduction 
The development of anti-doping educational interventions requires robust and valid 
methods in order to establish effectiveness. However, obtaining reliable self-report 
information about explicit doping behaviours is associated with several ethical and practical 
challenges, including the considerable problem that admission of use of a banned substance 
can result in the athlete losing their right to participate in sport (Box 2.1, p 46). For this 
reason, researchers generally use one or more psychological constructs as a proxy to doping 
behaviour. The use of sport supplements and beliefs about their effectiveness has been 
reported to increase the likelihood of an athlete doping (Backhouse et al., 2013; Boardley, 
Grix, & Harkin, 2015). A psychometric measure that can “tap in” to this psychological 
construct may help identify athletes at risk of doping and facilitate understanding of an 
intervention aimed at preventing supplement use. Therefore, the focus of this study is the 
development and validation of a psychometric measure of beliefs about sport supplements. 
Several authors have employed self-report instruments in the measurement of 
psychological variables related to supplement use and doping (Backhouse et al., 2013; 
Barkoukis et al., 2015; Dodge & Jaccard, 2008; Petróczi, 2007). Petróczi and Aidman (2009) 
used the Performance Enhancement Attitude Scale (PEAS) and reported that athletes with 
significantly more favourable attitudes towards doping substances were more likely to dope. 
Similarly, Ring and Kavussanu (2017) used the moral disengagement in doping scale and 
reported that athletes scoring higher on the scale were more likely to use banned substances. 
Barkoukis, Lazuras, Tsorbatzoudis, and Rodafinos (2011) used the Sport Motivation Scale 
and reported that athletes categorised as “amotivated” were more likely to dope than those 
categorised as “intrinsically motivated.” 
While a number of measures have been used to analyse predictors of doping 
behaviour, recent data suggest that athletes who use sport supplements are also more likely to 
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progress to doping (Backhouse et al., 2013; Barkoukis et al., 2015; Hildebrandt et al., 2012; 
Ntoumanis et al., 2014; Petróczi, 2013). This is underpinned by the gateway hypothesis, 
which posits that softer drugs can lead to harder drugs (Kandel, 1975). In sport, authors have 
reported that the prevalence of banned substance use is more than three times higher in 
athletes using sport supplements than non-users (Backhouse et al., 2013). Qualitative 
evidence presented by Boardley, Grix, and Dewar (2014) suggested that bodybuilders 
believed that once the benefits of sport supplements plateau, they would look to use banned 
substances to facilitate further performance enhancements. Given the difficulties in assessing 
actual doping behaviours in anti-doping educational interventions, targeting athletes’ sport 
supplement use may be fruitful.  
Recent research has suggested that athletes using sport supplements tend to express 
more favourable beliefs about the effectiveness of these types of substances than non-users 
(Backhouse et al., 2013). Furthermore, athletes’ beliefs about sport supplements are reported 
to influence future behaviours and intentions (Bell, Dorsch, McCreary, & Hovey, 2004). 
Hypothetically therefore, if athletes’ beliefs about sports supplements influence current and 
future supplement use, and if current/future supplement use predicts future doping, it is 
reasonable to suggest a relationship between current beliefs about supplements and future 
doping. Thus, an instrument facilitating the reliable and valid assessment of beliefs about 
supplements could represent a useful tool in the development and evaluation of anti-doping 
interventions. To the author’s knowledge, no validated measure of athletes’ beliefs about 
sport supplements has been published. 
The validation of any questionnaire requires multiple procedures, which are employed 
sequentially at different stages of its development. Thus, the validation of a test never ends 
and validity is built into the test at the outset rather than being limited to the last stages of test 
development, as in traditional criterion-related validation (Terry, Lane, & Fogarty, 2003). 
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Each of these procedures/stages can be seen as fundamental to demonstrating the two sources 
of information described by Murphy and Davidshofer (1988) as representing strong evidence 
for the validity of measurement, that is, content and construct validity. Murphy and 
Davidshofer (1988) proposed that the empirical and theoretical basis for the construct, the 
interpretability of that construct, the generalisability of the construct definition, and the 
applicability of the initial item pool to that definition, all jointly determine the content 
validity of the questionnaire. Similarly, the results of empirical item analyses, factor analyses, 
and criterion analyses jointly indicate construct validity. 
In line with the proposals above, this study aimed to report the multi-stage validation 
of a belief measure that could support evaluation of the effectiveness of anti-doping 
education interventions. This study reports the results of semi-structured interviews exploring 
athletes’ beliefs about sport supplements (phase 1), initial instrument development and 
content validity procedures (phase 2), exploratory and confirmatory factor analyses of 
responses to the questionnaire from 171 and 412 athletes respectively (phases 3 and 4), and 
relationships between questionnaire scores and supplement use (phase 5). Institutional 
research ethics committee approved all studies. Informed consent was obtained from each 
participant in each of the studies prior to their involvement (Appendix 1). 
4.2 Phase 1 
4.2.1 Aims 
Phase 1 aimed to explore and demonstrate the empirical basis for the questionnaire 
through the identification of themes and dimensions relating to the use of sports supplements 
by athletes.  
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4.2.2 Method 
 DeVellis (2016) and (Lynn, 1986) recommend that in questionnaire development, core 
concepts are identified using qualitative interviews. Semi-structured interviews were 
therefore used to explore athletes’ beliefs about sports supplements. 
Participants 
Sixteen athletes (6 females and 10 males; age = 24 ± 3; years training = 10 ± 4; hours 
per week training = 13 ± 4), were recruited via social media (Appendix 2). To ensure that 
responses were not affected by specific sport cultures and practices, athletes of varying 
abilities were recruited from various sports including football, gymnastics, mixed martial arts, 
rowing, Rugby union, track and field, and weightlifting. Participants had a range of athletic 
experience, with 13% competing at club level, 19% at county, 19% at regional, 25% at 
national and 25% at international.   
Procedure  
Each athlete was interviewed individually either face-to-face or via Skype. Initially 
adopting a deductive approach, an interview guide based upon the available literature was 
developed. However, the semi-structured interview schedule (Appendix 3) was developed to 
be sufficiently flexible to allow new concepts to surface inductively (Ntoumanis, Pensgaard, 
Martin, & Pipe, 2004). 
Athletes were asked to describe their decisions for using or not using sport 
supplements, the factors that influenced these decisions, and any experiences of using sport 
supplements. The semi-structured interviews consisted of a series of questions within four 
interrelated sections: 1) what is a sport supplement? 2) experiences of sport supplements 3) 
beliefs about sport supplements and 4) influences to use sport supplements. Interview times 
ranged from 36 to 91 minutes (mean ± SD = 56 ± 21 minutes). All participants had the right 
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to stop the interview and/or participation at any time. All participants were emailed a copy of 
the transcript to enable them to revise responses. Data analysis began after the athlete 
accepted the final version of the transcript.  
4.2.3 Data analysis.  
Audio recordings were transferred onto the software QSR NVivo 10. Each transcript 
was read several times, which allowed ordinate and sub-ordinate themes to emerge. Both 
deductive and inductive approaches to thematic analysis were used. Data analysis followed a 
three-stage coding process adapted from Smith et al. (2010): first, a summary report of the 
individual interviews to highlight the most pertinent issues; second, a pool of narratives 
centred on specific ordinate themes; and third, a thematic grouping structure around sub-
ordinate themes.  
4.2.4 Results 
A summary of the main findings is presented in Table 4.1. Four ordinate themes 
emerged from the data. The first related to the performance enhancing effects of sport 
supplements and contained three sub-ordinate themes: improved performance, higher chance 
of winning, and competitive edge. A second ordinate theme related to athletes’ perceptions 
that sport supplements could help improve recovery and health, which also contained three 
sub-ordinate themes: improved recovery, overcoming illness, and reduced chance of injury. A 
third ordinate theme related to athletes’ perceptions that sport supplements were necessary for 
performance and contained two sub-ordinate themes: performance advantage and the 
similarity between the use of supplements and the use of up-to-date equipment. A final 
ordinate theme related to the psychological effects associated with sport supplement use 
contained two sub-ordinate themes: confidence and anxiety.  
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Table 4.1  
 
Ordinate and subordinate themes derived through interview data 
 
Ordinate theme Sub-ordinate theme Transcript example 
Performance effects Improved performance "Supplements help me improve my performance. Whether pre, during or post 
competition" 
Higher chance of winning "It's really pushing you beyond what you could normally achieve" 
Competitive edge "I'm going to take full advantage of anything that is out there" 
Recovery and health effects Improve recovery "I know that I need to like recover as quickly as possible and therefore... a protein 
shake is ideal" 
Overcome illness "... a bit of supplementation wouldn’t go a miss… I think in terms of illness" 
Reduce injury "I tend to just have it, because... I don’t want to have another injury" 
Necessary for performance Necessary to improve "They were necessary... I felt a lot better after taking them and I felt that after a 
match where you feel beaten up… they were necessary" 
Same as equipment "We are always looking for the fastest gear and the fastest kit. Supplements are 
just part of that" 
Psychological effects Increase in confidence "I think it's as much confidence as well… you are maximising… you know, 
because recovery and preparation are as much part of the training and competitions 
as anything else" 
Decrease in anxiety "I was shit scared to be honest… The preparation became a very much part of that, 
nutrition became definitely a safety blanket in that sense" 
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4.3 Phase 2 
4.3.1 Aims 
Following the guidelines of Terry, Lane, Lane, and Keohane (1999), phase 2 aimed to 
assess the content validity of a pool of items derived from responses in phase 1 and reduce 
the number of items following subsequent analysis. 
4.3.2 Method 
Based on responses reported in phase 1, a pool of 26 items was developed. A panel of 
experts and athletes subsequently assessed the content validity of the resultant measure. 
Participants.  
Participants were a sample of six experts on anti-doping and 23 British athletes. 
Experts had all published in the anti-doping literature and were situated in Australia (n = 2), 
the United Kingdom (n = 1), the United States (n = 1), Italy (n = 1) and Canada (n = 1). 
Athletes (57% male, years training = 11 ± 6, hours per week training = 9 ± 6) were of a 
variety of ages, the majority between 18 and 24 years (48%). Athletes competed at various 
levels, with county being most common (48%), followed by national (35%), international 
(13%) and club (4%). Athletes were drawn from a variety of sports including athletics, 
weightlifting, triathlon, Rugby union, field hockey, and badminton. No participants from 
phase 1 were recruited to phase 2.  
Procedures.  
An online survey to enable academic experts to assess content validity was developed 
and emailed to a number of experts worldwide requesting their participation (Appendix 4). 
Experts were provided with the 26 items and asked to respond on a 4-point Likert-type scale 
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(1 = not relevant to 4 = highly relevant) as to how they believed each item related to athletes’ 
beliefs about sport supplements. Free-text boxes for each item facilitated comments 
(Appendix 5). An additional online survey was developed for athletes to provide feedback on 
each item and the structure of the questionnaire. Athletes were asked to complete the 26 item 
questionnaire by specifying their level of agreement with each statement on a six-point 
Likert-type Scale (1 = Strongly disagree to 6 = Strongly agree). A Likert-type scale was used 
following Comrey’s (1988) recommendations that multiple choice scales are more reliable 
and produce better scales than other formats (e.g., visual analogue scales, checklists). 
Athletes were also asked to evaluate and provide feedback on the questionnaire at the end of 
the survey (Appendix 6). 
4.3.3 Results 
Expert ratings of content validity were summarised by dividing the number of experts 
who provided a rating of 3 or 4 by the total number of experts (Lynn, 1986). Lynn proposed 
that when six or more experts review the content validity index (CVI) of a scale, values equal 
to or greater than .8 are acceptable (see also Polit, Beck, & Owen, 2007). CVI values of less 
than .8 were evident for seven items and these were removed from further analysis.  
Athletes reported that the items adequately represented their beliefs about sport 
supplements. However, athletes reported that certain types of sport supplements do not elicit 
specific performance effects and suggested that the type of supplement they used influences 
their belief about its effects. For example, athletes who used protein drinks did not believe 
that this type of supplement would influence performance, but did believe that it would 
improve recovery. Based upon these comments, eight items relating to specific performance 
enhancing effects of sport supplements (e.g., fatigue, pain, and recovery) were deleted. A 
final pool of 11 items remained.  
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4.4 Phase 3 
4.4.1 Aims 
Following content validity procedures, the factor structure of the 11 item measure was 
examined. Factor analysis is a statistical procedure applied to a single set of variables where 
the researcher is interested in discovering which variables in the set form coherent subsets 
that are relatively independent of each other. Essentially, the aim of factor analysis is to 
reduce a large number of variables to a smaller number of factors (Tabachnick, Fidell, & 
Osterlind, 2001), and to indicate how many factors are needed to describe the data.  
Researchers have often relied on exploratory factor analysis (EFA) to identify and 
distinguish between key psychological constructs (Marsh, Morin, Parker, & Kaur, 2014). 
EFA is an inductive process that in essence “explores” the data and results in a set of latent 
variables that explain correlations among the measured, or manifest, variables (Osborne, 
2015). Marsh and Yeung (1997) argued that “a long history of factor analytic research has 
demonstrated that this purely exploratory approach to factor analysis is typically ineffective” 
(p. 33), and Hendrickson and Jones (1987) suggested that EFA is no more than “an 
undisciplined romp through a correlation matrix” (p. 105). As a consequence of its 
limitations, it has been proposed that EFA is appropriate only when the analyst does not 
know what the underlying factor structure of a set of data should be (Biddle, Markland, 
Gilbourne, Chatzisarantis, & Sparkes, 2001). Several authors (Anastasi & Urbina, 1997; 
Bollen, 2002; Marsh & Yeung, 1997; Schutz, 1994; Schutz & Gessaroli, 1993; Strauss & 
Smith, 2009; Tabachnick et al., 2001) proposed that confirmatory factor analysis (CFA), 
which permits the analyst to test an a priori model of relationships between the manifest and 
latent variables, should be used in preference to EFA.  
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However, in phases 1 and 2 above, an empirical and largely atheoretical approach in 
deriving items was adopted. Thus, a priori theory as to any potential inter-correlations 
between items was posited. It has been suggested that CFAs fail to provide clear support for 
factor structure and are more restrictive than EFAs, in which cross-loadings between items 
are assumed to be exactly zero (Marsh et al., 2014; Morin, Arens, & Marsh, 2016). On this 
basis, the optimal approach to demonstrating factorial validity was considered to be to report 
the results of EFA first and then confirm the factor structure using CFA on a separate sample 
(Marsh et al., 2014). Phase 3 therefore used EFA on a first sample of athletes and 
subsequently interrogated, modified and confirmed the resultant factor structure using CFA 
on a different sample in phase 4. 
4.4.2 Method 
Participants 
Participants were 171 athletes (67% male; years training = 12 ± 9; hours per week 
training = 11 ± 7). Over 25 different sports were represented, with the highest proportions of 
athletes from athletics (43%), triathlon (18%), cycling (13%), and weightlifting (5%). 
Athletes were between the ages of 18 and 24 (24%), 25 and 34 (26%), 35 and 44 (25%) and 
45 or older (25%) and were of differing competitive levels with 30% competing at club level, 
19% county, 27% national, and 24% international. Athletes were recruited via social media, 
and asked to complete the questionnaire via a secure online survey platform 
(www.surveymonkey.com).  
Procedure  
Athletes completed the newly developed 11 item instrument (Appendix 7), which was 
labelled the “Sports Supplements Belief Scale” (SSBS). The SSBS required athletes to 
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respond on a 6-point Likert-type scale with scores ranging from strongly disagree (1) to 
strongly agree (6).  
Data analysis  
Data were inputted into SPSS v22.0. A missing values analysis indicated that of a 
possible 1,881 data points only 15 (0.7%) were missing from 12 respondents (8%). No 
respondents had less than 5% of missing data and Little’s MCAR test revealed that data were 
missing completely at random (χ2 =146.093, df = 50, p = .957). Missing values were replaced 
using a multiple imputation model that generated five data sets with a maximum number of 
parameters set at 100. The average value of the missing data sets was used for subsequent 
analysis. 
Exploratory factor analysis with the Maximum Likelihood method was used to 
examine the dimensionality of responses to items. Sample size recommendations for EFA 
vary, but given that 5-10 participants per item are considered acceptable (Bentler & Chou, 
1987), the sample size of 171 for the 11 items is adequate. Oblique (promax) rotation was 
used as it anticipates correlation among factors. Factors with eigenvalue greater than 1 were 
extracted, primary loadings of .3 or above were considered interpretable, and loadings 0.4 or 
above considered important (Hair, Black, Babin, Anderson, & Tatham, 2006). Any item 
associated with a loading below .3 was excluded. Cronbach’s alpha is reported to indicate the 
internal consistency of the scale, with adequate reliability demonstrated at levels above .7 
(Nunnally, 1978). 
4.4.3 Results 
A two-factor model emerged. Item 10 “Using supplements makes me optimistic about 
my performance” cross-loaded, so this item was removed and the analysis with 10 items was 
repeated. Once again a two-factor model emerged with an explained variance of 48.83%. 
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Factor 1 (7 items) appeared to describe the beliefs of athletes regarding the outcomes of using 
supplements themselves, while Factor 2 (3 items), although less clear, could be interpreted as 
normative beliefs of athletes about supplements, that is, athletes’ perceptions that 
supplements are an accepted means of performance enhancement. Bartlett’s test of sphericity 
was significant (χ2 = 490.963, df = 15, p < .001) and the Kaiser-Meyer-Olkin statistic was  
considered good (.884). The 10 items and their respective factor loadings are presented in 
Table 4.2. 
4.5 Phase 4 
4.5.1 Aims 
The penultimate stage of the development and validation process was to assess the 
factor structure of the instrument using confirmatory factor analysis (CFA).  
4.5.2 Method 
Confirmatory factor analysis is a statistical procedure for testing theory. As such, it 
contrasts with EFA in that in CFA, the test developer specifies the item-to-factor loadings in 
advance and assesses the “goodness of fit” between this model and the reported data. The 
principal indicator of good model fit is a small and non-significant χ2 (Biddle et al., 2001). 
However, it is often unclear whether a significant χ2 is the result of poor fit or large sample 
size (larger samples tend to produce larger values of χ2 that are also more likely to be 
significant, i.e. a Type I error, whereas small samples may accept poor models, i.e. a Type II 
error). To moderate the effects of sample size on model fit, several authors have 
recommended that the χ2 to degrees of freedom ratio be used in preference to χ2 alone (e.g. 
Heene, Hilbert, Draxler, Ziegler, & Bühner, 2011; Marsh, Balla, & McDonald, 1988) while  
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Table 4.2 
 
Factor structure matrix of the 10 item scale derived from exploratory factor analysis 
 
Item 
no. Items 
Factor loadings 
Factor 1 Factor 2 
1 Supplements improve my performance .800  
2 Supplements are necessary for me to be competitive .695  
3 Supplements improve my confidence .540  
4 My chances of winning improve when I use supplements .810  
5 Supplements help me realise my potential .725  
6 Supplements improve the quality of my training .830  
7 Athletes using supplements are usually the ones who medal at major championships  .394 
8 Supplements provide a greater improvement compared to a healthy diet  .496 
9 Supplements are the same as having the best equipment  .772 
10 Training increases the need for supplements .487  
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others have suggested that authors rely on other types of fit indices (Byrne, 2013; Hu & 
Bentler, 1999). These include Comparative Fit Index (CFI); Root Mean Square Error of 
Approximation (RMSEA); Standardized Root Mean Squared Residual (SRMR); Tucker-
Lewis Index (TLI), Akaike Information Criterion (AIC) and the Expected Cross-Validation 
Index (ECVI).  
Participants.  
Four hundred and sixty-eight competitive male and female athletes (81% male, years 
training = 10 ± 6, hours per week training = 6 ± 4) were recruited from sports clubs and 
volunteered to participate in the study. Over 12 different sports were represented, with the 
highest proportions of athletes from Rugby union (54%), football (23%), hockey (5%), and 
American football (4%). Athletes were between the ages of 18 and 24 (64%), 25 and 34 
(24%), 35 and 44 (4%) and undisclosed (8%) and were of differing competitive levels with 
23% competing at club level, 32% county, 26% national, 10% international and 9% 
undisclosed.  
Procedure.  
Athletes were asked to complete the 10 item SSBS reported in phase 3. Athletes were 
required to read and respond to each statement on a 6-point Likert-type scale ranging from 
strongly disagree (1) to strongly agree (6). All statements were scored in the same direction 
and total scores ranged from 10 to 60. 
Data analysis.  
Data were inputted into SPSS v22.0 and AMOS v22.0. Examination of data revealed 
that 16 respondents did not respond to any of the items on the scale and were thus deleted. A 
further 40 respondents were removed after examination of the data revealed they were 
disengaged (i.e. responses were coded identically for each item). A missing values analysis 
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indicated that, of a possible 2,652 data points, only 8 (0.17%) were missing from 8 
respondents (1.8%). Little’s MCAR test revealed data were missing completely at random (χ2 
= 25.775, df = 24, p = .365). Missing values were replaced using a multiple imputation model 
that generated five data sets with a maximum number of parameters set at 100. The average 
value of the missing data sets was used for subsequent analysis. 
Measurement model fit using CFA and the Maximum Likelihood procedure was 
examined using AMOS v22.0. Model fit was expressed as acceptable when the ratio between 
the χ2/df ranged between 1 and 3 (Kline, 2011). The overall fit of the model was also assessed 
with the RMSEA, SRMR, CFI, and TLI. Model fit was considered acceptable with values of 
RMSEA close to or less than .06, of SRMR close to or less than .08, and of CFI and TLI 
close to or greater than .95 (Hu & Bentler, 1999). The AIC and ECVI do not have a specified 
acceptable value, but the lower the value amongst competing models is considered to be the 
most parsimonious and most likely to be replicated by other samples. Finally, to determine 
the significant parameter estimates, t-values were calculated by dividing the factor loading by 
the standard error. t-values were classified by 1.96 and 2.56 as significant at the .05 and .01 
level respectively (Suhr, 2006).  
As per published recommendations (Bentler, 2006), each hypothesised relationship 
between the latent factor and factor loadings was a free parameter, with the exception of a 
single item that was randomly assigned to unity to define the scale of the factor. 
4.5.3 Results 
Mean scores on the 10 item SSBS were 31.69 ± 9.59. Scores ranged from 11 to 59, 
with increasingly higher scores representing increasingly favourable beliefs relating to sports 
supplements. 
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Confirmatory factor analysis of a two-factor, 10 item model revealed inadequate fit 
(χ2/df = 3.832, RMSEA = .083; 90% CI = .068 to .098, p < .001, SRMR = .0731, CFI = .950, 
TLI = .934, AIC = 172.304, ECVI = 0.419). After examination of the scale it was suspected 
that a single-factor, unidimensional scale, might improve model fit. The second factor of 
three items was therefore removed and the CFA was performed once more.  
Confirmatory factor analysis of a single-factor seven item model indicated improved 
model fit (χ2/df = 3.239, RMSEA = .074; 90% CI = .05 to .098, p = .047, SRMR = .0309, CFI 
= .978, TLI = .968, ACI = 73.349, ECVI = 0.178). However, modification indices revealed 
large overlap between item 1 (‘Supplements improve my training’) and item 7 (‘Training 
increases the need for supplements’). As the items related to similar theoretical constructs, 
item 7 was removed.  
Confirmatory factor analysis on a single-factor six item scale indicated acceptable 
loadings for all indices (χ2/df = 2.894, RMSEA = .068; 90% CI = .038 to .099, p = .146, 
SRMR = .0246, CFI = .987, TLI = .978, AIC = 50.045, ECVI = 0.122). The results of the 
final model are summarised in Table 4.3 and factor loadings with standard errors are shown 
in Figure 4.1.  
4.6 Phase 5 
4.6.1 Aim 
The aim of phase 5 was to demonstrate the construct validity of the SSBS by 
examining the relationships between SSBS scores and self-reported supplement use.  
4.6.2 Method 
Murphy and Davidshofer (1988) argue that, while in the past validation strategies 
were distinct, that is information relating to predictive, discriminant, concurrent, and 
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Table 4.3 
 
Factor structure matrix of the 10 item scale derived from confirmatory factor analysis 
 
Item no. Items Factor loading t-value 
1 Supplements improve my performance .652 13.306 
2 Supplements are necessary for me to be competitive .966 12.880 
3 Supplements improve my confidence .755 11.615 
4 My chances of winning improve when I use supplements .463 10.289 
5 Supplements help me realise my potential .581 11.173 
6 Supplements improve the quality of my training .868 12.400 
Figure 4.1. Single-factor model. Note. All parameters standardised and 
significant (p < .001) 
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construct validity would be presented separately, researchers increasingly recognise that all 
validation procedures can be grouped under the heading of construct validity. 
Participants  
Sport Supplements Beliefs Scale scores collected from participants (n = 468) in phase 
4 were used in this phase of the study. Participants were also asked to respond to a series of 
questions relating to the range of supplements they used and to the frequency of use.   
Data analysis  
Linear regression examined relationships between SSBS scores and both the total 
number of sport supplements used and the frequency of use (i.e. daily, weekly, monthly and 
never). Mann-Whitney U tests compared total SSBS scores of users and non-users of sport 
supplements followed by discriminant function analysis to determine the degree to which 
SSBS scores might predict which athletes fell into one of two groups; users of supplements 
and non-users of supplements. Finally, Cronbach’s alpha was calculated to provide an 
indication of internal consistency.  
4.6.3 Results 
A Kolmogorov Smirnov test indicated that data violated normality (p < .05). Linear 
regression indicated significant relationships between SSBS scores and supplement use. 
Specifically, higher SSBS scores were significantly associated with the use of a greater 
variety of supplements (β = 0.534, p < .001, r2 = .285). Likewise, higher SSBS scores were 
significantly related to higher frequency of supplement use (β = -0.517, p < .001, r2 = .267).  
Differences in SSBS scores between users and non-users were analysed using a 
Mann-Whitney U test. Users reported significantly higher SSBS scores than non-users (mean 
differences = 6.37 ± 0.5, U = 8,357, p < .001; Figure 4.2). Discriminant function analysis  
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indicated that SSBS scores correctly predicted 76% of sport supplement users and 66% of 
non-users (Wilks Lambda = 0.760 χ2 = 110.988, p < .001). Tests of equality between groups 
were significant (p < .001). Cronbach’s alpha of .891 indicated good internal consistency of 
the six item scale. 
4.7 Discussion 
The gateway hypothesis posits that athletes who use supplements are more likely to 
use banned substances. Given the demand characteristics inherent in any attempt to assess 
beliefs about banned substances, a measure of beliefs relating to supplements might have 
utility in both predicting at-risk athletes and in verifying the effectiveness of anti-doping 
interventions.  
This chapter reported the empirical five-stage development of the Sports Supplements 
Beliefs Scale (SSBS; Appendix 8), in which multiple methods were used to generate, 
synthesise, evaluate and test increasingly more parsimonious versions of the instrument. 
Figure 4.2. Differences in Sports Supplements Beliefs Scale 
(SSBS) scores between users and non-users. Note. **p = .001 
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From this, a brief, single-factor measure with six items emerged: “Supplements improve my 
performance,” “Supplements are necessary for me to be competitive,” “Supplements improve 
my confidence,” “My chances of winning improve when I use supplements,” “Supplements 
help me realise my potential,” and “Supplements improve the quality of my training.” These 
six items formed a theoretically and statistically coherent scale relating to athletes’ beliefs 
about the effects of supplements on their own performance and performance related 
constructs. One item was eliminated in phase 4 (“training increases the need for 
supplements”) to help improve model fit. Some authors have recommended that rather than 
deleting an item it should be covaried with overlapping items (Terry et al., 2003), however, it 
was decided that it should be dropped because of its close similarity with another item on the 
scale (“supplements improve the quality of my training”). Overall, the resultant six-item scale 
appears to tap into athletes’ personal perspective on the effects of supplements on themselves. 
The SSBS includes six, positively worded items. It has previously been suggested that 
the validity of a questionnaire is improved when both positive and negative worded items are 
included (Burke, 1999; Kam, 2017; Worcester & Burns, 1975). Some authors have suggested 
that without negatively worded items, respondents may act acquiescently and generally agree, 
rather than disagree with items (Barnette, 2001; Roszkowski & Soven, 2010). However, 
previous research has reported that negative worded items often perform poorly in single-
factor (Roszkowski & Soven, 2010; Woods, 2006) and multi-factor models (Lane et al., 
2009). Lane et al. (2009) suggested that poor factor loading is often demonstrated for 
negative worded items, which can be attributed to carelessness on the respondent’s behalf and 
not reading the item correctly. Van Sonderen, Sanderman, and Coyne (2013) argued that 
including negative worded items can lead to increased difficulty in answering the 
questionnaire and introduces further bias. Lane et al. (2009) also argued that negative worded 
items often perform poorly on athletic samples. Lane, Sewell, Terry, Bartram, and Nesti 
(1999) and Lane et al. (2009) both reported weak factor-loadings for reverse scoring items in 
 
 
86 
 
the Competitive State Anxiety Intevorty-2 (Martens, Vealey, & Burton, 1990) and the 
Emotional Intelligence Scale (Schutte et al., 1998), respectively. For these reasons, and given 
that the target audience in this research programme is athletes, no negative wording items 
were included in the SSBS. 
Scores on the SSBS were associated with both frequency and volume of supplement 
use among 412 athletes. Given that sport supplement use is reported to be associated with an 
increased likelihood of doping, it is reasonable to suggest that high scores on the SSBS might 
predict athletes at risk of doping. This has several implications for intervention and 
educational efforts targeting the use of sport supplements and doping behaviours. For 
example, National Anti-Doping Organisations (NADO) typically pursue a multifaceted 
approach in their education methods, where the aim is to cover a range of topics such as the 
values of sport, the testing procedures, medications and therapeutic use exemption forms (e.g. 
WADA’s Athlete Learning Program about Health and Anti-Doping, UKAD’s 100% me 
programme and USADA’s true sport community-based movement). This often leaves only a 
small portion of the intervention to the discussion of sport supplements. For an athlete that 
scores high on the SSBS, a greater proportion of time may be needed to discuss issues related 
to sport supplement use. To improve the effectiveness and efficiency of the educational 
interventions delivered, the NADO could instead target athletes who score high on the SSBS 
and provide a more bespoke and in-depth intervention. Targeting the behaviour at this stage 
could also improve the effectiveness of anti-doping education. As the consumption of sport 
supplements arguably creates a psychological and physiological need for further, stronger 
substances of the same type, athletes experimenting with chemically active supplements may 
experience no ill effects. This would appear to contradict and undermine the strong negative 
publicity directed at doping. The advice and education athletes receive in the future may then 
become less persuasive and could increase rather than reduce the number of athletes moving 
onto doping substances, undermining the interventions in place by WADA, International 
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Federations (IF) and NADOs. Educating athletes about sport supplementation may therefore 
help to prevent athletes from progressing to doping substances and improve the interventions 
WADA, IF’s and NADO’s implement. 
The SSBS could be used within the battery of self-report instruments researchers use 
to understand athletes’ doping behaviours. Doping is often viewed as a complex and 
multifaceted psychological phenomenon, where beliefs, desires, intentions, attitudes and 
perceptions of others, for example, intertwine and determine whether an athlete will decide to 
use banned substances or not (Hauw & McNamee, 2015). Researchers generally agree that 
there is no single factor that predisposes a person to use banned substances and the gateway 
hypothesis is just one factor to consider within the realm of anti-doping interventions. For 
future research aiming to understand and unravel the influences of doping behaviours, the 
SSBS could be used alongside other instruments to generate a more complete picture of 
doping behaviours. Future work will need to evaluate the predictive validity of the SSBS by 
reporting the degree to which scores relate to future supplement use by athletes not currently 
using supplements, and while problematic, to doping behaviours. Future work should also 
aim to demonstrate the construct validity of the measure by assessing pre-post changes in 
SSBS scores following interventions designed to reduce athletes’ reliance on and confidence 
in sports supplements. Interestingly, the SSBS will also have utility in research investigating 
the effectiveness of sport supplements. Specifically it has been reported that the performance 
of athletes with strong beliefs in the effectiveness of sports supplements were more likely to 
improve following the administration of both supplements and placebos than the 
performances of those with weaker beliefs (Beedie & Foad, 2009).  
 In conclusion, the SSBS is a valid and reliable measure for understanding athletes’ 
beliefs about sport supplements. In the context of this research programme, this measure is 
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used in the studies presented in subsequent chapters to allow the researcher to assess the 
influence of a placebo intervention on athletes’ beliefs towards sport supplements.  
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Chapter Five  
 
INVESTIGATING THE MAGNITUDE AND MODERATORS OF THE 
PLACEBO AND NOCEBO EFFECT ON REPEAT SPRINT 
PERFORMANCE 
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5.1 Introduction 
Placebo effects have been extensively studied in sport, with a systematic review 
(Beedie & Foad, 2009) reporting that placebo treatments can exert a significant effect on 
sports performance. Recently, Ross et al. (2015) reported a 1.2% improvement in 3 km 
running time-trial performance when participants self-administered saline injections believing 
it to be a performance enhancing substance. Likewise, Saunders et al. (2017) reported that 
mean power output improved by 3.7% among cyclists deceptively administered a placebo 
when they believed they had ingested caffeine.  
While there is empirical support for the potential role of the placebo effect in sports 
performance, there is less evidence for the nocebo effect. Arguably the first study of the 
nocebo effect in sport was conducted by Beedie et al. (2007). These authors reported that 21 
participants who believed they had ingested a placebo (a capsule described as a beneficial 
sport supplement), ran progressively faster compared to baseline. Likewise, 21 participants 
who believed they had ingested a nocebo (a capsule described as a supplement likely to 
impair performance), ran progressively slower compared to baseline. Findings highlighted the 
potentially significant impact of positive and negative expectations on sports performance.  
However, the study in question (Beedie et al., 2007) lacked a no-treatment control. It 
is therefore problematic to estimate the true relative magnitude of placebo and nocebo effects 
reported; changes in performance could be attributed to statistical or methodological artefacts 
such as regression to the mean or spontaneous improvements/decrements in performance. It 
is also problematic from this uncontrolled study to discern whether actual effects were all 
positive, all negative, or whether both placebo and nocebo effects occurred. As a result, the 
reported magnitude of either the nocebo or placebo effect might have been overestimated. 
Further, while the sample of 42 was relatively large for an intervention study in sport, it was 
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too small to facilitate reliable identification of any variables that might have been associated 
with the placebo and nocebo responses observed.  
In most studies of the placebo/nocebo effect in sport, the standard deviation of the 
dependent measure is greater in experimental conditions than at baseline (e.g. Beedie et al., 
2007; Beedie et al., 2006; de la Vega et al., 2017; Foad et al., 2008). This suggests that, even 
if a mean placebo effect is observed, there is considerable inter-individual variability in 
response to treatment. Few studies have attempted to identify the variables related to placebo 
effects, and those that have are arguably methodologically unsatisfactory. For example, 
Beedie et al. (2008) identified a possible link between placebo responding and personality 
factors, but the sample size was too small for their findings to be considered reliable. In fact, 
the small sample sizes of nearly all studies of the placebo effect in sport has precluded the 
reliable investigation of factors that might be associated with placebo responding (see Table 
2.1, p. 25). If knowledge and understanding of the placebo and nocebo effects is to progress 
beyond simple description, there needs to be a better understanding of the relevant 
antecedents and mechanisms.  
This study therefore aims to extend Beedie et al. (2007) study by 1) including a no-
treatment control to improve the precision of determining the magnitude of placebo and 
nocebo effects of a purported sport supplement and 2) using a sufficiently large sample to 
reliably identify factors that might be associated with observed placebo and/or nocebo 
responses.  
5.2 Methods 
5.2.1 Design 
The placebo and nocebo interventions used in this study required the deceptive 
administration of an inert capsule delivered to members of teams in their usual team 
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environment. A randomised controlled trial design was therefore used to minimize cross-
contamination between experimental and control treatments. Participants completed a pre-
experimental questionnaire relating to sport supplementation before performing 5 × 20 m 
repeat sprints with 30s recovery at baseline. Following Beedie et al’s (2007) original design, 
participants in the positive belief treatment (n = 288) were deceptively administered an inert 
capsule described as a potent supplement which would improve sprint performance, while 
participants in the negative belief treatment (n = 232) were deceptively administered an inert 
capsule described as a potent supplement which would negatively affect sprint performance. 
However, extending the original study, no-treatment control participants (n = 192) received 
neither instruction nor placebo. Twenty minutes following the administration of the capsules, 
participants completed the experimental condition, repeating the 5 × 20 m sprints.  
5.2.2 Participants 
Participants were recruited in person from sports clubs. Convenience sampling was 
used, where athletes from a range of sports were invited to participate in the study. Seven 
hundred and twelve competitive athletes from 43 different teams (number of athletes in each 
team: median = 14; range = 8 to 40) were initially recruited to the study from sports clubs. 
Participant demographics are presented in Table 5.1. All participants were aware that their 
involvement in the study was voluntary and that all data collected would be treated as 
confidential. Ethical approval was granted by the Institutional Research Ethics Committee. 
Participants gave written informed consent once they had read the participant information 
sheet (Appendix 9). 
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Table 5.1 
 
Demographics of participants between treatments 
 
  
    Positive Negative Control Overall 
n = 288 232 192 712 
      
Gender (%) Male 83.1 76.9 71.0 78.0 Female 16.9 23.1 29.0 22.0 
      
Age (%) 
18 to 24 66.7 65.0 79.0 69.4 
25 to 34 29.6 30.0 18.8 26.8 
35 to 44 3.7 5.1 2.3 3.8 
      
Sport (%) 
Rugby Union 46.2 42.7 22.3 39.0 
Football 42.9 36.9 44.1 41.3 
Field Hockey 5.3 8.9 2.8 5.8 
Other 5.6 11.6 30.7 13.9 
      
Ability (%) 
Club 25.5 35.4 21.1 27.5 
County 39.9 38.8 30.4 37.0 
Regional 25.9 19.6 32.7 25.7 
National 8.7 6.2 15.8 9.8 
      
Intention to use sport 
supplements (%) 
Not intending 23.9 33.5 35.6 30.0 
Undecided 21.6 18.9 18.1 19.8 
 Intending 54.5 47.6 46.3 50.2 
      
Use of supplements (%) Yes 51.1 50.9 52.7 51.5 No 48.9 49.1 47.4 48.5 
      
Frequency of 
supplement use (%) 
Daily 24.1 26.6 26.2 25.5 
Weekly 22.6 21.0 24.4 22.5 
Monthly 4.4 3.3 1.8 3.4 
Never 48.9 49.1 47.6 48.6       
Mean ± SEM 
Years training 10.77 ± 0.38 10.94 ± 0.59 9.68 ± 0.45 10.68 ± 0.24  
Hours per week 
training 6.13 ± 0.25 5.93 ± 0.25 5.84 ± 0.30  5.9 ± 0.15 
Amount of 
supplements used 1.14 ± 0.10 1.11 ± 0.10 1.20 ± 0.13 1.09 ± 0.06 
Note. SEM = standard error of the mean 
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5.2.3 Measures 
5.2.3.1 Pre-experimental questionnaire 
All participants were asked to complete a pre-experimental questionnaire detailing sex, 
age, sport played and competitive level (club, county, regional or national; Appendix10). 
They were asked to indicate whether they used sports supplements (yes or no), the total 
number of supplements used, and the frequency of use (daily, weekly, monthly or never). 
They were also asked to indicate their agreement with a statement of their intention to use 
sport supplements in the next three months on a 6 point Likert-type scale anchored at strongly 
disagree (1) through to strongly agree (6).  
5.2.3.2 Repeat sprint performance 
Whereas Beedie et al. (2007) used a 3 × 30 m repeat sprint protocol, Schimpchen, 
Skorski, Nopp and Meyer (2016) reported that four or more sprints should be used to 
decrease the typical error and improve the precision of estimating true changes in 
performance. Furthermore, the majority of sprinting in team sports events occurs over 
relatively short distances (i.e. <30 m; Cross et al., 2015) and short durations (i.e. <4 seconds; 
Spencer, Bishop, Dawson, & Goodman, 2005). For these reasons, participants were asked to 
complete five 20 m maximal intensity repeat sprints with 30 seconds recovery between each 
sprint. Sprint time was measured using an automated, single-beam photocell, light gate 
system (Smartspeed ProTM, Fusion Sport Inc., Australia). Single-beam light gate systems are 
the most common method for measuring sprint performance and have been shown to have 
good reliability (Haugen & Buchheit, 2016).  
5.2.3.3 Belief manipulation 
During the 20-minute recovery period between baseline and experimental conditions, 
participants in the positive- and negative-belief treatments were given a capsule described as 
a potent sport supplement, “inorganic nitrate.” Similar to Beedie et al. (2007), the positive-
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belief treatment participants were given two red and white, size 1 (20 mm), gelatine capsules 
containing 200 mg of cornflour (Sainsbury’s, London UK) and informed that the “inorganic 
nitrate” would improve both endurance and repeat sprint performance. Negative-belief 
treatment participants were given two red and black, size 1 (20 mm), gelatine capsules 
containing 200 mg of cornflour and informed that the inorganic nitrate would improve 
endurance but have a negative effect on sprint speed. The effectiveness of the belief 
manipulation was assessed during a debrief immediately following the experimental trials, at 
which point the true nature of the study was revealed. Participants were asked to respond on a 
10 point Likert-type scale, how much they believed the treatment influenced their 
performance (1 = no influence to 10 = high influence).  
5.2.4 Procedure 
Testing was performed at 43 different training facilities habitually used by the teams 
recruited to the study. All data for each participant were collected on one day to minimize 
meteorological and biological variation. Teams were randomised to the three treatments (i.e. 
positive, negative and control) using a computer generated cluster programme (allocation 
ratio 1:1:1). To reduce potential confounding, only one team per club were permitted to take 
part in the study. All treatments were conducted on separate days and at separate sites to 
maintain the experimental blind.  
Participants completed the sprints in footwear and clothing suitable for high intensity 
exercise, and were encouraged to perform their standard warm-up. They began each sprint in 
a stationary position, ~50 cm behind the first light gate. They were instructed not to rock back 
and forth prior to the sprint, but were permitted to start the sprint in any position (e.g. split-
stance or crouch start), and replicated this for each sprint. Each sprint was started by a green 
LED, which would flash up on the photocell. Participants were encouraged to sprint as fast as 
possible for the full 20 m, with times recorded to the nearest 1/100th of a second. Participants 
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were given thirty seconds to jog back to the start position and begin the next sprint. This 
process was continued until each participant had completed five sprints.  
After the baseline condition, participants in the positive- and negative-belief treatments 
received the capsules and the belief manipulation. All participants then completed a 20-
minute recovery consisting of light exercise to minimize the search for physiological 
symptoms associated with the intervention (Foad et al., 2008), before commencing the 
experimental condition in the same manner as the first. The total duration of the repeat sprint 
protocol, including recovery, was less than 30 minutes per participant. On completion, 
participants were debriefed about the true nature of the study in line with American 
Psychological Association guidelines for deceptive research (American Psychological 
Association, 2017). 
5.2.5 Data analysis 
Data were inputted into SPSS version 23.0 (IBM, Armonk, NY, USA) and tested for 
homogeneity of variance, normal distribution and anomalies. Inspection of the data indicated 
that 55 participants (8%) did not complete the experimental condition (positive-belief 
treatment n = 20; negative-belief treatment n = 16; control n = 19). In addition, data values 
that exceeded 2.5 times the standard deviation were identified as extreme outliers (Leys, Ley, 
Klein, Bernard, & Licata, 2013). Thirty participants (4%) were identified as extreme outliers 
(positive-belief treatment n = 7; negative-belief treatment n = 7; control n = 16) and were 
subsequently removed from further analysis (Judd, McClelland, & Ryan, 2011). Data for the 
remaining sample of 627 participants (positive-belief treatment n = 261; negative-belief 
treatment n = 209; control n = 157) were entered into subsequent statistical analyses.  
Further inspection of data relating to intentions to “use sport supplements in the next 
three months” statement revealed unequal responses in Likert-type scale ratings. For 
example, in the positive-belief treatment, 73 participants “agreed” to the statement whereas 
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only 9 participants “slightly disagreed.” This was similar in negative-belief and control 
treatments. Given the unequal responses between scale ratings, responses were categorised 
into three groups. Those scoring 1 and 2 were grouped as not intending, 3 and 4 as undecided, 
5 and 6 as intending. 
One-way Analysis of Variance (ANOVA) and chi-square (χ2) tests were used to 
compare continuous (years training, hours per week training and number of supplement used) 
and categorical (sex, age, sport, ability, supplement use, frequency of supplement use and 
intention to use supplements) variables between treatments, respectively.  
Sprint times for each condition (i.e. baseline and experimental) and treatment (i.e. 
positive, negative and control) were inputted into Hopkins (2015) reliability spreadsheet. 
Data were log transformed to reduce non-uniform errors and the intra-class correlation (ICC) 
provided estimates of reliability. The precision of ICC was interpreted as extremely high = 
.99; very high = .90; high = .75; moderate = .50; low = .20 (Hopkins, 2015).  
Hopkins, Hawley and Burke (1999) suggest that research investigating athletic 
performance should report outcome as a percentage change from baseline. Sprint times were 
therefore converted to the proportion of the first sprint speed, expressed as a percentage. 
Differences between participant’s average performance for each condition (i.e. performance 
average for baseline [sprints 1 to 5] and experimental conditions [sprints 6 to 10]), and the 
difference in the fastest sprint trial in each condition (i.e. fastest person sprint at baseline 
minus fastest person sprint at experimental) were calculated. 
Repeated measures ANOVA identified differences in sprint performance between 
each condition, with treatment included as a between-subject factor. Greenhouse-Geisser 
epsilon was reported where sphericity was violated, and post-hoc LSD tests were conducted 
where a significant interaction was observed. Point-Biserial correlations (rpb) were used to 
assess the relationship between performance and categorical variables (i.e. sex, age, ability, 
sport supplement use, frequency of sport supplement use, intention to use sport supplements, 
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belief manipulation scores). Variables that correlated significantly with performances were 
analysed further using repeated measures ANOVA and Multivariate ANOVA (MANOVA). 
Given the possibility that differences between treatments may reflect the large sample size 
and sampling variability (38), Cohen’s d (d) effect sizes were calculated. Differences between 
0.2 and <0.5 were interpreted as a small effect, between 0.5 and <0.8 as moderate, and ≥0.8 
as large (Cohen, 1992). Data are presented as mean ± standard error of the mean (SEM), with 
statistical significance accepted at p ≤ .05. 
5.3 Results 
5.3.1 Participant demographics 
No significant differences were observed between treatments for number of years 
training (F2,573 = 2.072, p = .127), hours per week training (F2,580 = 0.403 p = .669), sex (χ2 = 
5.28, p = .071), supplement use (χ2 = 2.32, p = .312), frequency of supplement use (χ2 = 6.50, 
p = .370) and intention to use supplements (χ2 = 4.65, p = .098). Differences between 
treatments were observed for age (χ2 = 21.99, p = .001), ability (χ2 = 21.69, p = .001) and 
sport played (χ2 = 225.76, p < .001). Covariate analysis, adjusting for the differences in 
categorical variables, revealed no effect on the outcome of the performance sprint data (p > 
.05). The results of the subsequent analyses are therefore reported with unadjusted covariate 
data. 
5.3.2 Reliability of sprint trials 
Baseline sprints (i.e. trials 1 – 5) were associated with very high reliability in the 
positive-belief treatment (ICC = .94), negative-belief treatment (ICC = .96) and control 
treatment (ICC = .90). Similar reliability coefficients were also observed for experimental 
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sprints (i.e. trials 6 – 10) in the positive-belief treatment (ICC = .94), negative-belief 
treatment (TE = .94) and control treatment (ICC = .94).  
The possibility that greater reliability was associated with fewer than 5 sprint trials 
was also investigated. If for example, reliability between sprint trials 1 – 4 or 1 – 3 are more 
reliable than 1 – 5, this could reduce the error and improve the chances of finding a true 
effect of the intervention on sprint performance. ICC’s were however, similar for trials 1 – 4 
(ICC range = .92 to .96) and 1 – 3 (ICC range = .93 to .96). Therefore, sprint trials 1 – 5 are 
reported in the subsequent analysis.  
5.3.3 Differences in baseline and experimental performance between treatments 
No between-treatment differences in performance were observed at baseline (F(2,624) = 
0.149, p = .861). However, between-treatment differences were observed in experimental 
trials (F(2,624) = 5.879, p = .001). In the negative-belief treatment, performance in 
experimental trials was worse than baseline (-1.42 ± 0.15%, p < .001, d = 0.56), and worse 
than performance in experimental trials in the positive-belief (-1.04 ± 0.28%, p < .001, d = 
0.34) and control treatments (-0.92 ± 0.31%, p < .001, d = 0.32). No differences were 
observed in performance in experimental trials between the positive-belief and control 
treatments (-0.07 ± 0.27%, p = .696, d = 0.02). Figure 5.1 illustrates the differences in 
performance for each condition between treatments.  
5.3.4 Correlations between performance and categorical variables 
Point-Biseral correlations revealed a significant relationship between participants’ 
intentions to use supplements and performance (mean performance in each condition rpb = 
.106, p = .012; fastest performance difference between conditions rpb = .101, p = .016).  
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No other significant relationships were observed between other categorical variables for 
mean performance in each condition (sex rpb = -.009, P = .819; age rpb = .006, p = 0.891; 
ability rpb = -.039, p = .353; use of supplements rpb = .071, p = .078; frequency of 
supplements rpb = between conditions (sex rpb = -.014, p = .723; age rpb = .005, p = .906; 
ability rpb = -.042, p = .318; use of supplements rpb = .075, p = .071; frequency of 
supplements rpb = -.062, p = .135; belief manipulation scores: rpb = .025, p = .677; fastest 
performance: rpb =.025, p = .677).  
5.3.5 Differences between baseline and experimental performance by supplement intention  
Further analysis using repeated measures ANOVA identified differences in 
participant’s repeat sprint performance in each treatment by intention to use sport 
supplements (i.e. not intending; n = 174; undecided; n = 112; and intending; n = 284). No 
differences between baseline and experimental conditions were observed for participants in 
the positive-belief treatment intending to use supplements (0.28 ± 0.14%, p = .886, d = 0.01). 
However, sprint performance worsened for participants in the positive-belief treatment who 
Figure 5.1. Mean performance in each condition between treatments. Note. *Baseline vs. 
Experimental for Negative-belief = p < .05; **Positive-belief and Control vs. Negative-
belief = p < .05. 
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were undecided about supplement use (-0.67 ± 0.36%, p = .039; d = 0.22), and not intending 
to use sport supplements (-0.64% ± 0.25, p = .036; d = 0.23; Figure 5.2A). No differences in 
sprint performance by intention to use supplements were observed in the negative-belief 
(Figure 5.2B) and control (Figure 5.2C) treatments (p > .05). 
5.3.6 Between-treatment differences in fastest performance by intention 
Differences in fastest sprint performance and intention to use supplements were 
analysed using MANOVA. The performance of participants intending to use supplements in 
the positive-belief treatment was better than the performance of participants in the negative-
belief (1.29 ± 0.37%, p = .001, d = 0.51) and control treatments (0.90 ± 0.41%, p = .029, d = 
0.33). The performance of participants not intending to use supplements in the negative-belief 
treatment was worse than control treatment (negative-belief vs. controls = -1.34 ± 0.48%, p = 
.005, d = 0.52). This trend was similar between the positive-belief and control treatment       
(-0.91 ± 0.45%, p = .060; d = 0.38). No differences were observed for participants’ 
undecided about supplement use between all three treatments (p > .05; Figure 5.3). 
5.3.7 Within-treatment differences in fastest performance by intention  
Differences in fastest sprint performance by intention to use supplements were 
observed in the positive-belief treatment (F(2,239) = 4.952, p = .008) but not in negative-belief 
(F(2,197) = 1.247, p = .290) or control treatments (F(2,131) = 0.637, p = .530). In the positive-
belief treatment, fastest sprint performance in experimental trials for participants not 
intending to use supplements decreased by -1.10% ± 0.30% from baseline, and for 
participants undecided about supplement use, by -0.64% ± 0.43%. However, the performance 
of participants intending to use supplements improved by 0.19% ± 0.24% between baseline  
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  Figure 5.2. Average performance in condition by each treatment separated by participants' 
intention to use supplements. A. Positive-belief treatment. Note. *Baseline vs. 
Experimental for those not intending to use supplements = p < .05; **intending to use 
supplements vs. not intending to use supplements = p < .05. B. Negative-belief treatment. 
Note. *Baseline vs. Experimental for those not intending, undecided and intending to use 
supplements = p < .05. C. No-treatment control. 
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and experimental conditions (Figure 5.3). In the positive-belief treatment, performance 
between baseline and experimental conditions also differed significantly between those  
participants intending to use supplements and those not intending to use supplements (1.29% 
± 0.38%, p = .003, d = 0.49). No other within-treatment differences in fastest sprint 
performance between baseline and experimental conditions were observed when classified by 
intention to use supplements (p > .05; Figure 5.3). 
5.4 Discussion 
This study aimed to examine the magnitude and moderators of placebo and nocebo 
effects on repeat sprint performance. Results showed a mean nocebo effect in repeat sprint 
performance across the sample, but no mean placebo effect when compared to a no-treatment 
control. This suggests that, while receiving a purported harmful supplement significantly 
impaired performance, receiving a purported beneficial supplement did not enhance it. This 
finding differs to those of Beedie et al. (2007) who reported significant placebo and nocebo 
effects in repeated sprinting.  
Figure 5.3.  Differences in fastest performance between conditions, grouped by intention 
to use sport supplements. Note. *Control vs. Positive-belief and Negative-belief = p < .05, 
**Positive-belief vs. Negative-belief = p < .05, †Positive-belief intention vs. Positive-
belief no intention = p < .05. 
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Although no mean placebo effect was observed, data from the positive-belief 
treatment did suggest that the performance of participants intending to use supplements 
improved to a greater degree in experimental trials than the performance of participants not 
intending to use supplements (d = 0.49, Figure 5.3). These improvements were also greater 
than those observed among participants of equivalent intention in the negative-belief (d = 
0.51) and control treatment (d = 0.33). Given that effect sizes >0.2 are considered potentially 
beneficial for sports performance (Hopkins, 2016), these improvements in repeat sprint 
performance are likely meaningful for athletes. Furthermore, the relationship between 
intention to use sport supplements and response to placebo in the positive-belief treatment is 
of particular importance, as it indicates that it is a predictor of the placebo effect and is not 
attributed to statistical or methodological artefacts. 
While intention to use supplements influenced the placebo response, this relationship 
was not shown for prior supplement use (rpb = .071, p = .078). There was however a strong 
relationship between intention to use supplements and prior supplement use (rpb = 0.666; p < 
.001). This suggests that intention to use supplements is associated with prior supplement use 
and may moderate an athlete’s response to a placebo intervention.  
The results of this study support the proposition that placebo responding is a learned 
phenomenon. Research has shown that placebo effects can be initiated via verbal instructions 
(creating an expectation of a drug; Kam-Hansen et al., 2014) and/or via repeat exposure to a 
drug with a subsequent placebo intervention mirroring the action of that drug (Benedetti et 
al., 2011). Previous experiences of a drug are therefore remembered, creating a memory of 
effective and ineffective treatments (Klinger, Colloca, Bingel, & Flor, 2014). This learning 
process is manifest in specific brain regions, with expectations and conditioning cues 
mediating and maintaining the turnover of, for example dopamine (Hall, Loscalzo, & 
Kaptchuk, 2015), and creating rewarding stimuli. On this basis, for a placebo responsive 
athlete, a placebo-induced improvement in performance is the result of verbal information 
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about the treatment (e.g. the suggestion that a supplement can improve performance) and/or 
cued or conditioning (e.g. repeated exposure to a real treatment that results in treatment-like 
effects even when the treatment is replaced by a placebo). Theoretically, the athlete recalls 
previous experiences and information about the effectiveness or ineffectiveness of the 
treatment, which shapes their subsequent intention to use it. This is perhaps one reason why 
athletes intending to use supplements are more likely to use these substances (Goulet et al., 
2010) and are arguably more likely to use other forms of performance enhancements.  
The finding that intention may influence the placebo effect has particular relevance to 
sports practitioners aiming to improve an athlete’s performance. Specifically, if 
improvements in performance following administration of a treatment (e.g. caffeine, sodium 
bicarbonate, β-alanine) are the result of both pharmacological and placebo effects (Beedie et 
al., 2015), but the athlete does not have a prior intention to use that treatment, it may not elicit 
a placebo response and the athlete may not fully benefit from the treatment. Ultimately, a 
treatment may be more effective when an athlete intends to use it than when they do not. 
Sport practitioners should therefore be aware of an athlete’s intentions towards a treatment 
prior to its administration, to facilitate the effectiveness of the treatment. This is also 
important in research, in which intentions towards a treatment could similarly influence 
outcomes.  
Any reference to the results of this study should take into account potential 
limitations. First, there was no control for the presence of others or social support (e.g. 
cheering from teammates) during the sprint trials, and this may have affected performance. 
Second, while participants were asked to report on a Likert-type scale from 1 to 10 the degree 
to which they believed the treatment influenced their performance, they were not specifically 
asked if they believed the information they were given. This therefore prevents assessment of 
the credibility of the belief-manipulation. Finally, the use of self-reported sport supplement 
use may not be reliable, as there may be differences between what athletes’ report and what 
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they actually think and/or do. However, given that previous studies have used expensive and 
complex techniques such as positron emission tomography (Atlas & Wager, 2014) and 
genotyping (Hall et al., 2012) to identify placebo responders/non-responders, a self-report 
measure could provide a cost-effective and practical alternative.  
In conclusion, the results of this study suggest that negative information about the 
effects of a supplement on repeat sprint performance impaired that performance (a mean 
nocebo effect), whereas positive information about the effects of supplement elicited no 
change (i.e. no mean placebo effect was observed). However, participants’ intention to use 
sport supplements influenced the direction and magnitude of subsequent placebo responses, 
with participants intending to use supplements more likely to respond to the positive 
intervention. The next step in this research programme is to understand the impact of the 
placebo intervention on athletes’ beliefs and intentions towards sport supplements and 
attitudes to doping. This study is presented in Chapter Six.  
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Chapter Six  
 
EFFECT OF A POSITIVE AND NEGATIVE BELIEF INTERVENTION ON 
ATHLETES’ BELIEFS AND INTENTION TOWARDS SPORT 
SUPPLEMENTS AND ATTITUDES TOWARDS DOPING   
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6.1 Introduction 
It has been proposed that athletes aware of placebo effects, or who have direct 
experience of them, may be less likely to use supplements and banned substances (Beedie, 
2007; Kalasountas et al., 2007; Maganaris et al., 2000; McClung & Collins, 2007). However, 
despite strong anecdotal evidence, this theory remains untested. The purpose of this study is 
to examine the impact of the placebo intervention described in Study 2 on participants’ 
beliefs and intentions towards sport supplements and attitudes to doping.  
In sport, use of banned performance enhancing substances is often referred to as 
doping. In the last decade, there has been a considerable increase in the understanding of 
psychosocial variables associated with doping (Ntoumanis et al., 2014). The Theory of 
Reasoned Action (TRA; Ajzen & Fishbein, 1975) and Theory of Planned Behaviour (TPB; 
Ajzen, 1985) are the most frequently used frameworks used to explain athletes’ doping 
behaviour (Chan, Hardcastle, et al., 2015). A central tenant of the TRA and TPB is the idea 
that a person’s intention is the most proximal determinant of behaviour (Kirby, Guerin, 
Moran, & Matthews, 2016), and this intention is influenced by their attitude and subsequent 
beliefs about the behaviour.  
While findings may vary by population group (e.g. male vs. females, elite vs. amateur 
athletes), there appears to be a consensus that the TRA and TPB largely explain an athlete’s 
decision to dope. For example, Barkoukis et al. (2013) reported that users of banned 
substances showed greater intentions to use these substances in the future than non-users 
(F(1,739) = 486, p < .001, η2 = 0.39), while Zelli, Mallia, and Lucidi (2010) reported that 
favourable attitudes towards doping predicted participant’s intention to use substances in the 
future (r2 = .31, p < .001). Similarly, Chan, Hardcastle, et al. (2015) reported that attitudes 
and beliefs about doping significantly influenced future doping intentions (p < .001).  
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Although this data has provided evidence to explain how variables such as intentions, 
attitudes and beliefs might predict future doping behaviours, there is a paucity of research 
utilising this understanding in interventions aimed at preventing doping. Two well-known 
interventions, the Athletes Training and Learning to Avoid Steroids (ATLAS; Goldberg et 
al., 1996) and the Athletes Targeting Healthy Exercise and Nutrition (ATHENA; Elliot et al., 
2004) programme, involve discussions about alternatives to doping and how to resist it. 
These discussions are assumed to increase participants’ knowledge about doping and are 
expected to empower them to resist doping. However, studies examining the effectiveness of 
these interventions have shown only small reductions in the number of participants reporting 
to use banned substances over a season or school year (Ntoumanis et al., 2014). Similar anti-
doping interventions have also reported that participants are more likely to use doping 
substances when they are educated about healthy alternatives to doping (e.g. nitrate rich 
beetroot juice instead of erythropoietin). Similar results have been shown by Jalilian, 
Allahverdipour, Moeini, and Moghimbeigi (2011) and Elbe and Brand (2016), both of whom 
reported increases in the likelihood of athletes doping following an intervention aimed at 
preventing it. From the available evidence, it is reasonable to suggest that interventions aimed 
at preventing banned substance use have been largely ineffective in reducing doping 
behaviour and in some cases, have increased the likelihood of athletes doping. 
A number of factors could explain this. Firstly, interventions often aim to influence 
athletes’ overall health-related behaviours and are not sufficiently focused on doping. The 
ATLAS and ATHENA interventions, for example, include information and activities about 
healthy and unhealthy eating, as well as use of alcohol, tobacco, marijuana and anabolic 
steroids. Secondly, ad hoc instruments are often used to identify changes in psychosocial 
variables associated with doping. These measures may not be sufficiently accurate or 
sensitive to identify changes following the intervention. Thirdly, participants’ intentions prior 
to the study may already be low making it difficult to identify changes following the 
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intervention. Finally, if an athlete admits to doping, they could be banned from competition 
for up to four years. Even an athlete that is not doping but who is tempted to do so might be 
reluctant to disclose this. Future interventions aimed at preventing doping behaviours must 
therefore recognise and address these challenges if such interventions are to be effective. 
In a recent meta-analysis, Ntoumanis et al. (2014) reported that doping is significantly 
associated with non-banned substance use such as sport supplements. One explanation for 
this association is the gateway hypothesis, which posits that the use of softer drugs can lead 
to harder ones (Kandel, 1975). Targeting an athlete’s use of sport supplements as opposed to 
banned substances might therefore constitute a legitimate doping intervention, and one that 
facilitates less problematic evaluation of its effectiveness, given that it is predicated on the 
use of supplements and not banned substances. 
Evidence suggests that the effectiveness of sport supplements may be influenced via 
the placebo effect (Beedie & Foad, 2009). It has been proposed that athletes aware of this 
phenomenon, or who have direct experience of it, may be less likely to use supplements and 
banned substances (Kalasountas et al., 2007; Maganaris et al., 2000; McClung & Collins, 
2007). The idea underpinning this proposal is that an athlete aware of the placebo effect 
might also recognise that this significant psychological contribution to the effectiveness of a 
supplement is something that they may be able to achieve through other means, such as 
mental preparation and psychological skills training. If such an athlete is less likely to use 
supplements, the gateway hypothesis predicts that the athlete is theoretically also less likely 
to use banned substances.  
The aim of this study was to understand the effect of a placebo intervention on 
athletes’ beliefs and intentions towards sport supplements and attitudes to doping. Study 2 of 
this research programme reported the effect of a positive (placebo) and negative (nocebo) 
intervention on repeat sprint performance among a large sample of athletes. This study 
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reports the effects of this intervention on participants’ beliefs and intentions towards sport 
supplements and attitudes to doping.  
6.2 Method 
6.2.1 Design  
A three-group, randomised intervention design was used. Intentions to use sport 
supplements, attitudes to doping and beliefs about sport supplements were assessed pre- and 
immediately post-treatment. In this study, the term treatment refers to the specific 
experimental condition to which the participant was allocated - positive, negative or control - 
while intervention refers to the entire process, including the subsequent debrief (below). 
6.2.2 Participants 
 Of the 627 participants that completed the placebo intervention outlined in Study 2, 64 
(10.11%) did not complete any pre and post-treatment measures. A sample size of 563 
remained in this study (Table 6.1). All participants provided written informed consent prior to 
participation (Appendix 9) and were informed they could withdraw from the study at any 
time. Ethical approval for the study was granted by the Faculty Research Ethics Committee at 
Canterbury Christ Church University. 
6.2.3 Measures 
Pre- and post-treatment, participants completed a bespoke single item question 
indicating their intention to use sport supplements, the Performance Enhancement Attitude 
Scale (PEAS; Petróczi, 2006) and the Sports Supplements Beliefs Scale (SSBS; see Study 1). 
To further understand athletes’ experience of the treatment, and the effectiveness or 
otherwise of the treatment on their decision to use sport supplements, participants in positive-  
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Table 6.1 
 
Demographics of participants between treatments 
 
 Positive Negative Control Overall 
n = 225 199 139 563 
Gender (%) Male 83.3 75.5 79.1 79.6 
Female 16.7 24.5 20.9 20.4 
Age (%) 18 to 24 66.9 63.1 83.1 69.6 
25 to 34 28.9 31.5 14.2 26.1 
35 to 44 4.1 5.4 2.7 4.2 
Sport (%) Rugby Union 49.4 33.5 24.2 42.0 
Football 41.8 38.5 35.3 39.1 
Field Hockey 2.7 7.7 3.3 4.5 
Other 6.1 9.6 35.3 14.3 
Ability (%) 
Club 22.5 35.5 22.2 26.9 
County 41.1 38.6 34.0 38.5 
Regional 27.5 19.8 27.8 25.0 
National 8.9 6.1 16 9.7 
Intention to use 
sport supplements 
(%) 
Not intending 25.5 34.8 34.1 30.8 
Undecided 21.3 18.2 17.4 19.3 
Intending 53.1 47.0 48.5 49.9 
Mean ± SEM 
Years training 10.70 ± 0.37 10.87 ± 0.42 9.68 ± 0.45 10.63 ± 0.25 
Hours per week 
training 6.17 ± 0.25 5.90 ± 0.25 6.23 ± 0.30 6.20 ± 0.16 
PEAS 10.67 ± 0.27 10.37 ± 0.30 10.20 ± 0.36 10.46 ± 0.18 
SSBS 18.47 ± 0.41 18.58 ± 0.52 18.57 ±0.61 18.66 ± 0.29 
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and negative-belief treatments were asked to respond to a series of open-ended questions. 
6.2.3.1 Intention to use supplements 
Participants were asked to respond on a scale from 1 (Strongly disagree) to 6 
(Strongly agree) how much they agreed with the following statement: “Over the next three 
months I think I will use sport supplements.” Assessing participants’ intentions towards the 
use of performance enhancing substances using single item rating scales has been used in 
previous research (e.g. Conner, Kirk, Cade, & Barrett, 2001; Lazuras, Barkoukis, Rodafinos, 
& Tzorbatzoudis, 2010; Lucidi et al., 2008; Mallia et al., 2016). Similar to Study 2, those 
scoring 1 and 2 were grouped as not intending, 3 and 4 as undecided, 5 and 6 as intending. 
6.2.3.2 Attitudes toward doping 
Participants were asked to complete the PEAS (Petróczi, 2006) which assesses 
general doping attitudes on a six-point Likert-type scale (1 = Strongly disagree to 6 = 
Strongly agree; Appendix 11). The PEAS consists of 17 items, with statements including 
“Doping is necessary to be competitive” and “The risks related to doping are exaggerated.” 
For the current sample, internal reliability was good (α = .90).  
6.2.3.3 Beliefs about sport supplements 
Participants were asked to complete the SSBS, which assesses athletes’ beliefs about 
sport supplements. The SSBS consists of six items measured on a Likert-type scale ranging 
from strongly disagree (1) to strongly agree (6). An example item is “Supplements improve 
my performance.” Previous use of this scale indicates that higher scores reflect greater beliefs 
in the effectiveness of sport supplements, and the scale has shown good internal consistency 
(α = .89; see Study 1). Similar reliability coefficients were evident in the current sample (α = 
.91). 
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6.2.3.4 Open-ended questions 
Qualitative responses to open-ended questions allowed participants to expand on their 
intentions, attitudes and beliefs towards sport supplements following the treatment (Appendix 
12). Participants were asked to respond to questions about the placebo effect and if it had any 
influence on their beliefs towards sport supplements, how much they believed sport 
supplements are influenced by the placebo effect, and if knowledge of the placebo effect 
influenced their decision to use sport supplements.  
6.2.4 Procedure 
Participants were asked to complete the battery of questionnaires before being 
randomised to one of three treatments: positive-belief (n = 225), negative-belief (n = 199), or 
no-treatment controls (n = 139). Participants then performed the repeat sprint protocol 
outlined in Study 2, which involved participants performing two sets of 5 × 20 m repeat 
sprints as fast as possible with ~30 seconds of recovery. In the 20 minutes between sets, 
positive- and negative-belief participants were given two capsules and informed it would be 
beneficial or harmful to performance respectively. No-treatment controls were told nothing 
and given nothing. Results of the sprint performance data are reported in Study 2. 
Following the performance measure, participants in the positive- and negative-belief 
treatments were debriefed about the true purpose of the study and informed as to the results 
of the sprints. During this debrief, they were encouraged to think about their own 
performance, and whether this was influenced via a placebo effect. Participants were 
provided with details of research that previously reported placebo effects in sport and 
exercise, and were informed that the effectiveness of sport supplements may be influenced by 
the placebo effect. A question and answer session followed, with participants encouraged to 
critically examine the need to use sport supplements, and to consider the role of placebo 
effects. Control participants were not shown the results of the sprints and received no 
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information about placebo effects in sport and exercise. Participants in all treatments then re-
completed the pre-treatment measures, while participants in the positive- and negative-belief 
treatments completed additional open-ended, post-treatment questions. 
6.2.5 Data analysis 
Before the main statistical analyses, Confirmatory Factor Analysis (CFA) using 
AMOS 24.0 was used to test the factorial validity of the SSBS and the PEAS. In regards to 
the PEAS, five other versions have been suggested to have better model fit than the original 
17 item version. Gucciardi et al. (2010) used an 11 and 8 item version, Vargo et al. (2014) an 
8 item, Elbe and Brand (2016) a 6 item and Gucciardi et al. (2011) a 5 item. All versions of 
the PEAS scale were inputted into the analysis to test the factorial validity of each version of 
the PEAS. To assess model fit, Chi-square (χ2), Tucker-Lewis Index (TLI), Comparative Fit 
Index (CFI), Root-Mean-Square Error of Approximation (RMSEA), Akaike Information 
Criterion (AIC) and the Expected Cross-Validation Index (ECVI) were used. Hu and Bentler 
(1999) suggest that good model fit yields values close to or greater than .95 for CFI and TLI, 
and values close to, or lower than .06 for RMSEA. The RMSEA 90% confidence intervals 
were also assessed to assist in interpreting point estimates. The AIC and ECVI do not have a 
specified acceptable value, but the lower the value amongst competing models is considered 
to be the most parsimonious.  
One-way Analysis of Variance (ANOVA) and Chi-square (χ2) tests were used to 
compare continuous (i.e. years training, hours per week training, PEAS, SSBS) and 
categorical (i.e. sex, age, ability, intention to use supplements) variables between treatments, 
respectively. To identify mains effects of the intervention, repeated measures ANOVA were 
conducted. Given that there may be “floor effects” with participants reporting low intentions 
prior to the beginning of the intervention (Backhouse et al., 2016; Ntoumanis et al., 2014), 
participants were divided by prior intentions to use sport supplements (i.e. not intending, 
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undecided and intending). A 2 (pre and post) × 3 (intention, attitude and belief) × 2 
(intervention × pre-intention) repeated measures ANOVA was therefore performed. The 
Greenhouse–Geisser epsilon was reported when the sphericity assumption was violated and 
the LSD post-hoc analysis conducted to examine differences between means of significant 
differences and interactions. Cohen’s d was calculated to determine effect sizes (d) of the 
mean differences and interpreted as 0.2 to < 0.5 = small effect, 0.5 to < 0.8 = moderate effect 
and ≥ 0.8 = large effect (Cohen, 1992). All data were analysed using SPSS version 23.0 
(IBM, Armonk, NY, USA). Data are reported as means ± standard error of the mean (SEM), 
with the level of statistical significance accepted at p ≤ .05. 
Data from the open-ended, post-treatment questions were transferred to Excel, 2016 
(Microsoft, Redmond, WA, USA) and inputted into NVivo 11 (QSR International Pty Ltd, 
Melbourne, Australia). All responses were read and re-read to establish main themes and 
emerging issues. A thematic content analysis was conducted, with data coded, indexed and 
organised into main themes. Throughout the analyses, connections were made between the 
main themes and the questionnaire change scores to gain a richer understanding of the 
effectiveness of the treatment.  
6.3 Results 
6.3.1 Model fit 
Confirmatory Factor Analysis of the SSBS revealed good model fit (χ2/df = 2.986; 
TLI = .954; CFI = .980; RMSEA = .068, 90% CI = .039 to 0.098; AIC = 62.876; ECVI = 
0.146). However, analysis of the 17 item PEAS model (Petróczi, 2006) revealed poor model 
fit (χ2/df = 3.532; TLI = .861, CFI = .859; RMSEA = .073, 90% CI = .065 to .080; AIC = 
488.259; ECVI = 1.015). Alternative models that have previously shown adequate model fit 
were tested and compared (Elbe & Brand, 2016; Gucciardi et al., 2010; Gucciardi et al., 
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2011; Vargo et al., 2014). All alternative models showed better fit than the original 17 item 
model (Table 6.2). The model from Gucciardi et al. (2011) showed the best model fit and is 
used in subsequent analysis. The items remaining in the analysis were: “Athletes often lose 
time due to injuries and drugs can be used to help to make up the lost time,” “Athletes who 
take recreational drugs use them because they help them in sport situations,” “The risks 
related to doping are exaggerated; doping is an unavoidable part of competitive sport” and 
“There is no difference between drugs and the technical equipment that can be used to 
enhance performance (e.g. hypoxic altitude simulating environments).”  
6.3.2 Preliminary analysis 
No differences between treatment groups were observed for number of years training 
(F(2, 561) = 1.966, p = .137), hours per week training (F(2, 561) = 0.408, p = .665), sex (χ2 = 5.28, 
p = .071), intention to use supplements (χ2 = 4.65, p = .098), attitudes to doping (F(2, 561), p = 
.536) and beliefs about sports supplements (F(2, 561) = 0.017, p = .983). Differences between 
treatments were shown for age (χ2 = 21.99, p = .001) and ability (χ2 = 21.69, p = .001).  
6.3.3 Treatment score differences pre and post-intervention  
Differences between pre- and post-scores for intention to use supplements (F(2, 561) = 
10.012, p = .002, 2η  = 0.022), attitudes to doping (F(2, 561) = 42.955, p < .001, 2η = 0.090) 
and beliefs about sport supplements (F(2, 561) = 19.065, p < .001, 2η  = 0.022) were shown. 
LSD post-hoc analysis indicated that the positive- and negative-belief treatment scores 
decreased following the intervention for intentions (positive belief: p < .001, d = 0.38; 
negative belief: p = .006, d = 0.23), attitudes d = 0.42) and beliefs (positive-belief: p = .001, 
d = 0.49; negative-belief: p < 0.001, d = 0.45). Scores were similar between pre- and post-
scores in the no-treatment control for intentions (p = .613; d = 0.01), attitudes (p = .840; d = 
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Table 6.2 
 
Model fit indices for competing models of the Performance Enhancement Attitude Scale 
 
  
Version n of items χ2/df CFI TLI RMSEA Lower Upper AIC ECVI 
Petróczi (2006) 17 3.532 .859 .861 .073 .065 .080 488.259 1.015 
Gucciardi et al. (2010) 11 2.860 .931 .914 .062 .050 .075 169.821 0.353 
Gucciardi et al. (2010) 6 2.277 .961 .936 .052 .022 .081 44.493 0.093 
Vargo et al. (2014) 8 1.554 .977 .978 .034 .000 .056 63.073 0.131 
Elbe and Brand (2016) 6 2.048 .973 .956 .047 .014 .077 42.433 0.088 
Gucciardi et al. (2011) 5 1.251 .995 .990 .023 .000 .070 26.253 0.055 
note. CFI = Comparative Fit Index; TLI = Tucker Lewis Index; RMSEA = The Root-Mean-Square-Error of Approximation; Upper = RMSEA Upper 95% 
Confidence interval; Lower = RMSEA Lower 95% Confidence Interval; AIC = Akaike Information Criterion; ECVI = the Expected Cross-Validation Index 
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0.04) and beliefs (p = .773; d = 0.03). All differences in scores for each treatment are shown 
in Figure 6.1.  
6.3.4 Treatment score differences pre- and post-intervention grouped by participants’ pre-
treatment intention to use sport supplements 
Significant interactions between pre-treatment intention to use sport supplements and 
pre- and post-scores for intention to use sport supplements (F(4, 554) = 5.459, p < .001, 2η  = 
0.046) and beliefs about sport supplements (F(4, 554) = 3.703, p = .006, 2η  = 0.034) were 
shown. No interaction was shown for attitudes to doping (F(4, 554) = 1.588, p = .176, 2η  = 
0.014). 
In the positive- and negative-belief treatments, intention scores increased following 
the intervention for those not intending to use supplements (positive: p < .001, d = 0.54; 
negative: p < .001, d = 0.58). However, intention scores decreased for those undecided 
(positive: p < .001, d = 0.59; negative: p = .030, d = 0.47) and intending to use sport 
supplements (positive: p < .001, d = 1.05; negative: p < .001, d = 0.90). No differences were 
identified following the intervention in the control treatment for those not intending (p = 
.617, d = 0.03), undecided (p = .349, d = 0.03), or intending to use sport supplements (p = 
.436, d = 0.04).  
Following the intervention, beliefs about sport supplement scores decreased for 
participants intending to use supplements in the positive- (p < .001; d = 0.88) and negative-
belief (p < .001, d = 1.00) treatments. No differences in belief scores were identified for 
controls (p = .773, d = 0.03). No difference in belief scores were identified for participants 
not intending or undecided about sport supplement use in the positive-belief (not intending: p 
= .221, d = 0.01; undecided: p = .100, d = 0.32), negative-belief (not intending: p = .525, d = 
0.06; undecided: p = .134, d = 0.32) and control treatments (not intending: p = .829, d =0.02;  
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Figure 6.1. Scores pre- and post-intervention between treatments. Note. 
** = p < .01; PEAS = Performance Enhancement Attitude Scale SSBS 
= Sports Supplements Beliefs Scale". 
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undecided: p = .741, d = 0.02). Scores pre- and post-treatment between each treatment 
grouped by participant’s prior intention to use sport supplements are shown in Table 6.3.  
6.3.5 Post-treatment open-ended questions 
 Response to open-ended questions indicated that post-treatment, the majority of 
participants were less likely to use sport supplements. Indicative responses from participants 
revealed that they believed supplements were “unnecessary” and that they “wouldn’t use 
them after learning about the placebo effect.” Many questioned the effectiveness of 
supplements and “doubted how much they actually work.” Responses to open-ended items 
was consistent with responses to quantitative questionnaires (and with previous qualitative 
research investigating the effects of athletes experience of the placebo effect of a purported 
banned substances; Beedie, 2007), indicating that some participants were less likely to use 
sport supplements following the treatment: 
I take protein, creatine, glutamine and pre-workout. Since realising that they may not 
be necessary, I will now just eat a more balanced diet and use natural products etc. to 
aid recovery and help me train. 
Consistent with the quote above, several participants indicated that instead of using 
sport supplements, they considered “moving away from supplements to a balanced diet” and 
“to put more thought into mental preparation.” Participants stated that there was no “magic 
bullet” to improve performance:
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Table 6.3 
 
Pre and post-score differences between treatments and pre-intervention intentions to use sport supplements 
 
Intention to use sport supplements scores (range = 1 to 3) 
Treatment Pre intention n Pre Post Diff p d 
Positive 
Not intending 52 1.00 ± 0.00 1.39 ± 0.11 0.39 ± 0.11 < .001 0.53** 
Undecided 58 2.00 ± 0.00 1.65 ± 0.10 -0.35 ± 0.10 .001 0.59** 
Intending 115 3.00 ± 0.00 2.31 ± 0.07 -0.69 ± 0.07 < .001 1.05** 
Overall 225 2.26 ± 0.00 1.92 ± 0.06 -0.27 ± 0.06 <. 001 0.38** 
Negative 
Not intending 67 1.00 ± 0.00 1.28 ± 0.10 0.28 ± 0.10 < .001 0.58** 
Undecided 43 2.00 ± 0.00 1.73 ± 0.13 -0.27 ± 0.12 .030 0.47* 
Intending 89 3.00 ± 0.00 2.51 ± 0.08 -0.49 ± 0.08 < .001 0.90** 
Overall 199 2.16 ± 0.00 1.96 ± 0.07 0.20 ± 0.06 .006 0.23** 
Control 
Not intending 45 1.00 ± 0.00 1.06 ± 0.13 0.06 ± 0.13 .617 0.03 
Undecided 33 2.00 ± 0.00 2.12 ± 0.15 0.13 ± 0.15 .394 0.03 
Intending 61 3.00 ± 0.00 2.92 ± 0.10 -0.08 ± 0.10 .436 0.04 
Overall 139 2.19 ± 0.00 2.20 ± 0.09 0.01 ± 0.07 .613 0.01 
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Table 6.3 cont.       
Performance Enhancement Attitude Scale (range = 6 to 30) 
Treatment Pre intention n Pre Post Diff p d 
Positive 
Not intending 52 9.64 ± 0.64 8.52 ± 0.59 -1.12 ± 0.45 .023 0.31* 
Undecided 58 10.58 ± 0.62 9.04 ± 0.57 -1.53 ± 0.47 .001 0.49** 
Intending 115 11.33 ± 0.43 9.32 ± 0.40 -2.01 ± 0.33 < .001 0.45** 
Overall 225 10.77 ± 0.31 9.12 ± 0.29 -1.65 ± 0.25 < .001 0.40**         
Negative 
Not intending 67 9.55 ± 0.60 7.19 ± 0.56 -2.36 ± 0.46 < .001 0.59** 
Undecided 43 10.00 ± 0.74 8.71 ± 0.68 -1.29 ± 0.57 .024 0.42* 
Intending 89 11.51 ± 0.48 9.96 ± 0.44 -1.55 ± 0.37 < .001 0.38** 
Overall 199 10.60 ± 0.34 8.85 ± 0.31 -1.75 ± 0.27 < .001 0.42** 
        
Control 
Not intending 45 8.53 ± 0.67 8.74 ± 0.62 0.21 ± 0.51 .682 0.12 
Undecided 33 12.14 ± 0.90 11.67 ± 0.83 -0.48 ± 0.69 .491 0.15 
Intending 61 9.90 ± 0.57 10.37 ± 0.53 0.46 ± 0.44 .294 0.09 
Overall 139 9.78 ± 0.39 9.96 ± 0.36 0.07 ± 0.32 .84 0.04 
Sports Supplements Beliefs Scale (range = 6 to 36) 
Treatment Pre intention n Pre Post Diff p d 
Positive 
Not intending 52 13.68 ± 0.99 15.24 ± 1.15 1.56 ± 1.27 .221 0.09 
Undecided 58 17.04 ± 0.86 15.22 ± 1.00 -1.82 ± 1.10 .100 0.32 
Intending 115 21.64 ± 0.62 15.83 ± 0.72 -5.82 ± 0.79 < .001 0.88** 
Overall 225 17.45 ± 0.49 15.43 ± 0.56 -2.02 ± 0.62 .001 0.49** 
Negative 
Not intending 67 14.41 ± 0.83 15.08 ± 0.96 0.67 ± 1.06 0.525 0.06 
Undecided 43 18.87 ± 1.06 16.83 ± 1.22 -2.03 ± 1.35 .134 0.32 
Intending 89 22.19 ± 0.70 15.18 ± 0.81 -7.01 ± 0.90 < .001 1.00** 
Overall 199 18.49 ± 0.51 15.70 ± 0.58 -2.79 ± 0.65 < .001 0.45** 
Control 
Not intending 45 11.79 ± 0.93 12.05 ± 1.07 0.26 ± 1.19 0.829 0.02 
Undecided 33 18.46 ± 1.18 17.96 ± 1.37 -0.50 ± 1.51 .741 0.02 
Intending 61 20.95 ± 0.78 20.56 ± 0.90 - 0.38 ± 1.00 .703 0.02 
Overall 139 17.07 ± 0.57 16.86 ± 0.65 -0.21 ± 0.72 .773 0.03 
Note. Data are means ± standard error of the mean; d = Cohen’s d; * = p < .05; ** = p < .01.    
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There is no easy way to increase fitness and performance. It is a case of persistent 
hard work and dedication towards a goal. It's more to do with a healthy diet than 
supplements, because supplements are probably a waste of money. 
While qualitative data suggest that many participants would be less likely to use sport 
supplements, some believed they could still “feel the benefit from using sport supplements.” 
Participants believed that certain supplements “improve performance regardless” and have 
“proven benefits.” However, participants also reported that involvement in the study 
encouraged them to make “a more informed decision before using sport supplements.” 
Participants stated that they would “put more thought and research in before using 
supplements” and that they would “not take a supplement without looking into it.”  
Participants also referenced the role of placebo effects in the effectiveness of sport 
supplements: 
 
I believe that some sport supplements have a desired effect, but this may be because 
of the placebo effect. 
 
Although providing information about the placebo effect may have decreased the 
likelihood of participants using sport supplements, a small number of participants not 
intending to use supplements (6%) suggested that it could have encouraged them to use 
certain substances. For example, after learning about the placebo effect, one participant 
reported that “sport supplements may be more useful” whereas another suggested that the 
treatment may have influenced their decision to use supplements: 
 
It would influence me to take supplements, such as vitamins. If they improve my 
performance by my positive mind-set by taking them, and they also provide 
nutritional benefits, it's a win-win situation. 
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Finally, the treatment appeared to reaffirm many participants’ pre-treatment decision 
to avoid sport supplements. Participants reported that the “testing has cemented their decision 
to not use supplements” and that the treatment was “an eye-opener.” One participant 
mentioned that they were already aware of the placebo effect, but recognised the importance 
of educating other athletes: 
I know about the placebo effect and how it can make athletes believe supplements 
help. It has reaffirmed my beliefs not to use them and it would be good for other 
athletes to learn about. 
6.4 Discussion 
Study 2 of the research programme reported the results of a positive and negative 
placebo intervention on repeat sprint performance. The aim of this study was to examine 
participants’ beliefs and intentions towards sport supplements and attitudes to doping after 
the placebo intervention. Results showed that after participating in a placebo intervention, 
participants reported lower scores for intention to use sport supplements, attitudes to doping 
and beliefs about the effectiveness of sport supplements. While the overall effect of the 
treatments appeared positive, this effectiveness was dependent on participants’ pre-existing 
intention to use sport supplements. Although participants identified as intending to use 
supplements pre-treatment were less likely to use sport supplements post-treatment, those 
identified as not intending to use supplements pre-treatment were more likely to use 
supplements post-treatment.  
Authors have suggested that informing athletes about the placebo effect may help to 
prevent doping in sport (Kalasountas et al., 2007; Maganaris et al., 2000; McClung & 
Collins, 2007). The present study has indicated that informing participants about the role of 
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placebo effects in the overall effectiveness of supplements can reduce the self-reported 
likelihood of participants using them. Following a brief educational intervention, participants 
in this study reported significantly reduced likelihood of future supplement use, whereas 
controls showed no changes in intention. Given the proposals of the gateway hypothesis, this 
could suggest that the placebo intervention presented in Study 2 might likewise reduce the 
risk of participants progressing to doping in the future.  
Given the difficulty in detecting changes in questionnaire data for those with low 
intentions to use sport supplements, an important aspect of this study was the sub-analyses of 
participants by their pre-treatment intention to use sport supplements (i.e. not intending, 
undecided and intending). Participants intending and undecided about using sport 
supplements pre-treatment reported greater post-treatment reductions for intention, attitudes 
and beliefs (Figure 6.1). While open-ended questions revealed that some participants would 
still use sport supplements, participants mentioned that they would put more research into the 
effectiveness and safety of supplements prior to use. This could reduce the risk of participants 
using banned substances inadvertently, which occurs via sport supplements containing 
banned substances that are not declared on the label (Maughan, 2013). 
For participants that were not intending to use sport supplements, data suggested 
potential boomerang effects of the treatment (i.e. an increased desire to use banned 
substances following a treatment aimed to prevent this; Elbe & Brand, 2016). Participants not 
intending to use supplements pre-treatment were more likely to use sport supplements post-
treatment. Given the potentially significant influence of placebo effects on performance, 
some participants indicated that they could benefit from sport supplementation, albeit 
psychologically. While delivering information about the placebo effect to participants was 
aimed at reducing supplement use, data from this group of participants suggests that a 
placebo treatment may, in fact, encourage it. The knowledge participants received about the 
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effectiveness of sport supplements could, in part, explain this; it has been reported that users 
of banned substances have more knowledge about the effects of these substances than non-
users (Wanjek, Rosendahl, Strauss, & Gabriel, 2007). This finding is similar to those relating 
to anti-smoking campaigns, in which greater awareness of the effects of smoking can increase 
smoking behaviour (Harris, Pierce, & Bargh, 2014). This suggests that involving non-users of 
banned substances in interventions designed to reduce incidence of use among those already 
using them may be counter-productive and in fact increase their likelihood of using these 
substances in the future.  
A number of limitations must be considered with respect to the current study. The 
data relied on information collected via self-report measures, and it is recognised that there 
may be a difference between what some athletes say and what they really believe (Morente-
Sanchez & Zabala, 2013). Secondly, only athletes above the age of 18 or older were recruited 
to the study. While it may be difficult to obtain ethical clearance for the use of a deceptive 
intervention on athletes under the ages of 18, future interventions should aim to educate 
adolescent athletes that are intending to use sport supplements, at a point in time at which 
they are arguably in a more formative stage of development, to maximise the impact of future 
banned substance use interventions.  
In conclusion, for participants intending to use and undecided about sport 
supplements, a placebo intervention reduced the reported likelihood of use, and, given the 
gateway hypothesis, arguably reduced the risk of using banned substances in the future. 
Importantly, such an approach to prevention might adversely affect the behaviour of athletes 
not originally intending to use supplements. It is therefore important for researchers to assess 
participants’ intention prior to an intervention aimed at preventing performance enhancing 
substance use.   
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Chapter Seven  
 
GENERAL DISCUSSION 
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7.1 Introduction 
The placebo effect has been of scientific interest in sport and exercise for nearly half a 
century. Ariel and Saville (1972) were the first to suggest that the placebo effect could have a 
significant impact on sports performance and since this publication, the evidence base in 
sport and exercise science has grown considerably. Saunders et al. (2017) reported that 
participants deceptively administered a placebo showed a 3.7% improvement in cycling mean 
power output when they believed they had ingested caffeine. Similarly, Ross et al. (2015) 
reported a 1.2% improvement in 3 km time-trial performance when participants self-
administered saline injections believing it to be a performance enhancing substance. 
However, while evidence suggests that the placebo effect can have a significant influence on 
sports performance, the methods used in the majority of placebo effect studies make it 
difficult to estimate the true magnitude of its effect. Many of the studies do not include a no-
treatment control, impeding differentiation between placebo effects and 
methodological/statistical artefacts (e.g. regression to the mean). In addition, most studies 
examining the placebo effect in sport are too small to facilitate reliable identification of 
variables associated with observed responses. This is problematic as the standard deviation of 
the dependent measure under investigation is often greater in experimental conditions than at 
baseline (Beedie & Foad, 2009). Thus if a placebo effect is observed, there is considerable 
inter-individual variability in the response to treatment which makes it difficult to estimate 
the true magnitude and moderators of the placebo effect on sports performance. An aim of 
this research was therefore to understand the magnitude and moderators of placebo effects on 
a large sample using a controlled randomised design in sport performance.  
A second aim of this research was to explore the influence of a placebo intervention 
on an athlete’s beliefs and intentions towards sport supplements and attitudes to doping. 
Numerous authors have made an explicit link between the placebo effect and doping 
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prevention in sport (Kalasountas et al., 2007; Maganaris et al., 2000; McClung & Collins, 
2007). Maganaris et al. (2000) first suggested that placebo effect studies offer support for the 
prevention of banned substance use behaviours. Similarly, McClung and Collins (2007) 
argued that if athletes are made aware of the significant role placebo effects may have in the 
effectiveness of a substance, they might be less likely to use performance enhancing 
substances. Although evidence is anecdotal, it does hint at the possibility that if athletes 
experience, or are made aware of the placebo effect, they might refrain from using 
performance enhancing substances in the future. Evidence suggests that beliefs about sport 
supplements influence future sport supplement use behaviours (Dascombe et al., 2010) and 
that users of sport supplements are at risk of progressing to doping (Backhouse et al., 2013). 
Hypothetically, therefore, if athletes’ beliefs about sports supplements influence current and 
future supplement use, and if current/future supplement use is a predictor of future doping, it 
is reasonable to suggest a relationship between current beliefs about supplements and future 
doping. Thus, this research aimed to empirically test the influence of a placebo intervention 
on athletes’ beliefs and intentions towards sport supplements and attitudes to doping. 
Assessment of athletes’ beliefs requires a reliable and valid measure, therefore a further aim 
of this research was to develop and validate a psychometric instrument that could identify 
changes in athletes’ beliefs following the placebo intervention.  
7.2 Executive summary of findings 
This research aimed to answer the following questions: 1) What is the magnitude of 
placebo and nocebo effects on the sprint performance of a large sample of athletes associated 
with the administration of a purported sport supplement? 2) What factors moderate observed 
placebo and nocebo effects in repeat sprint performance? and 3) What is the impact of a 
 
 
131 
 
placebo intervention on an athlete’s beliefs and intentions towards sport supplements and 
attitudes to doping?  
The main findings reported from the three studies include: 
1. The Sports Supplements Beliefs Scale (SSBS) is a reliable and valid psychometric 
tool for assessing athletes’ beliefs about sport supplements (Study 1) 
2. A placebo deceptively presented as a sport supplement likely to have a positive 
effect on performance did not elicit a placebo effect on repeat sprint performance 
(Study 2) 
3. A placebo deceptively presented as a sport supplement likely to have a negative 
effect on performance elicited a significant mean nocebo effect on repeat sprint 
performance (Study 2) 
4. Intentions to use sport supplements moderated the placebo effect in repeat sprint 
performance (Study 2) 
5. A placebo intervention significantly influenced participants’ beliefs and intentions 
towards sport supplements and attitudes to doping (Study 3) 
6. Participants not intending to use sport supplements prior to the placebo 
intervention were more likely to use them after the placebo intervention (Study 3) 
The present discussion draws together the main findings from the three studies and 
focuses on the empirical and practical implications of: 1) placebo and nocebo effects on 
repeat sprint performance; 2) intention as a moderator of the placebo effect and 3) the 
influence of a placebo intervention on athletes’ beliefs and intentions towards sport 
supplements and attitudes to doping. Strengths and limitations of the research programme and 
directions for future research are also discussed.  
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7.3 Empirical and practical implications 
 The studies in this research extend previous empirical evidence of placebo effect 
research and have practical implications for sport practitioners and policy makers interested 
in both improving performance and preventing doping.  
 Study 2 examined the magnitude of placebo and nocebo effects on repeat sprint 
performance. Data suggested that performance was unaffected by receipt of a potentially 
beneficial supplement (i.e. no placebo effect was observed), but impaired by receipt of a 
potentially harmful supplement (i.e. a nocebo effect was observed). These findings differ 
from recent placebo effect research whereby significant improvements in sports performance 
have been shown (de la Vega et al., 2017; Ross et al., 2015; Saunders et al., 2017). Although, 
no mean placebo effect was observed, further analysis indicated that participant’s prior 
intention to use supplements influenced the direction and magnitude of the placebo effect. 
That is, the performance of participants intending to use sport supplements improved, while it 
decreased for those not intending to use supplements. To the author’s knowledge, this is the 
first study to report a relationship between intention to use sport supplements and the 
response to a placebo supplement.  
 The current research programme provides some evidence for the role of placebo 
effects in reducing the risk of athletes progressing to doping. Backhouse et al. (2013) 
indicated that sport supplement users may be more likely to use banned performance 
enhancing substances and that beliefs and intentions towards supplements may influence 
future supplement use. In Study 3 of this research programme, participants reported changes 
in their beliefs and intentions towards sport supplements and attitudes to doping following the 
placebo intervention described in Study 2. However, changes in intention to use sport 
supplements may be influenced by participants’ prior intention to use them. That is, 
participants not intending to use sport supplements were more likely to use sport supplements 
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after the placebo intervention, whereas those intending and undecided were less likely. These 
results have potentially important implications for policy makers aiming to prevent future 
doping behaviours.  
7.3.1 Magnitude of placebo and nocebo effects on repeat sprint performance 
The difference in findings between Study 2 and Beedie et al. (2007) is possibly 
attributed to the inclusion of the no-treatment control. Inclusion of a no-treatment control 
facilitates more accurate identification of effects due to administration of the treatment as 
opposed to effects attributable to methodological artefacts or regression to the mean 
(Hróbjartsson & Gotzsche, 2003). In placebo effect studies that do not include a no-treatment 
control, researchers cannot be certain that the effects of the treatment are all positive, all 
negative, or whether any placebo and nocebo effects actually occurred. While it is 
acknowledged that an extra arm in study design requires additional resources, if researchers 
wish to understand placebo and nocebo effects, they must include a no-treatment condition or 
control potential confounds to generate accurate inferences about the magnitude, direction 
and mechanisms of these effects.  
The finding of no mean placebo effect in Study 2 also runs counter to the findings of 
other placebo effect research in sports performance published to date (Table 2.1 p. 25). One 
explanation for this disparity may be the context in which the placebo treatment was 
administered. Figure 2.1 (p. 18) suggests that the effectiveness of a treatment can be 
influenced by the context in which it is administered. A treatment may be more effective 
when it is delivered in full view of the patient (Amanzio et al., 2001) and/or when the 
researcher administering it is caring and emphatic (Kaptchuk, Kelley, Conboy, et al., 2008). 
Participants in this study were informed and administered the treatment within a group. This 
method may have precluded the key components for eliciting a placebo effect (e.g. attention 
 
 
134 
 
to the participant, rapport between researcher and participant) and may have decreased the 
likelihood of participants responding to the treatment. The rapport and relationship between 
researcher and participant is arguably weaker during larger sample size studies when the 
attention given to each individual participant is reduced. In contrast, in smaller sample size 
studies (e.g. ~20), the opportunity to engage with each participant is greater, which may 
facilitate a more conducive context for eliciting placebo effects (Kaptchuk, Kelley, Conboy, 
et al., 2008). However, while the context may have been a limiting factor in eliciting a 
placebo effect in this research, the 712 athletes recruited far exceed the number of 
participants recruited in studies investigating the placebo effect on sports performance to 
date. In fact, of the placebo effect studies reported in Table 2.1 (p. 25), only 24 participants 
are recruited on average. In these smaller sample size studies, the variation of the dependent 
measure is often greater in experimental conditions than at baseline, which limits the ability 
to accurately identify the magnitude and mechanisms of the placebo effect. Generalising 
these findings can therefore be extremely difficult. A tension clearly exists between small 
sample size studies with greater control over context but difficulties in generalising findings, 
and large sample size studies with greater likelihood of generalising findings but less control 
over context. Given the aims of this study (i.e. to replicate the investigation of Beedie et al. 
2007 and understand the magnitude of the placebo effect), a larger sample size was required, 
but it is recognised that this may have compromised the context in which placebo effect 
interventions are most effectively delivered.  
While no mean placebo effect was identified in Study 2, a significant mean nocebo 
effect was. This may suggest that nocebo effects are more likely to occur than placebo 
effects. Providing a clear explanation for this is difficult. In a highly cited review, 
Baumeister, Bratslavsky, Finkenauer, and Vohs (2001) suggested that negative information 
has a stronger influence on behaviour than positive information. Rozin and Royzman (2001) 
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reported that “in most situations, negative events are more salient, potent, dominant in 
combinations, and generally efficacious than positive events” (p. 297). Although it has been 
suggested that there is a considerable bias towards the measurement of negative affect in 
psychology (Peterson & Seligman, 2004; Szalma & Hancock, 2017), it could be suggested 
from data reported in this research programme, that nocebo effects are more likely to occur 
than placebo effects, and that the brain responds to negative information more pertinently 
than to positive information. If this is correct, when participants in the negative-belief 
treatment were administered the “supplement” and informed it may have a harmful effect on 
performance, they may have paid more attention and processed the information more 
thoroughly than participants in the positive-belief treatment who were told that the 
supplement was beneficial. Consequently, during experimental sprint trials, participants in 
the negative-belief treatment may have had greater expectations of the impact of the 
treatment than participants in the positive-belief treatment. Participants may also have felt 
demotivated as a result of the information and subsequently performed worse. Either way, the 
fact that nocebo effects were more likely to occur than placebo effects highlights the 
importance of athlete support personnel being aware of the importance of how they 
communicate with their athletes during administration of a treatment.  
To the author’s knowledge, this is only the third study to investigate the nocebo effect 
on sports performance. This paucity of evidence in relation to nocebo effects in sports 
performance is somewhat surprising given that, theoretically, negative information or beliefs 
about a legitimate treatment could offset some or all of the beneficial effects of that 
treatment. While it is unlikely that an athlete would use a treatment they believed was 
harmful to their performance, it does highlight that if an athlete does not fully believe in a 
treatment, they may not fully benefit from it.  
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The decrease in performance in the negative-belief treatment compared to the no 
control treatment in Study 2 of this research programme support the findings of Beedie et al. 
(2007) and Bottoms et al. (2013). These differences in performance could have significant 
implications for an athlete’s performance where it has been noted that reductions in speed of 
1% over a 20 m distance translate into distances of around 10-20 cm (Mujika, Padilla, Ibanez, 
Izquierdo, & Gorostiaga, 2000; Varley & Aughey, 2013). Therefore, changes in performance 
of this magnitude could have a significant influence during decisive match activities and on 
the outcome of a competition.  
7.3.2 Intention to use sport supplements as a moderator of the placebo effect 
It is generally accepted in placebo effect literature that the proportion of people that 
respond to a placebo treatment varies considerably from study to study. Identifying those who 
respond to a placebo treatment (i.e. placebo responders) is important for both clinical and 
applied practice. An aim of this research programme was therefore to examine potential 
moderators that influence the response to placebo and nocebo treatments. In Study 2, 
relationships between categorical variables (e.g. sex, sport supplement use, intention to use 
supplements) and repeat sprint performance in the positive and the negative belief treatment 
were examined. Although no mean placebo effect was observed, data from the positive-belief 
treatment suggested that the performance of participants intending to use supplements 
improved to a greater degree than the performance of those not intending to use supplements 
(Figure 5.3, p. 99). This relationship was observed only in the positive-belief treatment, 
suggesting that intention may moderate the placebo effect in this context and that the 
observed effect is not attributable to statistical or methodological artefacts.  
To the author’s knowledge, this is the first study to identify an association between 
intention to use a treatment and response to a placebo. Theoretically, intentions pertain to 
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volition to perform a given behaviour (Perugini & Bagozzi, 2004) and reflects how hard 
people are willing to try to enact that behaviour (Ajzen, 1991). In the context of the placebo 
effect and why intention may moderate the response to a placebo treatment, it is suggested 
that intention is heavily influenced by a person’s belief (Fishbein & Ajzen, 1977). Thus, an 
athlete who is administered a placebo purported to be a treatment they believe in and intend 
to use, may be more likely to respond to that treatment.  
These results have important implications for researchers and athlete support 
personnel invested in the efficacy and effectiveness of their treatments. Firstly, participants 
may not fully benefit from a treatment if they do not intend to use it. As highlighted in Figure 
5.3 (p. 100), a significant nocebo effect on performance was observed for participants not 
intending to use sport supplements. This suggests that receipt of a “supplement” purported to 
have a beneficial effect on performance actually impaired that performance. While this 
scenario is unlikely in the real world (i.e. an athlete is unlikely to use a supplement they do 
not intend to use), in clinical settings, the situation might be quite different. For example, a 
person recruited to a clinical trial may not necessarily believe that the treatment under 
consideration will be effective, and this lack of belief may affect their intention to use it in the 
future and subsequently, adversely affect their response to it. Understanding participants’ 
beliefs and intentions about a treatment may therefore serve to facilitate accurate estimation 
of the efficacy of a treatment, or at the very least help to explain an observed lack of efficacy. 
Participants identified as having negative beliefs and no intentions to use a treatment could be 
withdrawn from the study before assignment to the experimental treatment. While this does 
carry the risk of bias (i.e. a treatment works only in a predetermined or preselect group of 
people), it can help to offset potential nocebo effects that may confound accurate estimates of 
a treatment’s efficacy (Shah & Pimentel, 2014).  
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The second important finding of this study relates to the influence of intention on the 
effectiveness of a placebo treatment. As shown in Figure 5.3 (p. 99), the performance of 
participants intending to use sport supplements in the positive belief treatment was 
significantly faster than the performance of those intending to use sport supplements in the 
control treatment. This suggests that athletes’ intending to use supplements are more likely to 
respond to a placebo supplement. Using a placebo intervention could therefore be beneficial 
for athletes intending to use a treatment. However, to knowingly promote the benefits of a 
placebo through deception and false information is arguably unethical and counter to 
professional practice guidelines (Beedie et al., 2017). To put this into perspective, imagine an 
athlete falsely led to believe by their coach that they have ingested a potent sport supplement. 
While that athlete might produce a better performance than usual, that athlete - upon being 
debriefed or inadvertently finding out - might have less trust in their coach in future. In any 
athlete support personnel relationship (e.g. coach, physiotherapist, doctor) the need for trust 
and honesty is of paramount importance (Beedie et al., 2015). 
Clearly, use of a deceptive placebo treatment in applied practice is unethical. 
However, placebo effect research has highlighted that, in many instances, there is 
considerable headroom to improve an athlete’s performance by promoting the benefits of a 
treatment. If placebo effects are observed after the administration of a placebo, then this is 
arguably evidence of headroom between an athlete’s baseline and potential (Beedie et al., 
2017). Given the results of Study 2, intention may therefore influence the headroom for 
improvement after administration of a placebo, and arguably, from a legitimate treatment 
(e.g. sport supplement, training programme or physiotherapy). The extant placebo effect 
literature across disciplines suggests that the effects of a verum treatment are often the result 
of an interaction between the pharmacological (e.g. the drug) and psychological (e.g. the 
placebo effect) components of that treatment. In sport, if a coach administers a treatment to 
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an athlete, the psychological component of the treatment is influenced by the context in 
which it is administered, the person administering it, and the psychology of the athlete (e.g. 
personality, beliefs, and intentions). With respect to intention, if an athlete intends to use a 
treatment, the psychological component of that treatment may be maximised and the athlete 
may be more likely to exhibit an improvement in performance following receipt of that 
treatment. Intention to use a treatment could therefore be a strong component influencing 
how well, or not so well, a treatment works. On this basis, it is reasonable to suggest that 
athlete support personnel should endeavour to maximise the placebo effect component of a 
legitimate treatment by engendering a positive belief in its effectiveness. A positive belief in 
the efficacy of a treatment may increase intention to use (and to adhere) to that treatment, 
enhancing its effect. No deception is needed, it is simply applying an understanding of 
placebo effects to potentiate the response to a legitimate treatment.  
7.3.3 Using a placebo intervention as an anti-doping intervention 
The aim of Study 3 was to examine the influence of a placebo intervention on an 
athlete’s beliefs and intentions towards sport supplements and attitudes to doping. 
Differences between pre and post intervention scores revealed a reduction in intention to use 
sport supplements, less favourable attitudes to doping and modified beliefs about the 
effectiveness of sport supplements. However, while the intervention appeared to be effective 
in reducing self-reported likelihood of supplement use, sub-analyses indicated that ~25% of 
participants not intending to use supplements before the intervention were more likely to use 
them after. These results have important implications for researchers and policy makers 
aiming to prevent doping in sport. 
Given the difficulty in detecting changes in athletes’ doping behaviour (see Box 2.1, 
p. 46), an important aspect of this study was the sub-analyses of participants by their pre-
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treatment intention to use sport supplements (i.e. not intending, undecided and intending). 
The unintended consequence of the intervention increasing the likelihood of supplement use 
among participants with no intention to use sport supplements at the outset suggests that 
involving these participants in anti-doping interventions may be counterproductive and 
actually increase the likelihood of them doping in the future. While the data presented here 
only relate to this specific study, there is no reason to believe that the findings would be 
restricted to this style of intervention. James et al. (2010) reported that participants were more 
likely to use banned substances, such as EPO, after an intervention designed to reduce this 
behaviour and Elbe and Brand (2016) reported that athletes’ attitudes to doping increased 
after an ethical decision making training intervention. Agencies responsible for the delivery 
of anti-doping interventions (e.g. UKAD, USADA, and WADA) should therefore not only 
consider the possibility that participants may be more likely to use doping substances 
following an anti-doping intervention, but should actively investigate the risk of promoting 
the behaviours they seek to prevent via evaluation and research. 
Reasons for these unintended consequences could include priming and exposure to 
the use of sport supplements. Based upon associative models of human memory, it is 
suggested that a person’s mind is made up of connecting links that are activated in response 
to a stimulus (Anderson & Bower, 2014). Research has shown, for example, that children can 
become more aggressive after exposure to interventions designed to reduce aggression, with 
Byrne, Linz, and Potter (2009) reporting an increase in aggressive thoughts after children 
watched violent video clips. The authors concluded that exposure to the stimulus increased 
the salience of aggressive thoughts and in turn, children’s willingness to be aggressive. In the 
context of this study, administration of a “sport supplement” purported to influence sports 
performance may have primed participants with no intention to use sport supplements 
towards these supplements, increasing their likelihood of use.  
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With this in mind, the results of this study highlight the importance of assessing 
participants’ intentions to use sport supplements prior to an anti-doping intervention. If the 
aim of the intervention is to discourage athletes’ use of sport supplements, including athletes 
who have no, or minimal intention to use sport supplements may be unnecessary and 
potentially counterproductive. If an athlete with no intention to use sport supplements is 
involved in an anti-doping intervention, which exposes them to information and focuses their 
attention on sport supplements, they may be more willing to consider using them in the 
future. Thus, prior assessment of athletes’ intentions could enable anti-doping facilitators to 
make more informed decisions about the necessity or appropriateness of an anti-doping 
intervention for a particular athlete.  
While participants with no prior intention to use sport supplements reported an 
increase in their likelihood of using sport supplements, participants intending and undecided 
about using sport supplements exhibited a decrease in their intention (Table 6.3, p. 118). 
Specifically, these athletes reported lower scores on the Sports Supplements Beliefs Scale 
(SSBS) developed and validated in Study 1 after the placebo effect intervention.  
Dietz et al. (2013) reported that banned substance use was significantly greater among 
athletes using sport supplements and Backhouse et al. (2013) reported that sport supplement 
users were three and a half times more likely to use banned substances than non-users. 
Therefore the extant evidence suggests that supplement use can increase the likelihood of 
doping and that athletes with stronger beliefs about sport supplements are more likely to use 
these supplements (Dascombe et al., 2010). Given these reported relationships, it is 
reasonable to suggest that athletes that do not believe in the effectiveness of sport 
supplements may be less likely to use supplements and doping substances and, in the context 
of this study, athletes with lower scores on the SSBS after the placebo intervention may be 
less likely to progress to banned substances. These results are supported by changes in 
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athletes’ intentions to use sport supplements, as well as changes in their attitudes towards 
doping reported in Study 3 (Figure 6.1, p. 116).  
Open-ended questions revealed that some participants would still use sport 
supplements following the intervention. However, a number of these participants reported 
that they would conduct more research into the efficacy and safety of a substance prior to use. 
This could reduce the risk of participants using a banned substance inadvertently, which 
occurs via sport supplements containing banned substances (Maughan, 2013). This is an 
increasing occurrence in sport, where in 2012, 44% of United Kingdom anti-doping rule 
violations were attributed to the use of sport supplements (SENr, 2016). International and 
national anti-doping organisations advocate that athletes evaluate and research the safety and 
effectiveness of any sport supplement prior to use (e.g. British Athletics). Athletes in this 
study reported  greater due diligence with respect to researching supplements prior to their 
use, which may prevent them from using a banned substance unintentionally. 
Although the results of this research demonstrate that a placebo intervention can 
influence athletes’ beliefs and intentions towards sport supplements and attitudes to doping, it 
has not explicitly assessed or reported changes in sport supplement or doping use. An 
assumption of the Theory of Reasoned Action (TRA) and Theory of Planned Behaviour 
(TPB) is that a change in belief, attitude and intention is evidence of a change in behaviour. 
However, the overall predictive power of these theories in explaining changes in behaviour is 
subject to debate (Sniehotta, Presseau, & Araujo-Soares, 2014). One of the most highly 
debated issues is the association between intention and behaviour, in which intention is 
argued to be the most proximal determinant of behaviour. While intention is often the largest 
and most reliable psychosocial predictor of behaviour, with meta-analyses showing medium 
to large effect sizes for, for example, alcohol use (r = .62; Cooke, Dahdah, Norman, & 
French, 2016), physical activity adoption (r = .48; McEachan, Conner, Taylor, Lawton, 2011) 
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and condom use (r = .49; Starfelt Sutton & White, 2016), a change in intention does not 
necessarily indicate a change in behaviour. As Sniehotta et al. (2014) state: 
 
The main focus of criticism has been the limited predictive validity of the TPB. 
Reviews clearly show that the majority of variability in observed behaviour is not 
accounted for by measures of the TPB. In particular, the problem of “inclined 
abstainers,” individuals who form an intention and subsequently fail to act, has been a 
recognised limitation of the TPB that remains unaddressed by the theory (p. 2).  
 
In fact, taking the average effect size of the three meta-analyses reported above (i.e. Cooke et 
al., 2016; McEachan et al., 2011; Starfelt Sutton & White, 2016), 74% of the variability is 
unexplained, which is problematic when intention is considered the gate through which all 
social cognitive variables must pass to affect behaviour (Rhodes & Rebar, 2017). It is perhaps 
not surprising that authors such as Sniehotta et al. (2014) have suggested the TPB should be 
effectively retired.  
It is clear that the TRA and TPB do have limitations, with these limitations recognised 
by Ajzen and Fishbein (1975; 1985)  decades ago. However, despite such limitations, these 
theories have been shown to accurately predict a number of different health behaviours (e.g. 
physical activity, smoking and doping) and have made a considerable contribution to 
explanations for a variety of different behaviours. Conner (2015) suggested that the 
information gained from these theories should be used to identify key determinants of 
intentions and behaviour, and such an approach has been effectively used to demonstrate how 
non-conscious/automatic processes (Rebar et al., 2016; Sniehotta, 2009) and volitional 
factors (Bélanger-Gravel et al., 2013; Schwarzer, 2008) influence intention and behaviour. 
More specifically, and within the doping literature, this approach has been used to 
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demonstrate that performance enhancing substance use is rooted in two different kinds of 
thinking: fast and automatic processes influenced by emotional factors, and slower, reasoned 
processes consciously monitored by the intention to perform the behaviour (Baumgarten, 
Lucidi, Mallia, Zelli, & Brand, 2016). 
 In the context of Study 3 of this research, it is recognised that a change in intention to 
use sport supplements does not necessarily indicate a change in supplement use, however, it 
does indicate a change in a central construct in the processes in which people engage in prior 
to supplement use. The results of Study 3 therefore have important implications for 
researchers and policy makers aiming to reduce athletes’ risk of doping. An important 
consideration for future research is to assess whether there are any other determinants of 
intentions or behaviours that are not currently considered by the TRA or TPB. This research 
should seek to assess the amount of variance explained by other variables, the extent to which 
they overlap with existing variables, and their value across other types of behaviour.  
7.4 Limitations 
 This research has provided evidence of the magnitude and moderators of placebo and 
nocebo effects on repeat sprint performance. In addition, it has shown that a placebo 
intervention can significantly influence athletes’ beliefs and intentions towards sport 
supplements and attitudes to doping. However, these findings need to be interpreted in light 
of a number of limitations.  
Given that there is no universal definition of a sport supplement (Knapik et al., 2016; 
Maughan et al., 2018), participants’ responses to questions related to supplement use may 
have varied. While a brief definition of sport supplements was provided before participants 
responded to the relevant sport supplement questions (Appendix, pg xx), this may not have 
reflected participants understanding of a sport supplement, which in turn may have 
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influenced responses. In light of this, the validity of the SSBS (developed and validated in 
Study 1) may be limited and caution should be given to any inferences made from the use of 
this scale.  
The context in which the treatment was administered in Study 2 may not have been 
optimal for eliciting placebo effects. Placebo and nocebo effects are influenced by a range of 
individual and psychosocial factors, including expectation; previous experiences; the 
interaction between participant and researcher; trust; empathy; and the ritual surrounding the 
administration (Benedetti, 2013). It is recognised that conducting the placebo intervention 
and administering the treatment in a group setting in Study 2 may not have been the most 
appropriate context by which to induce placebo effects.  
This research examined the influence of a purported sport supplement and not that of 
a legitimate treatment (e.g. sport supplement, cold-water immersion and physiotherapy). 
While the results of Study 2 suggest that intention influenced the effects of a placebo 
treatment, these effects may operate somewhat differently in the presence of a legitimate 
treatment. Foad et al. (2008) speculated that when a treatment is received, participants are 
consciously or unconsciously responding to the subtle-cues that might suggest its presence. 
Thus, in a study where both verum and placebo treatments are administered, the participant’s 
intention may change during the course of the study when they are in a position to make a 
comparison between the two treatments.  
In placebo effect research a key methodological characteristic is that participants are 
led to believe that the treatment they receive will influence their performance. However, 
some participants in Study 2 may not have believed the information they received about the 
purported sport supplement. This may therefore have resulted in no change in their 
performance. Hulston and Jeukendrup (2009) reported no placebo effect on cycling 
performance after the ingestion of water informed to be carbohydrate, and Bottoms et al. 
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(2014) reported no change in peak minute power during incremental arm crank geometry 
after the ingestion of a 500ml “fatigue inducing” drink. Thus, while participants were 
administered a placebo coupled with information about its effectiveness, they may not have 
believed this information, which in turn may have resulted in no change in performance. 
The results of Study 3 reflect assessment of athletes’ beliefs, attitudes and intentions 
immediately before and after the intervention; no follow-up assessment was conducted. It is 
therefore not possible to provide any indication of the impact of the intervention on athletes’ 
beliefs, attitudes and intentions over time. An absence of longitudinal study is evident in most 
anti-doping education intervention evaluations (Backhouse et al., 2016) and the lack of 
follow-up measures makes it impossible to determine whether changes are sustained. A 
further limitation relates to the age of participants sampled in Study 3 (>18). Interventions 
should ideally be targeted at adolescence (11 to 17), a formative period in the development of 
attitudes and beliefs (Elbe & Brand, 2014). Delivering the intervention at this stage of 
development may have a greater and more sustained impact on an athlete’s beliefs and 
intentions towards sport supplements and attitudes to doping.  
7.5 Future research directions 
 Where possible, future research should aim to include no-treatment controls alongside 
placebo and experimental treatments. Inclusion of a no-treatment control is vital to enable 
researchers to accurately differentiate between effects due to a placebo and those due to 
methodological/statistical artefacts. The results of Study 2 in this research programme 
highlight that without no-treatment controls, the results of placebo and nocebo effect studies 
could be misinterpreted. Including no-treatment controls will not only improve the validity 
and reliability of findings from placebo effect research; it will also help to increase our 
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understanding of role of the placebo effect in the outcomes of treatment, an understanding 
that could have a significant influence on both research and applied practice.  
 Secondly, the finding that intention moderates the placebo effect in Study 2 was only 
shown after a single placebo administration. It could be argued that participants who respond 
to a particular placebo treatment may not respond in a similar way to subsequent 
administrations. Reproducibility of participants’ response to a placebo treatment is subject to 
debate (Horing et al., 2014; Kaptchuk, Kelley, Deykin, et al., 2008) and there is a lack of 
evidence to suggest that whatever predicts a placebo effect on one occasion will be predictive 
on another. Future research should aim to replicate the findings from Study 2 of this research 
and determine if intention accurately and reliably predicts the placebo effect across multiple 
placebo administrations.  
While it has been recognised for some time that the placebo effect could be used as a 
vehicle to prevent substance use behaviours (Beedie, 2007; Kalasountas et al., 2007; 
Maganaris et al., 2000; McClung & Collins, 2007), to the authors knowledge, Study 3 of this 
research programme is the first to empirically test whether a placebo intervention can 
influence an athlete’s beliefs and intentions towards sport supplements and attitudes to 
doping. However, future research is needed to extend this research and determine the extent 
to which a placebo intervention influences future doping behaviours, challenging though this 
is recognised to be. Furthermore, and in light of the finding that around a quarter of 
participants with no intention to use supplements prior to the placebo intervention reported 
they were more likely to after the intervention, future research is needed to determine the 
effectiveness of other types of anti-doping interventions. It is possible that other anti-doping 
education interventions elicit similarly unintended effects, but this proposition remains 
untested. International (e.g. WADA, IAAF and UCI) and national (e.g. UKAD, USADA and 
ASADA) anti-doping organisations implement educational interventions worldwide but there 
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is little evidence regarding the efficacy of these interventions. Future research should 
prioritise the evaluation of anti-doping educational interventions to ensure they are achieving 
their objectives.  
7.6 Conclusion 
This research programme investigated the magnitude and moderators of the placebo 
and nocebo effect on sport performance and the impact of a placebo intervention on athletes’ 
beliefs and intentions towards sport supplements and attitudes to doping. Data from Study 2 
of this research suggest that on average the ingestion of a purported sport supplement does 
not improve performance (i.e. no mean placebo effect was observed), but can significantly 
impair it (i.e. a mean nocebo effect). These findings run counter to the majority of placebo 
effect research reported elsewhere, which suggest both placebo and nocebo effects 
significantly influence sports performance. An explanation for the difference in findings may 
be attributed to the inclusion of the no-treatment control, which facilitates more accurate 
identification of effects. Although no mean placebo effect was observed, results indicated that 
athletes’ intention to use sport supplements influenced the direction and magnitude of 
subsequent placebo responses, with athletes intending to use supplements more likely to 
respond to a placebo intervention. These results highlight the significant contribution 
intention may have in the effectiveness of a treatment and have particular relevance for sport 
practitioners and researchers invested in the efficacy of a treatment and the validity of an 
intervention respectively. 
The results of this study also highlight the significant impact of a placebo intervention 
on athletes’ beliefs and intention to use sport supplements and attitudes to doping. While a 
placebo intervention appeared to be effective in reducing the self-reported likelihood of 
supplement use, sub-analyses indicated that approximately one quarter of participants not 
 
 
149 
 
intending to use supplements prior to the intervention were more likely to use them 
afterwards. This highlights the potential risk of administering anti-doping interventions to 
athletes not intending to use supplements, as exposure may increase sport supplement use and 
their risk of progressing to doping. Anti-doping interventions designed to reduce incidence of 
substance use among those not intending to use them may therefore be counter-productive. 
These findings have potentially important implications for the interventions used by policy 
makers and national governing bodies, and suggest that it is important to assess participants’ 
intention prior to any intervention aimed to reduce performance enhancing substance use.  
 
 
150 
 
 
Chapter Eight  
 
REFERENCES 
  
 
 
151 
 
Reference list 
 
Ajzen, I. (1985). From Intentions to Actions: A Theory of Planned Behavior. Berlin: 
Springer. 
Ajzen, I. (1991). The Theory of Planned Behavior. Organizational behavior and human 
decision processes, 50(2), 179-211.  
Ajzen, I., & Fishbein, M. (1975). Belief, attitude, intention and behavior: An introduction to 
theory and research: Reading, MA: Addison-Wesley. 
Albring, A., Wendt, L., Benson, S., Nissen, S., Yavuz, Z., Engler, H., . . . Schedlowski, M. 
(2014). Preserving learned immunosuppressive placebo response: perspectives for 
clinical application. Clinical Pharmacology & Therapeutics, 96(2), 247-255.  
Amanzio, M., & Benedetti, F. (1999). Neuropharmacological dissection of placebo analgesia: 
expectation-activated opioid systems versus conditioning-activated specific 
subsystems. Journal of Neuroscience, 19(1), 484-494.  
Amanzio, M., Pollo, A., Maggi, G., & Benedetti, F. (2001). Response variability to 
analgesics: a role for non-specific activation of endogenous opioids. Pain, 90(3), 205-
215.  
American Psychological Association. (2017). Ethical principles of psychologists and code of 
conduct. Amer Psychol, 57(12), 1060-1073. doi:10.1037/0003-066X.57.12.1060 
Anastasi, A., & Urbina, S. (1997). Psychology testing. In: New Jersey: Prentice Hall. 
Anderson, J. R., & Bower, G. H. (2014). Human associative memory: Psychology press. 
Andrew, B. J., Mullan, B. A., de Wit, J. B., Monds, L. A., Todd, J., & Kothe, E. J. (2016). 
Does the theory of planned behaviour explain condom use behaviour among men who 
have sex with men? a meta-analytic review of the literature. AIDS and Behavior, 
20(12), 2834-2844.  
 
 
152 
 
Ariel, G., & Saville, W. (1972). Effect of anabolic steroids on reflex components. Journal of 
applied physiology, 32(6), 795-797.  
Arnold, M. H., Finniss, D. G., & Kerridge, I. (2014). Medicine's inconvenient truth: the 
placebo and nocebo effect. Intern Med J, 44(4), 398-405. doi:10.1111/imj.12380 
ASADA. (2017). 2015-16 Annual Report.  Retrieved from 
https://www.asada.gov.au/sites/g/files/net126/f/ASADA%20AR1516%20AccPDF_w
eb.pdf?v=1477893100. 
Atlas, L. Y., & Wager, T. D. (2014). A meta-analysis of brain mechanisms of placebo 
analgesia: consistent findings and unanswered questions. Handb Exp Pharmacol, 225, 
37-69. doi:10.1007/978-3-662-44519-8_3 
Avena, N. M., Carrillo, C. A., Needham, L., Leibowitz, S. F., & Hoebel, B. G. (2004). Sugar-
dependent rats show enhanced intake of unsweetened ethanol. Alcohol, 34(2), 203-
209.  
Backhouse, S., McKenna, J., Robinson, S., & Atkin, A. (2007). International literature 
review: attitudes, behaviours, knowledge and education–drugs in sport: past, present 
and future. Report to the World Anti-Doping Agency (WADA).  
Backhouse, S., Whitaker, L., Patterson, L., Erickson, K., & McKenna, J. (2016). Social 
Psychology of Doping in Sport: A Mixed Studies Narrative Synthesis. Montreal, 
Canada: World Anti-Doping Agency. 
Backhouse, S. H., Patterson, L., & McKenna, J. (2012). Achieving the Olympic ideal: 
Preventing doping in sport. Performance Enhancement & Health, 1(2), 83-85. 
doi:10.1016/j.peh.2012.08.001 
Backhouse, S. H., Whitaker, L., & Petroczi, A. (2013). Gateway to doping? Supplement use 
in the context of preferred competitive situations, doping attitude, beliefs, and norms. 
 
 
153 
 
The Scandinavian Journal of Medicine & Science in Sports, 23(2), 244-252. 
doi:10.1111/j.1600-0838.2011.01374.x 
Bailey, R. L., Gahche, J. J., Miller, P. E., Thomas, P. R., & Dwyer, J. T. (2013). Why US 
adults use dietary supplements. JAMA internal medicine, 173(5), 355-361.  
Bandura, A. (1986). The explanatory and predictive scope of self-efficacy theory. Journal of 
social and clinical psychology, 4(3), 359-373.  
Bandura, A. (1989). Human agency in social cognitive theory. American Psychologist, 44(9), 
1175.  
Bandura, A. (1991). Social cognitive theory of self-regulation. Organizational behavior and 
human decision processes, 50(2), 248-287.  
Barbieri, F., Thellung, S., Ratto, A., Carra, E., Marini, V., Fucile, C., . . . Gatti, M. (2015). In 
vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated 
from spontaneous canine mammary carcinomas: translational implications for human 
tumors. BMC cancer, 15(1), 228.  
Barefoot, J. C., Brummett, B. H., Williams, R. B., Siegler, I. C., Helms, M. J., Boyle, S. H., . 
. . Mark, D. B. (2011). Recovery expectations and long-term prognosis of patients 
with coronary heart disease. Archives of internal medicine, 171(10), 929-935.  
Barkoukis, V., Kartali, K., Lazuras, L., & Tsorbatzoudis, H. (2016). Evaluation of an anti-
doping intervention for adolescents: Findings from a school-based study. Sport 
Management Review, 19(1), 23-34. doi:10.1016/j.smr.2015.12.003 
Barkoukis, V., Lazuras, L., Lucidi, F., & Tsorbatzoudis, H. (2015). Nutritional supplement 
and doping use in sport: Possible underlying social cognitive processes. Scand J Med 
Sci Sports, 25(6), e582-588. doi:10.1111/sms.12377 
 
 
154 
 
Barkoukis, V., Lazuras, L., Tsorbatzoudis, H., & Rodafinos, A. (2011). Motivational and 
sportspersonship profiles of elite athletes in relation to doping behavior. Psychology 
of Sport and Exercise, 12(3), 205-212.  
Barkoukis, V., Lazuras, L., Tsorbatzoudis, H., & Rodafinos, A. (2013). Motivational and 
social cognitive predictors of doping intentions in elite sports: an integrated approach. 
Scand J Med Sci Sports, 23(5), e330-340. doi:10.1111/sms.12068 
Barnette, J. J. (2001). Likert Survey Primacy Effect in the Absence or Presence of 
Negatively-Worded Items. Research in the Schools, 8(1), 77-82.  
Baron, R. M., & Kenny, D. A. (1986). The moderator–mediator variable distinction in social 
psychological research: Conceptual, strategic, and statistical considerations. Journal 
of Personality and Social Psychology, 51(6), 1173.  
Baumeister, R. F., Bratslavsky, E., Finkenauer, C., & Vohs, K. D. (2001). Bad is stronger 
than good. Review of general psychology, 5(4), 323.  
Baumgarten, F., Lucidi, F., Mallia, L., Zelli, A., & Brand, R. (2016). Bury the inner hatchet: 
Complex propositions mediate the relationship of potentially discrepant implicit and 
explicit attitudes on doping intention. Performance Enhancement & Health, 5(1), 10-
16. doi:10.1016/j.peh.2016.01.002 
Beecher, H. K. (1955). The powerful placebo. Journal of the American Medical Association, 
159(17), 1602-1606.  
Beedie, C. (2007). Placebo effects in competitive sport: qualitative data. J Sports Sci Med, 
6(1), 21-28.  
Beedie, C., Coleman, D. A., & Foad, A. J. (2007). Positive and negative placebo effects 
resulting from the deceptive administration of an ergogenic aid. Int J Sport Nutr Exerc 
Metab, 17(3), 259-269.  
 
 
155 
 
Beedie, C., Foad, A., & Hurst, P. (2015). Capitalizing on the placebo component of 
treatments. Current sports medicine reports, 14(4), 284-287.  
Beedie, C., & Foad, A. J. (2009). The placebo effect in sports performance: a brief review. 
Sports Med, 39(4), 313-329. doi:10.2165/00007256-200939040-00004 
Beedie, C., Foad, A. J., & Coleman, D. A. (2008). Identification of placebo responsive 
participants in 40km laboratory cycling performance. J Sports Sci Med, 7(1), 166-175.  
Beedie, C., Stuart, E. M., Coleman, D. A., & Foad, A. J. (2006). Placebo effects of caffeine 
on cycling performance. Med Sci Sports Exerc, 38(12), 2159-2164. 
doi:10.1249/01.mss.0000233805.56315.a9 
Beedie, C., Whyte, G., Lane, A. M., Cohen, E., Raglin, J., Hurst, P., . . . Foad, A. (2017). 
‘Caution, this treatment is a placebo. It might work, but it might not’: why emerging 
mechanistic evidence for placebo effects does not legitimise complementary and 
alternative medicines in sport. In: BMJ Publishing Group Ltd and British Association 
of Sport and Exercise Medicine. 
Bélanger-Gravel, A., Godin, G., & Amireault, S. (2013). A meta-analytic review of the effect 
of implementation intentions on physical activity. Health Psychology Review, 7(1), 
23-54.  
Bell, A., Dorsch, K. D., McCreary, D. R., & Hovey, R. (2004). A look at nutritional 
supplement use in adolescents. J Adolesc Health, 34(6), 508-516. 
doi:10.1016/j.jadohealth.2003.07.024 
Bellinger, P. M., & Minahan, C. L. (2016). Performance effects of acute beta-alanine induced 
paresthesia in competitive cyclists. Eur J Sport Sci, 16(1), 88-95. 
doi:10.1080/17461391.2015.1005696 
Benedetti, F. (2008). Placebo Effects: Understanding the mechanisms in health and disease. 
U.S.A.: Oxford University Press. 
 
 
156 
 
Benedetti, F. (2013). Placebo and the new physiology of the doctor-patient relationship. 
Physiol Rev, 93(3), 1207-1246. doi:10.1152/physrev.00043.2012 
Benedetti, F. (2014). Placebo effects: from the neurobiological paradigm to translational 
implications. Neuron, 84(3), 623-637. doi:10.1016/j.neuron.2014.10.023 
Benedetti, F. (2016). Beecher as Clinical Investigator: Pain and the Placebo Effect. 
Perspectives in biology and medicine, 59(1), 37-45.  
Benedetti, F., Amanzio, M., Rosato, R., & Blanchard, C. (2011). Nonopioid placebo 
analgesia is mediated by CB1 cannabinoid receptors. Nat Med, 17(10), 1228-1230. 
doi:10.1038/nm.2435 
Benedetti, F., Arduino, C., & Amanzio, M. (1999). Somatotopic activation of opioid systems 
by target-directed expectations of analgesia. Journal of Neuroscience, 19(9), 3639-
3648.  
Benedetti, F., Carlino, E., & Piedimonte, A. (2016). Increasing uncertainty in CNS clinical 
trials: the role of placebo, nocebo, and Hawthorne effects. The Lancet Neurology, 
15(7), 736-747. doi:10.1016/s1474-4422(16)00066-1 
Benedetti, F., & Dogue, S. (2015). Different Placebos, Different Mechanisms, Different 
Outcomes: Lessons for Clinical Trials. PLoS One, 10(11), e0140967. 
doi:10.1371/journal.pone.0140967 
Benedetti, F., Durando, J., & Vighetti, S. (2014). Nocebo and placebo modulation of 
hypobaric hypoxia headache involves the cyclooxygenase-prostaglandins pathway. 
Pain, 155(5), 921-928. doi:10.1016/j.pain.2014.01.016 
Benedetti, F., Pollo, A., Lopiano, L., Lanotte, M., Vighetti, S., & Rainero, I. (2003). 
Conscious expectation and unconscious conditioning in analgesic, motor, and 
hormonal placebo/nocebo responses. Journal of Neuroscience, 23(10), 4315-4323.  
 
 
157 
 
Bentler, P. M. (2006). EQS 6 structural equations program manual. In: Encino, CA: 
Multivariate Software, Inc. 
Bentler, P. M., & Chou, C.-P. (1987). Practical issues in structural modeling. Sociological 
Methods & Research, 16(1), 78-117.  
Biddle, S. J., Markland, D., Gilbourne, D., Chatzisarantis, N. L., & Sparkes, A. C. (2001). 
Research methods in sport and exercise psychology: Quantitative and qualitative 
issues. Journal of Sports Sciences, 19(10), 777-809.  
BOA. (2017). Get Set for the Spirit of Sport. Retrieved from http://www.getset.co.uk 
Boardley, I. D., Grix, J., & Dewar, A. J. (2014). Moral disengagement and associated 
processes in performance-enhancing drug use: a national qualitative investigation. J 
Sports Sci, 32(9), 836-844. doi:10.1080/02640414.2013.862842 
Boardley, I. D., Grix, J., & Harkin, J. (2015). Doping in team and individual sports: a 
qualitative investigation of moral disengagement and associated processes. 
Qualitative Research in Sport, Exercise and Health, 7(5), 698-717. 
doi:10.1080/2159676X.2014.992039 
Bollen, K. A. (2002). Latent variables in psychology and the social sciences. Annual review 
of psychology, 53(1), 605-634.  
Bottoms, L., Buscombe, R., & Nicholettos, A. (2014). The placebo and nocebo effects on 
peak minute power during incremental arm crank ergometry. Eur J Sport Sci, 14(4), 
362-367. doi:10.1080/17461391.2013.822564 
Broatch, J. R., Petersen, A., & Bishop, D. J. (2014). Postexercise cold water immersion 
benefits are not greater than the placebo effect. Med Sci Sports Exerc, 46(11), 2139-
2147. doi:10.1249/MSS.0000000000000348 
Burke, B. G. (1999). Item reversals and response validity in the Job Diagnostic Survey. 
Psychological Reports, 85(1), 213-219.  
 
 
158 
 
Byrne, B. M. (2013). Structural equation modeling with LISREL, PRELIS, and SIMPLIS: 
Basic concepts, applications, and programming: Psychology Press. 
Byrne, S., Linz, D., & Potter, W. J. (2009). A test of competing cognitive explanations for the 
boomerang effect in response to the deliberate disruption of media-induced 
aggression. Media Psychology, 12(3), 227-248.  
Carlino, E., & Benedetti, F. (2016). Different contexts, different pains, different experiences. 
Neuroscience, 338, 19-26. doi:10.1016/j.neuroscience.2016.01.053 
Carlino, E., Piedimonte, A., & Benedetti, F. (2016). Nature of the placebo and nocebo effect 
in relation to functional neurologic disorders. Handb Clin Neurol, 139, 597-606. 
doi:10.1016/B978-0-12-801772-2.00048-5 
Carlino, E., Piedimonte, A., & Frisaldi, E. (2014). The effects of placebos and nocebos on 
physical performance. Handb Exp Pharmacol, 225, 149-157. doi:10.1007/978-3-662-
44519-8_9 
Castell, L. M., Stear, S. J., & Burke, L. M. (2015). Nutritional supplements in sport, exercise 
and health: an AZ guide: Routledge. 
Champagne, A. B., & Emmel, K. V. (2011). Rapid screening test for adulteration in raw 
materials of dietary supplements. Vibrational Spectroscopy, 55(2), 216-223.  
Chan, D. K., Dimmock, J. A., Donovan, R. J., Hardcastle, S., Lentillon-Kaestner, V., & 
Hagger, M. S. (2015). Self-determined motivation in sport predicts anti-doping 
motivation and intention: a perspective from the trans-contextual model. J Sci Med 
Sport, 18(3), 315-322. doi:10.1016/j.jsams.2014.04.001 
Chan, D. K., Donovan, R. J., Lentillon-Kaestner, V., Hardcastle, S. J., Dimmock, J. A., 
Keatley, D. A., & Hagger, M. S. (2015). Young athletes' awareness and monitoring of 
anti-doping in daily life: Does motivation matter? Scand J Med Sci Sports, 25(6), 
e655-663. doi:10.1111/sms.12362 
 
 
159 
 
Chan, D. K., Hardcastle, S., Dimmock, J. A., Lentillon-Kaestner, V., Donovan, R. J., Burgin, 
M., & Hagger, M. S. (2015). Modal salient belief and social cognitive variables of 
anti-doping behaviors in sport: Examining an extended model of the theory of planned 
behavior. Psychology of Sport and Exercise, 16, 164-174. 
doi:10.1016/j.psychsport.2014.03.002 
Christiansen, P., Townsend, G., Knibb, G., & Field, M. (2017). Bibi ergo sum: the effects of 
a placebo and contextual alcohol cues on motivation to drink alcohol. 
Psychopharmacology, 234(5), 827-835.  
Clark, V. R., Hopkins, W. G., Hawley, J. A., & Burke, L. M. (2000). Placebo effect of 
carbohydrate feedings during a 40-km cycling time trial. Medicine and science in 
sports and exercise, 32(9), 1642-1647.  
Cohen, J. (1992). A power primer. Psychol Bull, 112(1), 155.  
Cohen, P. A., Bloszies, C., Yee, C., & Gerona, R. (2016). An amphetamine isomer whose 
efficacy and safety in humans has never been studied, beta-methylphenylethylamine 
(BMPEA), is found in multiple dietary supplements. Drug Test Anal, 8(3-4), 328-333. 
doi:10.1002/dta.1793 
Colloca, L., Klinger, R., Flor, H., & Bingel, U. (2013). Placebo analgesia: psychological and 
neurobiological mechanisms. Pain, 154(4), 511-514. doi:10.1016/j.pain.2013.02.002 
Colloca, L., & Miller, F. G. (2011a). Harnessing the placebo effect: the need for translational 
research. Philos Trans R Soc Lond B Biol Sci, 366(1572), 1922-1930. 
doi:10.1098/rstb.2010.0399 
Colloca, L., & Miller, F. G. (2011b). How placebo responses are formed: a learning 
perspective. Philos Trans R Soc Lond B Biol Sci, 366(1572), 1859-1869. 
doi:10.1098/rstb.2010.0398 
 
 
160 
 
Comrey, A. L. (1988). Factor-analytic methods of scale development in personality and 
clinical psychology. Journal of consulting and clinical psychology, 56(5), 754.  
Conner, M. (2015). Extending not retiring the theory of planned behaviour: a commentary on 
Sniehotta, Presseau and Araújo-Soares. Health Psychology Review, 9(2), 141-145.  
Conner, M., Kirk, S. F., Cade, J. E., & Barrett, J. H. (2001). Why do women use dietary 
supplements? The use of the theory of planned behaviour to explore beliefs about 
their use. Social science & medicine, 52(4), 621-633.  
Cooke, R., Dahdah, M., Norman, P., & French, D. P. (2016). How well does the theory of 
planned behaviour predict alcohol consumption? A systematic review and meta-
analysis. Health Psychology Review, 10(2), 148-167.  
Coomber, R. (2014). How social fear of drugs in the non-sporting world creates a framework 
for doping policy in the sporting world. International Journal of Sport Policy and 
Politics, 6(2), 171-193.  
Cross, M. R., Brughelli, M., Brown, S. R., Samozino, P., Gill, N. D., Cronin, J. B., & Morin, 
J. B. (2015). Mechanical Properties of Sprinting in Elite Rugby Union and Rugby 
League. Int J Sports Physiol Perform, 10(6), 695-702. doi:10.1123/ijspp.2014-0151 
Dascombe, B. J., Karunaratna, M., Cartoon, J., Fergie, B., & Goodman, C. (2010). 
Nutritional supplementation habits and perceptions of elite athletes within a state-
based sporting institute. Journal of Science and Medicine in Sport, 13(2), 274-280. 
doi:10.1016/j.jsams.2009.03.005 
de Craen, A. J., Tijssen, J., de Gans, J., & Kleijnen, J. (2000). Placebo effect in the acute 
treatment of migraine: subcutaneous placebos are better than oral placebos. Journal of 
neurology, 247(3), 183-188.  
de Hon, O. (2016). Striking the Right Balance. (PhD), Utrecht University, Amsterdam.  
 
 
161 
 
de Hon, O., Kuipers, H., & van Bottenburg, M. (2015). Prevalence of doping use in elite 
sports: a review of numbers and methods. Sports Med, 45(1), 57-69. 
doi:10.1007/s40279-014-0247-x 
de la Fuente-Fernández, R., Ruth, T. J., Sossi, V., Schulzer, M., Calne, D. B., & Stoessl, A. J. 
(2001). Expectation and dopamine release: mechanism of the placebo effect in 
Parkinson's disease. Science, 293(5532), 1164-1166.  
de la Vega, R., Alberti, S., Ruiz-Barquin, R., Soos, I., & Szabo, A. (2017). Induced beliefs 
about a fictive energy drink influences 200-m sprint performance. Eur J Sport Sci, 
17(8), 1084-1089. doi:10.1080/17461391.2017.1339735 
De Pascalis, V., Chiaradia, C., & Carotenuto, E. (2002). The contribution of suggestibility 
and expectation to placebo analgesia phenomenon in an experimental setting. Pain, 
96(3), 393-402.  
Deci, E., & Ryan, R. M. (1985). Intrinsic motivation and self-determination in human 
behavior: Springer Science & Business Media. 
Deci, E. L., & Ryan, R. M. (2008). Self-determination theory: A macrotheory of human 
motivation, development, and health. Canadian psychology/Psychologie canadienne, 
49(3), 182.  
Desbrow, B., McCormack, J., Burke, L. M., Cox, G. R., Fallon, K., Hislop, M., . . . Leveritt, 
M. (2014). Sports Dietitians Australia position statement: sports nutrition for the 
adolescent athlete. Int J Sport Nutr Exerc Metab, 24(5), 570-584. 
doi:10.1123/ijsnem.2014-0031 
DeVellis, R. F. (2016). Scale development: Theory and applications (Vol. 26): Sage 
publications. 
 
 
162 
 
Dickinson, A., Blatman, J., El-Dash, N., & Franco, J. C. (2014). Consumer usage and reasons 
for using dietary supplements: report of a series of surveys. Journal of the American 
College of Nutrition, 33(2), 176-182.  
Dietz, P., Ulrich, R., Dalaker, R., Striegel, H., Franke, A. G., Lieb, K., & Simon, P. (2013). 
Associations between physical and cognitive doping--a cross-sectional study in 2.997 
triathletes. PLoS One, 8(11), e78702. doi:10.1371/journal.pone.0078702 
Dimeo, P. (2008). A history of drug use in sport: 1876–1976: Beyond good and evil: 
Routledge. 
Dimeo, P. (2016). The myth of clean sport and its unintended consequences. Performance 
Enhancement & Health, 4(3-4), 103-110. doi:10.1016/j.peh.2016.04.001 
Dodge, T., & Jaccard, J. J. (2007). Negative Beliefs as a Moderator of the Intention–Behavior 
Relationship: Decisions to Use Performance‐Enhancing Substances. Journal of 
Applied Social Psychology, 37(1), 43-59.  
Dodge, T., & Jaccard, J. J. (2008). Is abstinence an alternative? Predicting adolescent 
athletes' intentions to use performance enhancing substances. J Health Psychol, 13(5), 
703-711. doi:10.1177/1359105307082460 
Duncan, M. J. (2010). The effect of caffeine ingestion on anaerobic performance in 
moderately trained adults. Serbian Journal of Sports Sciences, 3(4), 129-134.  
Duncan, M. J., Lyons, M., & Hankey, J. (2009). Placebo effects of caffeine on short-term 
resistance exercise to failure. International Journal of Sports Physiology and 
Performance, 4(2), 244-253.  
Dvorak, J., Saugy, M., & Pitsiladis, Y. P. (2014). Challenges and threats to implementing the 
fight against doping in sport. Br J Sports Med, 48(10), 807-809. doi:10.1136/bjsports-
2014-093589 
 
 
163 
 
Elbe, A.-M., & Brand, R. (2014). The Effect of an Ethical Decision-Making Training on 
Young Athletes’ Attitudes Toward Doping. Ethics & Behavior, 26(1), 32-44. 
doi:10.1080/10508422.2014.976864 
Elbe, A.-M., & Brand, R. (2016). The effect of an ethical decision-making training on young 
athletes’ attitudes toward doping. Ethics & Behavior, 26(1), 32-44. 
doi:10.1080/10508422.2014.976864 
Elliot, D. L., Goldberg, L., Moe, E. L., DeFrancesco, C. A., Durham, M. B., & Hix-Small, H. 
(2004). Preventing substance use and disordered eating: initial outcomes of the 
ATHENA (athletes targeting healthy exercise and nutrition alternatives) program. 
Archives of Pediatrics & Adolescent Medicine, 158(11), 1043-1049.  
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013). The placebo response in medicine: 
minimize, maximize or personalize? Nat Rev Drug Discov, 12(3), 191-204. 
doi:10.1038/nrd3923 
Estabrooks, P. A. (2017). Physical activity promotion and translational research. In: Springer. 
Everitt, B. J., & Robbins, T. W. (2005). Neural systems of reinforcement for drug addiction: 
from actions to habits to compulsion. Nat Neurosci, 8(11), 1481-1489. 
doi:10.1038/nn1579 
Everitt, B. J., & Robbins, T. W. (2013). From the ventral to the dorsal striatum: devolving 
views of their roles in drug addiction. Neuroscience & Biobehavioral Reviews, 37(9), 
1946-1954.  
Eysenck, H. (1959). The differentiation between normal and various neurotic groups on the 
Maudsley Personality Inventory. British Journal of Psychology, 50(2), 176-177.  
Fergusson, D. M., & Horwood, L. J. (2000). Does cannabis use encourage other forms of 
illicit drug use? Addiction, 95(4), 505-520.  
 
 
164 
 
Ferrario, C. R., & Robinson, T. E. (2007). Amphetamine pretreatment accelerates the 
subsequent escalation of cocaine self-administration behavior. European 
neuropsychopharmacology, 17(5), 352-357.  
FIFA. (2017). 11 rules to prevent doping Retrieved from https://no-
doping.fifa.com/en/prevention/11-rules-of-the-game.html 
Finlay, L., & Gough, B. (2008). Reflexivity: A practical guide for researchers in health and 
social sciences: John Wiley & Sons. 
Finniss, D. G., Kaptchuk, T. J., Miller, F., & Benedetti, F. (2010). Biological, clinical, and 
ethical advances of placebo effects. The Lancet, 375(9715), 686-695.  
Fishbein, M., & Ajzen, I. (1977). Belief, attitude, intention, and behavior: An introduction to 
theory and research. 
Foad, A. J., Beedie, C., & Coleman, D. A. (2008). Pharmacological and psychological effects 
of caffeine ingestion in 40-km cycling performance. Med Sci Sports Exerc, 40(1), 
158-165. doi:10.1249/mss.0b013e3181593e02 
Fulda, S., & Wetter, T. C. (2007). Where dopamine meets opioids: a meta-analysis of the 
placebo effect in restless legs syndrome treatment studies. Brain, 131(4), 902-917.  
Furmark, T., Appel, L., Henningsson, S., Åhs, F., Faria, V., Linnman, C., . . . Bettica, P. 
(2008). A link between serotonin-related gene polymorphisms, amygdala activity, and 
placebo-induced relief from social anxiety. Journal of Neuroscience, 28(49), 13066-
13074.  
Garcia, J. (2015). Teaching the placebo effect. Acad Psychiatry, 39(1), 122. 
doi:10.1007/s40596-014-0225-5 
Geers, A. L., Helfer, S. G., Kosbab, K., Weiland, P. E., & Landry, S. J. (2005). 
Reconsidering the role of personality in placebo effects: dispositional optimism, 
 
 
165 
 
situational expectations, and the placebo response. J Psychosom Res, 58(2), 121-127. 
doi:10.1016/j.jpsychores.2004.08.011 
Geers, A. L., & Miller, F. G. (2014). Understanding and translating the knowledge about 
placebo effects: the contribution of psychology. Curr Opin Psychiatry, 27(5), 326-
331. doi:10.1097/YCO.0000000000000082 
Geers, A. L., Wellman, J. A., Fowler, S. L., Helfer, S. G., & France, C. R. (2010). 
Dispositional optimism predicts placebo analgesia. J Pain, 11(11), 1165-1171. 
doi:10.1016/j.jpain.2010.02.014 
Geyer, H., Parr, M., Mareck, U., Reinhart, U., Schrader, Y., & Schänzer, W. (2004). Analysis 
of non-hormonal nutritional supplements for anabolic-androgenic steroids-results of 
an international study. International journal of sports medicine, 25(02), 124-129.  
Geyer, H., Parr, M. K., Koehler, K., Mareck, U., Schanzer, W., & Thevis, M. (2008). 
Nutritional supplements cross-contaminated and faked with doping substances. J 
Mass Spectrom, 43(7), 892-902. doi:10.1002/jms.1452 
Gheorghiu, V. A., & Reyher, J. (1982). The effect of different types of influence on an 
“indirect-direct” form of a scale of sensory suggestibility. American Journal of 
Clinical Hypnosis, 24(3), 191-199.  
Glasser, S. P., & Frishman, W. (2008). Essentials of clinical research: Springer. 
Gleaves, J., & Hunt, T. (2016). A Global History of Doping in Sport: Drugs, Policy, and 
Politics: Routledge. 
Goldberg, L., Elliot, D., Clarke, G. N., MacKinnon, D. P., Moe, E., Zoref, L., . . . Miller, D. 
J. (1996). Effects of a multidimensional anabolic steroid prevention intervention: The 
Adolescents Training and Learning to Avoid Steroids (ATLAS) Program. JAMA, 
276(19), 1555-1562.  
 
 
166 
 
Gosnell, B. A. (2005). Sucrose intake enhances behavioral sensitization produced by cocaine. 
Brain Research, 1031(2), 194-201.  
Goulet, C., Valois, P., Buist, A., & Cote, M. (2010). Predictors of the use of performance-
enhancing substances by young athletes. Clin J Sport Med, 20(4), 243-248. 
doi:10.1097/JSM.0b013e3181e0b935 
Gucciardi, D. F., Jalleh, G., & Donovan, R. J. (2010). Does social desirability influence the 
relationship between doping attitudes and doping susceptibility in athletes? 
Psychology of Sport and Exercise, 11(6), 479-486. 
doi:10.1016/j.psychsport.2010.06.002 
Gucciardi, D. F., Jalleh, G., & Donovan, R. J. (2011). An examination of the Sport Drug 
Control Model with elite Australian athletes. J Sci Med Sport, 14(6), 469-476. 
doi:10.1016/j.jsams.2011.03.009 
Hair, J. F., Black, W. C., Babin, B. J., Anderson, R. E., & Tatham, R. L. (2006). Multivariate 
data analysis (Vol. 6): Pearson Prentice Hall Upper Saddle River. NJ. 連結.  
Hall, K. T., Lembo, A. J., Kirsch, I., Ziogas, D. C., Douaiher, J., Jensen, K. B., . . . Kaptchuk, 
T. J. (2012). Catechol-O-methyltransferase val158met polymorphism predicts placebo 
effect in irritable bowel syndrome. PLoS One, 7(10), e48135. 
doi:10.1371/journal.pone.0048135 
Hall, K. T., Loscalzo, J., & Kaptchuk, T. J. (2015). Genetics and the placebo effect: the 
placebome. Trends Mol Med, 21(5), 285-294. doi:10.1016/j.molmed.2015.02.009 
Harris, J. L., Pierce, M., & Bargh, J. A. (2014). Priming effect of antismoking PSAs on 
smoking behaviour: a pilot study. Tobacco control, 23(4), 285-290.  
Haugen, T., & Buchheit, M. (2016). Sprint running performance monitoring: Methodological 
and practical considerations. Sports Med, 46(5), 641-656.  
 
 
167 
 
Hauw, D., & McNamee, M. (2015). A critical analysis of three psychological research 
programs of doping behaviour. Psychology of Sport and Exercise, 16, 140-148. 
doi:10.1016/j.psychsport.2014.03.010 
Hayes, A. F. (2009). Beyond Baron and Kenny: Statistical mediation analysis in the new 
millennium. Communication monographs, 76(4), 408-420. 
doi:10.1080/03637750903310360 
Heene, M., Hilbert, S., Draxler, C., Ziegler, M., & Bühner, M. (2011). Masking misfit in 
confirmatory factor analysis by increasing unique variances: a cautionary note on the 
usefulness of cutoff values of fit indices. Psychological methods, 16(3), 319.  
Heikkinen, A., Alaranta, A., Helenius, I., & Vasankari, T. (2011). Use of dietary supplements 
in Olympic athletes is decreasing: a follow-up study between 2002 and 2009. Journal 
of the International Society of Sports Nutrition, 8(1), 1.  
Hendrickson, L., & Jones, B. (1987). A study of longitudinal causal models comparing gain 
score analysis with structural equation approaches. Structural modeling by example: 
Applications in educational, sociological and behavioral research, 86-107.  
Henne, K. (2015). Testing for athlete citizenship: Regulating doping and sex in sport: Rutgers 
University Press. 
Henne, K., Koh, B., & McDermott, V. (2013). Coherence of drug policy in sports: Illicit 
inclusions and illegal inconsistencies. Performance Enhancement & Health, 2(2), 48-
55. doi:10.1016/j.peh.2013.05.003 
Hildebrandt, T., Harty, S., & Langenbucher, J. W. (2012). Fitness supplements as a gateway 
substance for anabolic-androgenic steroid use. Psychology of Addictive Behaviors, 
26(4), 955-962. doi:10.1037/a0027877 
Hoberman, J. (2001). Mortal engines: The science of performance and the dehumanization of 
sport: Blackburn Press. 
 
 
168 
 
Hoberman, J. (2013). How much do we (really) know about anti-doping education? 
Performance Enhancement & Health, 2(4), 137-143. doi:10.1016/j.peh.2014.09.002 
Holroyd, K. A., Labus, J. S., & Carlson, B. (2009). Moderation and mediation in the 
psychological and drug treatment of chronic tension-type headache: the role of 
disorder severity and psychiatric comorbidity. PAIN®, 143(3), 213-222.  
Hopkins, W. G. (2015). Speadsheets for Analysis of Validity and Reliability. Sportsci, 19, 
26-42.  
Hopkins, W. G. (2016). Estimating sample size for magnitude-based inferences. Sportsci, 10, 
63-69.  
Hopkins, W. G., Hawley, J. A., & Burke, L. M. (1999). Design and analysis of research on 
sport performance enhancement. Med Sci Sports Exerc, 31(3), 472-485.  
Horing, B., Weimer, K., Muth, E. R., & Enck, P. (2014). Prediction of placebo responses: a 
systematic review of the literature. Front Psychol, 5, 1079. 
doi:10.3389/fpsyg.2014.01079 
Houlihan, B. (2002). Dying to win: Doping in sport and the development of anti-doping 
policy (Vol. 996): Council of Europe. 
Hróbjartsson, A., & Gotzsche, P. (2003). Placebo treatment versus no treatment. Cochrane 
Database Syst Rev, 1, CD003974.  
Hróbjartsson, A., & Gøtzsche, P. C. (2001). Is the placebo powerless? N Engl J Med, 
2001(344), 1594-1602.  
Hu, L. t., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure 
analysis: Conventional criteria versus new alternatives. Structural equation modeling: 
a multidisciplinary journal, 6(1), 1-55.  
 
 
169 
 
Huber, A., Lui, F., & Porro, C. A. (2013). Hypnotic susceptibility modulates brain activity 
related to experimental placebo analgesia. Pain, 154(9), 1509-1518. 
doi:10.1016/j.pain.2013.03.031 
Hulston, C. J., & Jeukendrup, A. E. (2009). No placebo effect from carbohydrate intake 
during prolonged exercise. International journal of sport nutrition and exercise 
metabolism, 19(3), 275-284.  
Hyman, S. E., & Malenka, R. C. (2001). Addiction and the brain: the neurobiology of 
compulsion and its persistence. Nature reviews. Neuroscience, 2(10), 695.  
Jalilian, F., Allahverdipour, H., Moeini, B., & Moghimbeigi, A. (2011). Effectiveness of 
anabolic steroid preventative intervention among gym users: Applying theory of 
planned behavior. Health promotion perspectives, 1(1), 32.  
Jarcho, J. M., Feier, N. A., Labus, J. S., Naliboff, B., Smith, S. R., Hong, J. Y., . . . London, 
E. D. (2016). Placebo analgesia: Self-report measures and preliminary evidence of 
cortical dopamine release associated with placebo response. Neuroimage Clin, 10, 
107-114. doi:10.1016/j.nicl.2015.11.009 
Jensen, J. S., Bielefeldt, A. Ø., & Hróbjartsson, A. (2017). Active placebo control groups of 
pharmacological interventions were rarely used but merited serious consideration: A 
methodological overview. Journal of clinical epidemiology, 87, 35-46.  
Johnston, L. D., O’Malley, P. M., Bachman, J. G., Schulenberg, J. E., Patrick, M. E., & 
Miech, R. (2013). HIV/AIDS: Risk Protective Behaviors among American Young 
Adults, 2004-2012.  
Judd, C. M., McClelland, G. H., & Ryan, C. S. (2011). Data analysis: A model comparison 
approach: Routledge. 
 
 
170 
 
Kalasountas, V., Reed, J., & Fitzpatrick, J. (2007). The Effect of Placebo-Induced Changes in 
Expectancies on Maximal Force Production in College Students. Journal of Applied 
Sport Psychology, 19(1), 116-124. doi:10.1080/10413200601123736 
Kam-Hansen, S., Jakubowski, M., Kelley, J. M., Kirsch, I., Hoaglin, D. C., Kaptchuk, T. J., 
& Burstein, R. (2014). Altered placebo and drug labeling changes the outcome of 
episodic migraine attacks. Sci Transl Med, 6(218), 218ra215. 
doi:10.1126/scitranslmed.3006175 
Kam, C. C. S. (2017). Novel Insights Into Item Keying/Valence Effect Using Latent 
Difference (LD) Modeling Analysis. Journal of personality assessment, 1-9.  
Kandel, D. (1975). Stages in adolescent involvement in drug use. Science, 190(4217), 912-
914.  
Kandel, E. R., & Kandel, D. B. (2014). Shattuck Lecture. A molecular basis for nicotine as a 
gateway drug. N Engl J Med, 371(10), 932-943. doi:10.1056/NEJMsa1405092 
Kaptchuk, T. J., Goldman, P., Stone, D. A., & Stason, W. B. (2000). Do medical devices 
have enhanced placebo effects? Journal of clinical epidemiology, 53(8), 786-792.  
Kaptchuk, T. J., Kelley, J. M., Conboy, L. A., Davis, R. B., Kerr, C. E., Jacobson, E. E., . . . 
Lembo, A. J. (2008). Components of placebo effect: randomised controlled trial in 
patients with irritable bowel syndrome. BMJ, 336(7651), 999-1003. 
doi:10.1136/bmj.39524.439618.25 
Kaptchuk, T. J., Kelley, J. M., Deykin, A., Wayne, P. M., Lasagna, L. C., Epstein, I. O., . . . 
Wechsler, M. E. (2008). Do "placebo responders" exist? Contemp Clin Trials, 29(4), 
587-595. doi:10.1016/j.cct.2008.02.002 
Kavussanu, M., & Ring, C. (2017). Moral identity predicts doping likelihood via moral 
disengagement and anticipated guilt. Journal of sport & exercise psychology, 39(4), 
293-301. doi:10.1123/jsep.2016-0333 
 
 
171 
 
Kessner, S., Forkmann, K., Ritter, C., Wiech, K., Ploner, M., & Bingel, U. (2014). The effect 
of treatment history on therapeutic outcome: psychological and neurobiological 
underpinnings. PLoS One, 9(9), e109014. doi:10.1371/journal.pone.0109014 
Kienle, G. S., & Kiene, H. (1997). The powerful placebo effect: fact or fiction? Journal of 
clinical epidemiology, 50(12), 1311-1318.  
Kirby, K., Guerin, S., Moran, A. P., & Matthews, J. (2016). Doping in Elite Sport: Linking 
Behavior, Attitudes, and Psychological Theory. In V. Barkoukis, L. Lazuras, & H. 
Tsorbatzoudis (Eds.), The Psychology of Doping in Sport (pp. 3-17). New York: 
Routledge. 
Kirsch, I. (1985). Response expectancy as a determinant of experience and behavior. 
American Psychologist, 40(11), 1189.  
Kirsch, I. (2004). Conditioning, expectancy, and the placebo effect: comment on Stewart-
Williams and Podd (2004).  
Kirsch, I. (2013). The placebo effect revisited: lessons learned to date. Complement Ther 
Med, 21(2), 102-104. doi:10.1016/j.ctim.2012.12.003 
Kirsch, I., Kong, J., Sadler, P., Spaeth, R., Cook, A., Kaptchuk, T., & Gollub, R. (2014). 
Expectancy and Conditioning in Placebo Analgesia: Separate or Connected 
Processes? Psychol Conscious (Wash D C), 1(1), 51-59. doi:10.1037/cns0000007 
Kirsch, I., Wampold, B., & Kelley, J. M. (2016). Controlling for the placebo effect in 
psychotherapy: Noble quest or tilting at windmills? Psychology of Consciousness: 
Theory, Research, and Practice, 3(2), 121.  
Kirsch, I., & Weixel, L. J. (1988). Double-blind versus deceptive administration of a placebo. 
Behav Neurosci, 102(2), 319-323.  
Kleinig, J. (2015). Ready for Retirement: The Gateway Drug Hypothesis. Subst Use Misuse, 
50(8-9), 971-975. doi:10.3109/10826084.2015.1007679 
 
 
172 
 
Klinger, R., Colloca, L., Bingel, U., & Flor, H. (2014). Placebo analgesia: clinical 
applications. Pain, 155(6), 1055-1058. doi:10.1016/j.pain.2013.12.007 
Knapik, J. J., Steelman, R. A., Hoedebecke, S. S., Austin, K. G., Farina, E. K., & Lieberman, 
H. R. (2016). Prevalence of Dietary Supplement Use by Athletes: Systematic Review 
and Meta-Analysis. Sports Medicine, 46(1), 103-123. doi:10.1007/s40279-015-0387-7 
Knowles, J., & Lucas, C. (1960). Experimental studies of the placebo response. The British 
Journal of Psychiatry, 106(442), 231-240.  
Kong, J., Gollub, R. L., Rosman, I. S., Webb, J. M., Vangel, M. G., Kirsch, I., & Kaptchuk, 
T. J. (2006). Brain activity associated with expectancy-enhanced placebo analgesia as 
measured by functional magnetic resonance imaging. Journal of Neuroscience, 26(2), 
381-388.  
Kong, J., Kaptchuk, T. J., Polich, G., Kirsch, I., Vangel, M., Zyloney, C., . . . Gollub, R. 
(2009). Expectancy and treatment interactions: a dissociation between acupuncture 
analgesia and expectancy evoked placebo analgesia. Neuroimage, 45(3), 940-949.  
la Fuente‐Fernández, R. (2012). The powerful pre‐treatment effect: placebo responses in 
restless legs syndrome trials. European journal of neurology, 19(10), 1305-1310.  
Lane, A. M., Meyer, B. B., Devonport, T. J., Davies, K. A., Thelwell, R., Gill, G. S., . . . 
Weston, N. (2009). Validity of the emotional intelligence scale for use in sport. 
Journal of sports science & medicine, 8(2), 289.  
Lane, A. M., Sewell, D. F., Terry, P. C., Bartram, D., & Nesti, M. S. (1999). Confirmatory 
factor analysis of the competitive state anxiety inventory-2. Journal of Sports 
Sciences, 17(6), 505-512.  
Lavalle-González, F., Januszewicz, A., Davidson, J., Tong, C., Qiu, R., Canovatchel, W., & 
Meininger, G. (2013). Efficacy and safety of canagliflozin compared with placebo and 
 
 
173 
 
sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a 
randomised trial. Diabetologia, 56(12), 2582-2592.  
Lazuras, L., Barkoukis, V., Mallia, L., Lucidi, F., & Brand, R. (2017). More than a feeling: 
The role of anticipated regret in predicting doping intentions in adolescent athletes. 
Psychology of Sport and Exercise, 30, 196-204. doi:10.1016/j.psychsport.2017.03.003 
Lazuras, L., Barkoukis, V., Rodafinos, A., & Tzorbatzoudis, H. (2010). Predictors of doping 
intentions in elite-level athletes: a social cognition approach. Journal of Sport and 
Exercise Psychology, 32(5), 694-710.  
Lee, I.-S., Lee, B., Park, H.-J., Olausson, H., Enck, P., & Chae, Y. (2015). A new animal 
model of placebo analgesia: involvement of the dopaminergic system in reward 
learning. Scientific reports, 5, 17140.  
Levine, A., Huang, Y., Drisaldi, B., Griffin, E. A., Pollak, D. D., Xu, S., . . . Kandel, E. R. 
(2011). Molecular mechanism for a gateway drug: epigenetic changes initiated by 
nicotine prime gene expression by cocaine. Science translational medicine, 3(107), 
107ra109-107ra109.  
Levine, J., Gordon, N., & Fields, H. (1978). The mechanism of placebo analgesia. The 
Lancet, 312(8091), 654-657.  
Leys, C., Ley, C., Klein, O., Bernard, P., & Licata, L. (2013). Detecting outliers: Do not use 
standard deviation around the mean, use absolute deviation around the median. 
Journal of Experimental Social Psychology, 49(4), 764-766. 
doi:doi.org/10.1016/j.jesp.2013.03.013 
Lheureux, F., Auzoult, L., Charlois, C., Hardy‐Massard, S., & Minary, J. P. (2016). Traffic 
Offences: Planned or Habitual? Using the Theory of Planned Behaviour and habit 
strength to explain frequency and magnitude of speeding and driving under the 
influence of alcohol. British Journal of Psychology, 107(1), 52-71.  
 
 
174 
 
Lieberman, H. R., Marriott, B. P., Williams, C., Judelson, D. A., Glickman, E. L., Geiselman, 
P. J., . . . Mahoney, C. R. (2015). Patterns of dietary supplement use among college 
students. Clin Nutr, 34(5), 976-985. doi:10.1016/j.clnu.2014.10.010 
López, B. (2014). Creating fear: the ‘doping deaths’, risk communication and the anti-doping 
campaign. International Journal of Sport Policy and Politics, 6(2), 213-225.  
Lopez, C.-A. (1993). Franklin and Mesmer: an encounter. The Yale journal of biology and 
medicine, 66(4), 325.  
Lucidi, F., Grano, C., Leone, L., Lombardo, C., & Pesce, C. (2004). Determinants of the 
intention to use doping substances: An empirical contribution in a sample of Italian 
adolescents. International journal of sport psychology, 35(2), 133-148.  
Lucidi, F., Mallia, L., Alivernini, F., Chirico, A., Manganelli, S., Galli, F., . . . Zelli, A. 
(2017). The Effectiveness of a New School-Based Media Literacy Intervention on 
Adolescents’ Doping Attitudes and Supplements Use. Frontiers in psychology, 8, 749.  
Lucidi, F., Zelli, A., Mallia, L., Grano, C., Russo, P. M., & Violani, C. (2008). The social-
cognitive mechanisms regulating adolescents' use of doping substances. J Sports Sci, 
26(5), 447-456. doi:10.1080/02640410701579370 
Lun, V., Erdman, K. A., Fung, T. S., & Reimer, R. A. (2012). Dietary supplementation 
practices in Canadian high-performance athletes. International journal of sport 
nutrition and exercise metabolism, 22(1), 31-37.  
Lund, K., Vase, L., Petersen, G. L., Jensen, T. S., & Finnerup, N. B. (2014). Randomised 
controlled trials may underestimate drug effects: balanced placebo trial design. PLoS 
One, 9(1), e84104. doi:10.1371/journal.pone.0084104 
Lynn, M. R. (1986). Determination and quantification of content validity. Nursing research, 
35(6), 382-386.  
 
 
175 
 
MacKinnon, D. P., Fairchild, A. J., & Fritz, M. S. (2007). Mediation analysis. Annu. Rev. 
Psychol., 58, 593-614.  
Maganaris, C. N., Collins, D., & Sharp, M. (2000). Expectancy effects and strength training: 
do steroids make a difference? The Sport Psychologist, 14(3), 272-278.  
Mallia, L., Lazuras, L., Barkoukis, V., Brand, R., Baumgarten, F., Tsorbatzoudis, H., . . . 
Lucidi, F. (2016). Doping use in sport teams: The development and validation of 
measures of team-based efficacy beliefs and moral disengagement from a cross-
national perspective. Psychology of Sport and Exercise, 25, 78-88. 
doi:10.1016/j.psychsport.2016.04.005 
Marsh, H. W., Balla, J. R., & McDonald, R. P. (1988). Goodness-of-fit indexes in 
confirmatory factor analysis: The effect of sample size. Psychological Bulletin, 
103(3), 391.  
Marsh, H. W., Morin, A. J., Parker, P. D., & Kaur, G. (2014). Exploratory structural equation 
modeling: An integration of the best features of exploratory and confirmatory factor 
analysis. Annual review of clinical psychology, 10, 85-110.  
Marsh, H. W., & Yeung, A. S. (1997). Academic Self-Concept and Achievement. American 
Educational Research Journal, 34(4), 691-720.  
Martens, R., Vealey, R. S., & Burton, D. (1990). Competitive anxiety in sport: Human 
kinetics. 
Maughan, R. J. (2013). Quality assurance issues in the use of dietary supplements, with 
special reference to protein supplements. J Nutr, 143(11), 1843S-1847S. 
doi:10.3945/jn.113.176651 
Maughan, R. J., Burke, L. M., Dvorak, J., Larson-Meyer, D. E., Peeling, P., Phillips, S. M., . . 
. Geyer, H. (2018). IOC consensus statement: dietary supplements and the high-
 
 
176 
 
performance athlete. International journal of sport nutrition and exercise metabolism, 
28(2), 104-125. doi:10.1123/ijsnem.2018-0020 
Maughan, R. J., Depiesse, F., & Geyer, H. (2007). The use of dietary supplements by 
athletes. J Sports Sci, 25 Suppl 1, S103-113. doi:10.1080/02640410701607395 
Maughan, R. J., King, D. S., & Lea, T. (2004). Dietary supplements. J Sports Sci, 22(1), 95-
113. doi:10.1080/0264041031000140581 
Mazanov, J. (2016). Some guidelines for reporting research on performance enhancement. 
Performance Enhancement & Health, 5(1), 1-3. doi:10.1016/j.peh.2016.07.001 
McClung, M., & Collins, D. (2007). “Because I know it will!”: placebo effects of an 
ergogenic aid on athletic performance. Journal of Sport and Exercise Psychology, 
29(3), 382-394.  
McDermott, M. S., Oliver, M., Svenson, A., Simnadis, T., Beck, E. J., Coltman, T., . . . 
Sharma, R. (2015). The theory of planned behaviour and discrete food choices: a 
systematic review and meta-analysis. International Journal of Behavioral Nutrition 
and Physical Activity, 12(1), 162.  
McEachan, R. R. C., Conner, M., Taylor, N. J., & Lawton, R. J. (2011). Prospective 
prediction of health-related behaviours with the Theory of Planned Behaviour: a 
meta-analysis. Health Psychology Review, 5(2), 97-144. 
doi:10.1080/17437199.2010.521684 
McVeigh, J., Evans-Brown, M., & Bellis, M. A. (2012). Human enhancement drugs and the 
pursuit of perfection. Adicciones, 24(3).  
Medoff, Z. M., & Colloca, L. (2015). Placebo analgesia: understanding the mechanisms. Pain 
management, 5(2), 89-96.  
 
 
177 
 
Meissner, K., Bingel, U., Colloca, L., Wager, T. D., Watson, A., & Flaten, M. A. (2011). The 
placebo effect: advances from different methodological approaches. J Neurosci, 
31(45), 16117-16124. doi:10.1523/JNEUROSCI.4099-11.2011 
Meissner, K., Kohls, N., & Colloca, L. (2011). Introduction to placebo effects in medicine: 
mechanisms and clinical implications. Philos Trans R Soc Lond B Biol Sci, 
366(1572), 1783-1789. doi:10.1098/rstb.2010.0414 
Michael, R. B., Garry, M., & Kirsch, I. (2012). Suggestion, cognition, and behavior. Current 
directions in Psychological science, 21(3), 151-156.  
Mitsikostas, D. D., Mantonakis, L. I., & Chalarakis, N. G. (2011). Nocebo is the enemy, not 
placebo. A meta-analysis of reported side effects after placebo treatment in 
headaches. Cephalalgia, 31(5), 550-561. doi:10.1177/0333102410391485 
Moerman, D. E., & Jonas, W. B. (2002). Deconstructing the placebo effect and finding the 
meaning response. Annals of Internal medicine, 136(6), 471-476.  
Montgomery, G., & Kirsch, I. (1997). Classical conditioning and the placebo effect. Pain, 
72(1), 107-113.  
Morente-Sanchez, J., & Zabala, M. (2013). Doping in sport: a review of elite athletes' 
attitudes, beliefs, and knowledge. Sports Med, 43(6), 395-411. doi:10.1007/s40279-
013-0037-x 
Morin, A. J., Arens, A. K., & Marsh, H. W. (2016). A bifactor exploratory structural equation 
modeling framework for the identification of distinct sources of construct-relevant 
psychometric multidimensionality. Structural Equation Modeling: A 
Multidisciplinary Journal, 23(1), 116-139.  
Morral, A. R., McCaffrey, D. F., & Paddock, S. M. (2002). Reassessing the marijuana 
gateway effect. Addiction, 97(12), 1493-1504.  
 
 
178 
 
Mujika, I., Padilla, S., Ibanez, J., Izquierdo, M., & Gorostiaga, E. (2000). Creatine 
supplementation and sprint performance in soccer players. Medicine & Science in 
Sports & Exercise, 32(2), 518. doi:10.1097/00005768-200002000-00039 
Murphy, K. R., & Davidshofer, C. O. (1988). Psychological testing. Principles, and 
Applications, Englewood Cliffs.  
Muthén, B., & Brown, H. C. (2009). Estimating drug effects in the presence of placebo 
response: causal inference using growth mixture modeling. Statistics in medicine, 
28(27), 3363-3385.  
Nicholls, A. R., Madigan, D. J., & Levy, A. R. (2017). A Confirmatory Factor Analysis of the 
Performance Enhancement Attitude Scale for adult and adolescent athletes. 
Psychology of Sport and Exercise, 28, 100-104. doi:10.1016/j.psychsport.2016.10.010 
Nieper, A. (2005). Nutritional supplement practices in UK junior national track and field 
athletes. Br J Sports Med, 39(9), 645-649. doi:10.1136/bjsm.2004.015842 
Ntoumanis, N., Ng, J. Y., Barkoukis, V., & Backhouse, S. (2014). Personal and psychosocial 
predictors of doping use in physical activity settings: a meta-analysis. Sports 
Medicine, 44(11), 1603-1624.  
Ntoumanis, N., Pensgaard, A.-M., Martin, C., & Pipe, K. (2004). An idiographic analysis of 
amotivation in compulsory school physical education. Journal of Sport and Exercise 
Psychology, 26(2), 197-214.  
Osborne, J. W. (2015). What is rotating in exploratory factor analysis. Practical Assessment, 
Research & Evaluation, 20(2), 1-7.  
Outram, S., & Stewart, B. (2015). Doping through supplement use: a review of the available 
empirical data. International journal of sport nutrition and exercise metabolism, 
25(1), 54-59.  
 
 
179 
 
Oxford English Dictionary. (2017). "supplement, n.1". Retrieved from 
http://www.oed.com/view/Entry/194624?rskey=kVk0l8&amp;result=1&amp;isAdvan
ced=false 
Pecina, M., Stohler, C. S., & Zubieta, J. K. (2014). Neurobiology of placebo effects: 
expectations or learning? Soc Cogn Affect Neurosci, 9(7), 1013-1021. 
doi:10.1093/scan/nst079 
Perugini, M., & Bagozzi, R. P. (2004). The distinction between desires and intentions. 
European Journal of Social Psychology, 34(1), 69-84. doi:10.1002/ejsp.186 
Peterson, C., & Seligman, M. E. (2004). Character strengths and virtues: A handbook and 
classification (Vol. 1): Oxford University Press. 
Petróczi, A. (2006). Measuring attitude toward doping: Further evidence for the 
psychometric properties of the Performance Enhancement Attitude Scale. Paper 
presented at the 14th Congress of the European Association for Sport Management. 
Nicosia, Cyprus. 
Petróczi, A. (2007). Attitudes and doping: a structural equation analysis of the relationship 
between athletes' attitudes, sport orientation and doping behaviour. Substance Abuse 
Treatment, Prevention, and Policy, 2, 34. doi:10.1186/1747-597X-2-34 
Petróczi, A. (2013). The doping mindset—Part I: Implications of the Functional Use Theory 
on mental representations of doping. Performance Enhancement & Health, 2(4), 153-
163. doi:10.1016/j.peh.2014.06.001 
Petróczi, A., & Aidman, E. (2009). Measuring explicit attitude toward doping: Review of the 
psychometric properties of the Performance Enhancement Attitude Scale. Psychology 
of Sport and Exercise, 10(3), 390-396. doi:10.1016/j.psychsport.2008.11.001 
 
 
180 
 
Petróczi, A., & Naughton, D. P. (2011). Impact of multidisciplinary research on advancing 
anti-doping efforts. International Journal of Sport Policy and Politics, 3(2), 235-259. 
doi:10.1080/19406940.2011.577083 
Petrovic, P., Kalso, E., Petersson, K. M., & Ingvar, M. (2002). Placebo and opioid analgesia-- 
imaging a shared neuronal network. Science, 295(5560), 1737-1740. 
doi:10.1126/science.1067176 
Pezdirc, K., Hutchesson, M., Whitehead, R., Ozakinci, G., Perrett, D., & Collins, C. E. 
(2015). Can dietary intake influence perception of and measured appearance? A 
systematic review. Nutrition Research, 35(3), 175-197.  
Polit, D. F., Beck, C. T., & Owen, S. V. (2007). Is the CVI an acceptable indicator of content 
validity? Appraisal and recommendations. Research in nursing & health, 30(4), 459-
467.  
Pollo, A., Carlino, E., & Benedetti, F. (2008). The top-down influence of ergogenic placebos 
on muscle work and fatigue. Eur J Neurosci, 28(2), 379-388. doi:10.1111/j.1460-
9568.2008.06344.x 
Pollo, A., Torre, E., Lopiano, L., Rizzone, M., Lanotte, M., Cavanna, A., . . . Benedetti, F. 
(2002). Expectation modulates the response to subthalamic nucleus stimulation in 
Parkinsonian patients. Neuroreport, 13(11), 1383-1386.  
Potkin, S., Agid, O., Siu, C., Watsky, E., Vanderburg, D., & Remington, G. (2011). Placebo 
response trajectories in short-term and long-term antipsychotic trials in schizophrenia. 
Schizophrenia research, 132(2), 108-113.  
Pound, R., Ayotte, C., Parkinson, A., Pengilly, A., & Ryan, A. (2013). Report to WADA 
executive committee on lack of effectiveness of testing programs. World Anti-Doping 
Agency, Canada.  
 
 
181 
 
Price, D. D., Finniss, D. G., & Benedetti, F. (2008). A comprehensive review of the placebo 
effect: recent advances and current thought. Annu Rev Psychol, 59, 565-590. 
doi:10.1146/annurev.psych.59.113006.095941 
Price, D. D., Milling, L. S., Kirsch, I., Duff, A., Montgomery, G. H., & Nicholls, S. S. 
(1999). An analysis of factors that contribute to the magnitude of placebo analgesia in 
an experimental paradigm. Pain, 83(2), 147-156.  
Prince van Leeuwen, A., Creemers, H. E., Verhulst, F. C., Vollebergh, W. A., Ormel, J., 
Oort, F., & Huizink, A. C. (2014). Legal substance use and the development of a 
DSM‐IV cannabis use disorder during adolescence: the TRAILS study. Addiction, 
109(2), 303-311.  
Quigley, E., Tack, J., Chey, W., Rao, S., Fortea, J., Falques, M., . . . Johnston, J. (2013). 
Randomised clinical trials: linaclotide phase 3 studies in IBS‐C–a prespecified further 
analysis based on European Medicines Agency‐specified endpoints. Alimentary 
pharmacology & therapeutics, 37(1), 49-61.  
Rebar, A. L., Dimmock, J. A., Jackson, B., Rhodes, R. E., Kates, A., Starling, J., & 
Vandelanotte, C. (2016). A systematic review of the effects of non-conscious 
regulatory processes in physical activity. Health Psychology Review, 10(4), 395-407.  
Reicherts, P., Gerdes, A. B., Pauli, P., & Wieser, M. J. (2013). On the mutual effects of pain 
and emotion: facial pain expressions enhance pain perception and vice versa are 
perceived as more arousing when feeling pain. PAIN®, 154(6), 793-800.  
Rhodes, R. E., & Rebar, A. L. (2017). Conceptualizing and Defining the Intention Construct 
for Future Physical Activity Research. Exercise and Sport Sciences Reviews, 45(4), 
209-216.  
 
 
182 
 
Rief, W., Bingel, U., Schedlowski, M., & Enck, P. (2011). Mechanisms involved in placebo 
and nocebo responses and implications for drug trials. Clin Pharmacol Ther, 90(5), 
722-726. doi:10.1038/clpt.2011.204 
Ring, C., & Hurst, P. (2019). The effects of moral disengagement mechanisms on doping 
likelihood are mediated by guilt and moderated by moral traits. Psychology of Sport 
and Exercise, 40, 33-41. doi:10.1016/j.psychsport.2018.09.001 
Ring, C., & Kavussanu, M. (2017). The role of self-regulatory efficacy, moral disengagement 
and guilt on doping likelihood: A social cognitive theory perspective. J Sports Sci, 1-
7. doi:10.1080/02640414.2017.1324206 
Ring, C., Kavussanu, M., Lucidi, S., & Hurst, P. (2019). Effects of personal and situational 
factors on self-referenced doping likelihood. Psychology of Sport and Exercise, 41, 
29-35.  
Robinson, T. E., & Berridge, K. C. (1993). The neural basis of drug craving: an incentive-
sensitization theory of addiction. Brain research reviews, 18(3), 247-291.  
Rohsenow, D. J., & Marlatt, G. A. (1981). The balanced placebo design: Methodological 
considerations. Addictive behaviors, 6(2), 107-122.  
Ross, R., Gray, C. M., & Gill, J. M. (2015). Effects of an Injected Placebo on Endurance 
Running Performance. Med Sci Sports Exerc, 47(8), 1672-1681. 
doi:10.1249/MSS.0000000000000584 
Roszkowski, M. J., & Soven, M. (2010). Shifting gears: Consequences of including two 
negatively worded items in the middle of a positively worded questionnaire. 
Assessment & Evaluation in Higher Education, 35(1), 113-130.  
Rozin, P., & Royzman, E. B. (2001). Negativity bias, negativity dominance, and contagion. 
Personality and social psychology review, 5(4), 296-320.  
 
 
183 
 
Rubio, D. M., Schoenbaum, E. E., Lee, L. S., Schteingart, D. E., Marantz, P. R., Anderson, 
K. E., . . . Esposito, K. (2010). Defining translational research: implications for 
training. Academic medicine: journal of the Association of American Medical 
Colleges, 85(3), 470.  
Rütgen, M., Seidel, E.-M., Silani, G., Riečanský, I., Hummer, A., Windischberger, C., . . . 
Lamm, C. (2015). Placebo analgesia and its opioidergic regulation suggest that 
empathy for pain is grounded in self pain. Proceedings of the National Academy of 
Sciences, 112(41), E5638-E5646.  
Ružić, V., Ivanec, D., & Stanke, K. M. (2017). Effect of expectation on pain assessment of 
lower-and higher-intensity stimuli. Scandinavian Journal of Pain, 14, 9-14.  
Sagoe, D., Holden, G., Rise, E. N. K., Torgersen, T., Paulsen, G., Krosshaug, T., . . . 
Pallesen, S. (2016). Doping prevention through anti-doping education and practical 
strength training: The Hercules program. Performance Enhancement & Health, 5(1), 
24-30. doi:10.1016/j.peh.2016.01.001 
Saunders, B., de Oliveira, L. F., da Silva, R. P., de Salles Painelli, V., Goncalves, L. S., 
Yamaguchi, G., . . . Gualano, B. (2017). Placebo in sports nutrition: a proof-of-
principle study involving caffeine supplementation. Scand J Med Sci Sports, 27(11), 
1240-1247. doi:10.1111/sms.12793 
Scheier, M. F., Carver, C. S., & Bridges, M. W. (1994). Distinguishing optimism from 
neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the 
Life Orientation Test. Journal of Personality and Social Psychology, 67(6), 1063.  
Schimpchen, J., Skorski, S., Nopp, S., & Meyer, T. (2016). Are "classical" tests of repeated-
sprint ability in football externally valid? A new approach to determine in-game 
sprinting behaviour in elite football players. J Sports Sci, 34(6), 519-526. 
doi:10.1080/02640414.2015.1112023 
 
 
184 
 
Schutte, N. S., Malouff, J. M., Hall, L. E., Haggerty, D. J., Cooper, J. T., Golden, C. J., & 
Dornheim, L. (1998). Development and validation of a measure of emotional 
intelligence. Personality and Individual Differences, 25(2), 167-177.  
Schutz, R. (1994). Methodological issues and measurement problems in sport psychology. 
International perspectives on sport and exercise psychology, 35-57.  
Schutz, R., & Gessaroli, M. (1993). Use, misuse, and disuse of psychometrics in sport 
psychology research. Handbook of research on sport psychology, 901-917.  
Schwarzer, R. (2008). Modeling health behavior change: How to predict and modify the 
adoption and maintenance of health behaviors. Applied Psychology, 57(1), 1-29.  
Scott, D. J., Stohler, C. S., Egnatuk, C. M., Wang, H., Koeppe, R. A., & Zubieta, J.-K. 
(2008). Placebo and nocebo effects are defined by opposite opioid and dopaminergic 
responses. Archives of general psychiatry, 65(2), 220-231.  
SENr. (2016). Supplement Use in Sport Position Statement. Retrieved from 
http://www.senr.org.uk/wp-content/uploads/160803SupplementStatement.pdf 
Shah, E., & Pimentel, M. (2014). Placebo effect in clinical trial design for irritable bowel 
syndrome. J Neurogastroenterol Motil, 20(2), 163-170. 
doi:10.5056/jnm.2014.20.2.163 
Shaibani, A., Frisaldi, E., & Benedetti, F. (2017). Placebo response in pain, fatigue, and 
performance: Possible implications for neuromuscular disorders. Muscle Nerve, 56(3), 
358-367. doi:10.1002/mus.25635 
Smith, A. C. T., Stewart, B., Oliver-Bennetts, S., McDonald, S., Ingerson, L., Anderson, A., . 
. . Graetz, F. (2010). Contextual influences and athlete attitudes to drugs in sport. 
Sport Management Review, 13(3), 181-197. doi:10.1016/j.smr.2010.01.008 
Sniehotta, F. F. (2009). Towards a theory of intentional behaviour change: Plans, planning, 
and self‐regulation. British journal of health psychology, 14(2), 261-273.  
 
 
185 
 
Sniehotta, F. F., Presseau, J., & Araujo-Soares, V. (2014). Time to retire the theory of 
planned behaviour. Health Psychol Rev, 8(1), 1-7. 
doi:10.1080/17437199.2013.869710 
Spencer, M., Bishop, D., Dawson, B., & Goodman, C. (2005). Physiological and metabolic 
responses of repeated-sprint activities:specific to field-based team sports. Sports Med, 
35(12), 1025-1044.  
Starfelt Sutton, L. C., & White, K. M. (2016). Predicting sun-protective intentions and 
behaviours using the theory of planned behaviour: a systematic review and meta-
analysis. Psychology & health, 31(11), 1272-1292.  
Stewart-Williams, S., & Podd, J. (2004). The placebo effect: dissolving the expectancy versus 
conditioning debate. Psychol Bull, 130(2), 324-340. doi:10.1037/0033-
2909.130.2.324 
Stewart, J., De Wit, H., & Eikelboom, R. (1984). Role of unconditioned and conditioned drug 
effects in the self-administration of opiates and stimulants. Psychological review, 
91(2), 251.  
Strauss, M. E., & Smith, G. T. (2009). Construct validity: Advances in theory and 
methodology. Annual review of clinical psychology, 5, 1-25.  
Substance Abuse and Mental Health Services Administration. (2013). Results from the 2012 
National Survey on Drug Use and Health: Summary of national findings. In NSDUH 
Series H-46, HHS Publication No.(SMA) 13-4795: Substance Abuse and Mental 
Health Services Administration Rockville, MD. 
Szalma, J. L., & Hancock, P. A. (2017). Positive Psychology: Adaptation, Leadership, and 
Performance in Exceptional Circumstances Michael D. Matthews. In Performance 
Under Stress (pp. 179-196): CRC Press. 
Tabachnick, B. G., Fidell, L. S., & Osterlind, S. J. (2001). Using multivariate statistics.  
 
 
186 
 
Tallis, J., Muhammad, B., Islam, M., & Duncan, M. J. (2016). Placebo effects of caffeine on 
maximal voluntary concentric force of the knee flexors and extensors. Muscle Nerve, 
54(3), 479-486. doi:10.1002/mus.25060 
Terry, P. C., Lane, A. M., & Fogarty, G. J. (2003). Construct validity of the Profile of Mood 
States—Adolescents for use with adults. Psychology of Sport and Exercise, 4(2), 125-
139.  
Terry, P. C., Lane, A. M., Lane, H. J., & Keohane, L. (1999). Development and validation of 
a mood measure for adolescents. Journal of Sports Sciences, 17(11), 861-872.  
The Guardian. (2016). Usain Bolt stars in old-fashioned battle between ‘good and evil’ at Rio 
2016. Retrieved from https://www.theguardian.com/sport/2016/aug/13/usain-bolt-
olympics-rio-sunshine 
Thorndike, E. L. (1911). Animal intelligence: Experimental studies: Macmillan. 
Tolusso, D. V., Laurent, C. M., Fullenkamp, A. M., & Tobar, D. A. (2015). Placebo effect: 
influence on repeated intermittent sprint performance on consecutive days. The 
Journal of Strength & Conditioning Research, 29(7), 1915-1924.  
Tscholl, P., Alonso, J. M., Dolle, G., Junge, A., & Dvorak, J. (2010). The use of drugs and 
nutritional supplements in top-level track and field athletes. Am J Sports Med, 38(1), 
133-140. doi:10.1177/0363546509344071 
Tsochas, K., Lazuras, L., & Barkoukis, V. (2013). Psychosocial predictors of nutritional 
supplement use among leisure time exercisers. Performance Enhancement & Health, 
2(1), 17-23. doi:10.1016/j.peh.2013.02.001 
UNESCO. (2015). UNESCO fights doping in sport: 15 new projects supported. Retrieved 
from http://en.unesco.org/news/unesco-fights-doping-sport-15-new-projects-
supported 
 
 
187 
 
USADA. (2003). 2002 Annual Report.  Retrieved from https://www.usada.org/wp-
content/uploads/2001_annual_report.pdf. 
USADA. (2017). 2016 Annual Report.  Retrieved from https://www.usada.org/about/annual-
report/. 
Van Sonderen, E., Sanderman, R., & Coyne, J. C. (2013). Ineffectiveness of reverse wording 
of questionnaire items: Let’s learn from cows in the rain. PLoS One, 8(7), e68967.  
Vanyukov, M. M., Tarter, R. E., Kirillova, G. P., Kirisci, L., Reynolds, M. D., Kreek, M. J., . 
. . Ridenour, T. A. (2012). Common liability to addiction and "gateway hypothesis": 
theoretical, empirical and evolutionary perspective. Drug Alcohol Depend, 123 Suppl 
1, S3-17. doi:10.1016/j.drugalcdep.2011.12.018 
Vargo, E. J., James, R. A., Agyeman, K., MacPhee, T., McIntyre, R., Ronca, F., & Petróczi, 
A. (2014). Perceptions of assisted cognitive and sport performance enhancement 
among university students in England. Performance Enhancement & Health, 3(2), 66-
77. doi:10.1016/j.peh.2015.02.001 
Varley, M. C., & Aughey, R. J. (2013). Acceleration profiles in elite Australian soccer. Int J 
Sports Med, 34(1), 34-39. doi:10.1055/s-0032-1316315 
Vits, S., Cesko, E., Enck, P., Hillen, U., Schadendorf, D., & Schedlowski, M. (2011). 
Behavioural conditioning as the mediator of placebo responses in the immune system. 
Philos Trans R Soc Lond B Biol Sci, 366(1572), 1799-1807. 
doi:10.1098/rstb.2010.0392 
Voudouris, N. J., Peck, C. L., & Coleman, G. (1990). The role of conditioning and verbal 
expectancy in the placebo response. Pain, 43(1), 121-128.  
WADA. (2003). Annual Report 2002.  Retrieved from https://www.wada-
ama.org/sites/default/files/resources/files/WADA_Annual_Report_2002_EN.pdf. 
 
 
188 
 
WADA. (2004). WADA Annual Report 2003. Montreal, Canada Retrieved from 
https://www.wada-
ama.org/sites/default/files/resources/files/WADA_Annual_Report_2003_EN.pdf. 
WADA. (2017a). Annual Report 2016. Montreal, Canada Retrieved from https://www.wada-
ama.org/sites/default/files/resources/files/wada_annual_report_2016_en.pdf. 
WADA. (2017b). Play True Quiz. Retrieved from https://www.wada-ama.org/en/play-true-
quiz 
WADC. (2015). The World Anti-Doping Code. Montreal, Canada: The World Anti-Doping 
Agency Retrieved from https://www.wada-
ama.org/sites/default/files/resources/files/wada-2015-world-anti-doping-code.pdf. 
Waddington, I. (2001). Doping in sport: a medical sociological perspective. Research in 
Doping in Sport, 11-21.  
Wanjek, B., Rosendahl, J., Strauss, B., & Gabriel, H. H. (2007). Doping, drugs and drug 
abuse among adolescents in the State of Thuringia (Germany): prevalence, knowledge 
and attitudes. Int J Sports Med, 28(4), 346-353. doi:10.1055/s-2006-924353 
Weimer, K., Colloca, L., & Enck, P. (2015). Age and sex as moderators of the placebo 
response - an evaluation of systematic reviews and meta-analyses across medicine. 
Gerontology, 61(2), 97-108. doi:10.1159/000365248 
Wendt, L., Albring, A., Benson, S., Engler, H., Engler, A., Hinney, A., . . . Schedlowski, M. 
(2014). Catechol-O-methyltransferase Val158Met polymorphism is associated with 
somatosensory amplification and nocebo responses. PLoS One, 9(9), e107665. 
doi:10.1371/journal.pone.0107665 
Whitaker, L., Long, J., Petróczi, A., & Backhouse, S. H. (2014). Using the prototype 
willingness model to predict doping in sport. Scandinavian Journal of Medicine & 
Science in Sports, 24(5), e398-e405. doi:10.1111/sms.12148 
 
 
189 
 
Willick, S. E., Miller, G. D., & Eichner, D. (2016). The Anti-Doping Movement. PM R, 8(3 
Suppl), S125-132. doi:10.1016/j.pmrj.2015.12.001 
Woods, C. M. (2006). Careless responding to reverse-worded items: Implications for 
confirmatory factor analysis. Journal of Psychopathology and Behavioral Assessment, 
28(3), 186.  
Worcester, R. M., & Burns, T. R. (1975). Statistical examination of relative precision of 
verbal scales. Journal of the Market Research Society, 17(3), 181-197.  
Wright, G., Porcari, J., Foster, C., Felker, H., Koshololek, A., Otto, J., . . . Udermann, B. 
(2009). Placebo effects on exercise performance. Gundersen Lutheran Medical 
Journal, 6(1), 3-7.  
Yesalis, C. E., & Bahrke, M. S. (2002). History of doping in sport. International sports 
studies, 24(1), 42-76.  
Zabala, M., Morente-Sánchez, J., Mateo-March, M., & Sanabria, D. (2016). Relationship 
between self-reported doping behavior and psychosocial factors in adult amateur 
cyclists. The Sport Psychologist, 30(1), 68-75.  
Zelli, A., Mallia, L., & Lucidi, F. (2010). The contribution of interpersonal appraisals to a 
social-cognitive analysis of adolescents' doping use. Psychology of Sport and 
Exercise, 11(4), 304-311. doi:10.1016/j.psychsport.2010.02.008 
Zhang, W., Guo, J., Zhang, J., & Luo, J. (2013). Neural mechanism of placebo effects and 
cognitive reappraisal in emotion regulation. Progress in Neuro-Psychopharmacology 
and Biological Psychiatry, 40, 364-373.  
Zubieta, J.-K., Bueller, J. A., Jackson, L. R., Scott, D. J., Xu, Y., Koeppe, R. A., . . . Stohler, 
C. S. (2005). Placebo effects mediated by endogenous opioid activity on μ-opioid 
receptors. Journal of Neuroscience, 25(34), 7754-7762.  
 
 
 
190 
 
  
 
 
191 
 
Chapter Nine 
 
APPENDICES 
 
  
 
 
192 
 
Appendix 1 – Participant information sheet and informed consent for Study 1 
(phase 1) 
 
 
 
 
Information Sheet and informed consent 
 
Validation of the Sports Supplements Beliefs Scale 
Thank you for showing an interest in this research project. Please read the information below 
carefully and decide if you would like to participate. 
Participant Information 
This research will be conducted by Philip Hurst as part of a PhD at Canterbury Christ Church 
University. 
Background 
Doping in sport is a widespread occurrence across all Olympic events. The World Anti-
Doping Agency aims to prohibit doping behaviour through medical, analytical and 
physiological investigations. However, it also includes prevention and education 
investigations through understanding athlete’s intentions, attitudes and beliefs about banned 
performance enhancing substances. Research now suggests that athletes who use non-banned 
sport supplements are more likely to progress to banned substance. It is proposed that athletes 
who hold a positive belief towards banned substances will be more likely to use such 
substances. However, measuring athletes’ beliefs using a validated questionnaire has not been 
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achieved. This interview is therefore aimed at understanding athlete’s beliefs towards sport 
supplements. 
 
What is the aim of this research? 
This research is aimed to understand athlete’s beliefs about sport supplements through semi-
structured interviews. The semi-structured interviews will allow an in-depth understanding of 
athlete’s beliefs towards sport supplements, and what causes and shapes these beliefs. The 
research undertaken is part of a PhD in Sport and Exercise Science, and forms the first part 
for validating a questionnaire.  
What will be required from this session? 
If you agree to take part, you will be asked to attend a semi-structured interview that will last 
approximately 30 to 60 minutes at Canterbury Christ Church University. The session will be 
aimed at understanding your beliefs towards sport supplements and what influences your 
beliefs to use these substances. There will be a variety of questions for you to answer in your 
own time. If you do not wish to answer any questions, this is entirely acceptable and you may 
leave the interviewing process at any time. All interviews will be audiotaped to ensure all 
phrases are recorded. Once data has been recorded, you will be sent an email copy of the 
transcript, to allow you to read what was said. You will be given the opportunity to add, 
delete or make changes to the transcript if you wish. 
Typical questions will include: 
• Please could you describe what you believe to be a sport supplements 
• Please tell me any experience you may have had with sport supplements 
• Please describe your decision to either use, or not use, sport supplements 
Confidentiality  
All information collected by the researcher will be stored securely in accordance with the 
Data Protection act (1998) and the University’s own data protection requirements. You will 
 
 
194 
 
be given a copy of the transcript and have the opportunity to adapt, change or delete any 
statements you have made until the transcript is shared with the research team. All personal 
data e.g. names and email addresses, will be removed and you will be given a unique 
character I.D. Dr Abigail Foad, Dr Damian Coleman and Dr Chris Beedie will then be given 
access to the data once all personal information is removed. The transcript shown to the 
research team and any other third parties will not indicate any information identifiable to you. 
For example, if you were a 1500m runner with a personal best of 3:41 that lives in Kent, this 
information will be transcribed as: The athlete is involved in an individual sport, is national 
standard and resides in the South East of England. No personal information e.g. email address 
or date of birth, will be shared publicly.  
Dissemination of results  
The results will help formulate and shape a questionnaire to understand athlete’s beliefs 
towards sport supplements. No information that could identify an individual will be contained 
in the questionnaire. The results obtained through the interview may be disseminated through 
journal articles, conference proceedings/posters and thesis.  
 
If you have any questions or queries regarding the study please do not hesitate to contact me. 
If you are willing to participate, you will be free to withdraw at any time without reason.  
 
Philip Hurst 
PhD student and University Instructor 
Department of Sport Science, Tourism and Leisure 
Canterbury Christ Church University 
North Holmes Road 
Canterbury  
Kent CT1 1QU 
01227 767 700 (extension 3130)  
Email: Philip.hurst@canterbury.ac.uk 
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Informed Consent  
 
I have read the following information sheet concerning this research and understand what the study 
entails. All my questions have been answered to my full satisfaction and I understand that I am free to 
leave at any stage during this study. 
 
I fully recognise what is expected of me from this study and understand that my results will be used 
for academic purposes. I know that I am able to ask any questions regarding the procedure. I 
understand why the interview will be recorded and I know how the information will be used. I am 
aware I can adapt or change my transcript once it has been transcribed.  
 
I …………………………………… have read the information above and fully understand what is 
expected of me in this study. I am now ready to take part in the research process. 
 
Participant’s signature  
Signed: ..............................  Date: ....../....../.......... 
 
Researchers Signature  
Signed: ..............................  Date: ....../....../.......... 
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Appendix 2 – Social media recruitment poster for Study 1 (phase 1) 
PhD research project at Canterbury Christ Church University is investigating 
athletes’ beliefs towards sport supplements.  
If you are an athlete over the age of 18, and have played at a competitive level 
(country or above) please get in touch. All is required is a discussion about sport 
supplements in person or over Skype.  
This study is not solely interested in athletes that use sport supplements, non-
users are encouraged to also participate 
For more information please contact: 
Phil Hurst 
philip.hurst@canterbury.ac.uk 
@Phil_Hurst1  
  
 
The image part with relationship ID rId55 was not found in the file.
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Appendix 3 – Interview questions used in Study 1 (phase 1) 
Layout of interview 
Demographic information 
 
1. What is your age? 
2. What sport do you compete in? 
3. Do you compete for individual or team purposes? Or both? 
4. What is the highest level of competition you have competed for? 
a. School  
b. Local or club level 
c. County 
d. Regional 
e. National 
5. How many years have you been training? 
6. How many hours a week do you train? 
7. What is your highest level of education? 
a. High school 
b. College 
c. University  
d. Postgraduate 
 
Sports supplements beliefs 
1. Please could you describe what you believe to be a sport supplement 
2. Please tell me any experience you may have had with sport supplements 
3. Please could you describe your beliefs about sport supplements 
4. Do you feel sport supplements are necessary? 
5. Please describe your decision to either use, or not use sport supplements 
6. If you feel there are any influences to use, or not use, sport supplements, please describe them 
7. If you have experienced any of the following, please could you detail 
a. A teammate’s experience of using sport supplements 
b. A coach’s experience of sport supplements 
c. A competitor’s experience of using sport supplements 
8. After a competition or training session when you have used sport supplements, could you 
describe it? 
a. If you have not used sport supplements during training or competition, but felt on an 
occasion that it may have been beneficial, please describe it 
9. Tell me about sport supplements you are aware of 
10. Claims are often made about sport supplements, how do you feel about the claims made? 
a. How have these claims influenced your beliefs about sport supplements 
11. If you feel sport supplements enable you to perform better than usual, please describe it  
12. ‘Sport supplements are necessary to reach your athletic potential’ – how do you feel about 
this statement? 
13. Please describe a situation where you feel you maybe more likely to use a sport supplement 
14. Please describe any other experiences of when you have, or have been tempted to use sport 
supplements? 
15. Are there any other aspects of your experiences of sport supplements, that have not been 
discussed, you would like to tell me about? 
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Appendix 4 – Example email to experts for Study 1 (phase 2) 
Dear (Experts name) 
I am a PhD researcher at Canterbury Christ Church University where I am investigating 
athletes’ beliefs towards sport supplements. You have been identified as an expert in this 
field and I was wondering if you would be able to evaluate an instrument for content validity 
that has recently been developed.  
Myself and my research supervisors have created an initial instrument of 26 items that we 
think pertain to athletes beliefs about sport supplements. These items were generated through 
interviewing athletes’ about the reasons they use sport supplements. The next stage would be 
to obtain expert opinion and determine the validity of each item.  
If you choose to evaluate the instrument could you please click on the link below and follow 
the instructions. I would appreciate any comments (positive and negative) you may have for 
each item and encourage you to be as honest and critical as possible. 
Athlete Belief Questionnaire  
If you have any questions, please don’t hesitate to contract me. 
Thank you, 
Philip Hurst 
Canterbury Christ Church University 
philip.hurst@canterbury.ac.uk 
+44 (0)1227 767700 Ext 3130 
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Appendix 5 – Expert survey used in Study 1 (phase 2) 
 
 
Beliefs about Sports Supplements 
Questionnaire 
 
Thank you for taking part in this research project. 
The questionnaire you have been asked to evaluate aims to understand athletes' beliefs 
towards sports supplements (e.g. whey protein, caffeine, and creatine). 
 
Twenty six items are included in the measure and relate to athletes use of sports supplements, 
whether they believe these substances influence performance and if they believe sports 
supplements are necessary for training and competition. The measure requires athletes' to 
respond to each item on a 6 point Likert-type scale ranging from strongly disagree to strongly 
agree. No neutral point is offered, with a high score indicating a positive belief towards sports 
supplements and a low score indicating a negative belief. 
 
Please rate the relevancy of each item from 1 to 4 (1 = not relevant to 4 = highly relevant). 
After each item, there is space provided for any other comments you may have. 
 
If you have any further comments relating to each item or general structure and coherence of 
the measure, please use the free text boxes provided at the bottom of the webpage. 
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Beliefs about Sports Supplements 
Please read each question carefully and specify your level of agreement (between “not 
relevant and “relevant”) with the following: 
1. Sport supplements improve my performance 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
2. Sports supplements are necessary for me to be competitive 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
3. Sport supplements help me make up for lost time during injury 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
4. Sports supplements improve my confidence 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
5. My chances of winning improve when I use sports supplements 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
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6. Sport supplements help me realise my potential 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
7. Sports supplements are necessary for me to perform 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
8. Sport supplements reduce fatigue from performing 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
9. Sports supplements allow me to improve the quality of my training 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
10. Sports supplements reduce the pain I feel 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
11. A higher consumption of sports supplements is needed to manage higher training 
loads, maximise recovery and improve performance 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
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12. Sports supplements improve my recovery 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
13. Athletes using sports supplements are usually the ones who medal at major 
championships 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
14. I don’t perform well when I have used sports supplements 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
15. I am more in control of my performance when I use sports supplements 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
16. Sports supplements provide a greater improvement compared to a healthy diet 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
17. My training is compromised when I use sports supplements 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
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18. I don’t believe sports supplements improve my performance, but I take them 
just in case  
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
19. Sports supplements have more of an effect on elite level athletes 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
20. Sports supplements are just the same as having the most up to date equipment  
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
21. Sports supplements reduce my anxiety 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
22. Sports supplements used by other athletes gives them an advantage 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
23. I am satisfied with the outcomes sports supplements have on my performance 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
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24. I am optimistic about my performance when I use sports supplements  
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
25. Training increases the need for sports supplements 
□ Not relevant □ Somewhat relevant □ Quite relevant □ Highly relevant 
Specific comments: 
 
26. Are there any questions relating to the instrument that you feel are missing? 
 
 
 
27. Are there any other comments or concerns you have about the instrument? 
 
 
 
 
Thank you 
 
Thank you for evaluating the questionnaire. 
 
I am very grateful for your responses and taking the time to complete it. 
 
If you have any questions or queries about the research or measure, please do not hesitate to 
contact me. 
 
Phil Hurst 
Canterbury Christ Church University 
philip.hurst@canterbury.ac.uk  
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Appendix 6 – Athlete survey used in Study 1 (phase 2) 
 
 
Beliefs about Sports Supplements Scale 
Thank you for considering taking part in this research project. 
My name is Phil Hurst and I am a PhD researcher at Canterbury Christ Church University. I 
was wondering if you would be interested in evaluating a questionnaire that aims to 
understand athletes' beliefs about sport supplements (e.g. protein shakes, caffeine, creatine). 
The questionnaire has initially been developed and it would be useful to gain feedback about 
the clarity and conciseness for each question. 
The research takes part in two stages: 
• The first stage will require you to complete the questionnaire that assesses your 
beliefs about sport supplements. 
• The second stage asks you to comment about the questionnaire and if there are any 
improvements or amendments you feel are necessary 
This process is completely voluntary and if you choose to accept you may withdraw from the 
study at any time. Consent will be taken once you have completed the questionnaire. 
If you have any questions or would like more information about the study, please do not 
hesitate to contact me. 
Philip Hurst  
philip.hurst@canterbury.ac.uk 
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Demographic information 
1. What is your gender 
□ Female  □ Male 
2. What is your age 
□ Under 18 
□ 18 to 24 
□ 25 to 34 
□ 35 to 44 
□ 45 to 54 
□ 55 to 64 
□ 65 to 74 
□ 75 or older 
3. What sport do you compete in? 
 
4. What event or position? 
 
5. What is your highest level of competition 
 
6. How many years have you been training? 
 
7. How many hours a week do you train? 
 
8. What is your highest level of education? 
□ High school 
□ College/A-level 
□ BSc University degree or equivalent  
□ MSc University degree or equivalent  
□ PhD
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Sport Supplement Use 
Sport supplements are substances used by athletes with the belief that they will improve or 
facilitate athletic performance (e.g. Lucozade, multi-vitamins, caffeine, and creatine). 
1. Do you use sport supplements?  
□ Yes   □ No 
2. If yes, please select which sport supplements you use 
□ Β-Alanine 
□ Beetroot juice 
□ Caffeine 
□ Creatine 
□ Electrolytes 
□ Energy gels 
□ Protein shakes 
□ Vitamins and minerals 
 
Other (please specify): 
  
 
3. On average, how often do you use sport supplements? 
□ Never  □ Monthly  □ Weekly  □ Daily 
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Beliefs about Sport Supplements  
 Please read each question carefully and specify your level of agreement (between “not 
relevant and “relevant”) with the following: 
1. Sport supplements improve my performance 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
2. Sports supplements are necessary for me to be competitive 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
3. Sport supplements help me make up for lost time during injury 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
4. Sports supplements improve my confidence 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
5. My chances of winning improve when I use sports supplements 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
6. Sport supplements help me realise my potential 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
7. Sports supplements are necessary for me to perform 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
8. Sport supplements reduce fatigue from performing 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
9. Sports supplements allow me to improve the quality of my training 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
10. Sports supplements reduce the pain I feel 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
11. A higher consumption of sports supplements is needed to manage higher training 
loads, maximise recovery and improve performance 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
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12. Sports supplements improve my recovery 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
13. Athletes using sports supplements are usually the ones who medal at major 
championships 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
14. I don’t perform well when I have used sports supplements 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
15. I am more in control of my performance when I use sports supplements 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
16. Sports supplements provide a greater improvement compared to a healthy diet 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
17. Supplements are a substitute for hard work 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
18. My training is compromised when I use sports supplements 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
19. I don’t believe sports supplements improve my performance, but I take them 
just in case  
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
20. Sports supplements have more of an effect on elite level athletes 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
21. Sports supplements are just the same as having the most up to date equipment  
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
22. Sports supplements reduce my anxiety 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
23. Sports supplements used by other athletes gives them an advantage 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
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24. I am satisfied with the outcomes sports supplements have on my performance 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
25. I am optimistic about my performance when I use sports supplements  
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
26. Training increases the need for sports supplements 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
 
Questionnaire Evaluation and Feedback 
1. Are there any questions you find difficult to understand or interpret? 
□ Yes   □ No 
If yes, which questions? 
 
 
 
 
 
2. Are there any questions that you feel are missing and need including? 
□ Yes   □ No 
If yes, what questions could be included? 
 
 
3. Did you find yourself becoming bored while doing the questionnaire? 
□ Yes   □ No 
If yes, what could be changed? 
 
 
 
 
 
4. Are there too many or too few questions? 
□ Yes   □ No 
If yes, how many questions would be more appropriate? 
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5. Is there anything about the questionnaire that you feel needs changing? 
□ Yes   □ No 
If yes, what should be included? 
 
 
 
 
6. Is there anything else you feel may need to be included? 
□ Yes   □ No 
If yes, what should be included? 
 
 
7. Do you think that this questionnaire assess athletes’ beliefs about sport supplements 
□ Yes   □ No 
Any others comments? 
 
 
 
 
8. Are there any other comments you have about the questionnaire? 
 
 
 
 
 
 
Thank you 
 
Thank you for completing the questionnaire. 
I am very grateful for your responses and taking the time to complete it. 
 
If you know anyone else that would be interested in taking part in the research, could you please 
forward them the link below: 
https://www.surveymonkey.com/s/Athletesbeleifs  
 
If you have any questions or queries about the research or questionnaire, please do not hesitate to 
contact me. 
 
Phil Hurst 
Canterbury Christ Church University 
philip.hurst@canterbury.ac.uk  
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Appendix 7 – 11 item questionnaire survey for Study 1 (phase 3)  
 
 
 
 
Introduction 
Thank you for considering taking part in this research project. 
 
My name is Phil Hurst and I am a PhD researcher at Canterbury Christ Church University. I 
am conducting a research project aimed at understanding athletes’ beliefs about sport 
supplements 
 
The research will ask a series of questions  about  your  use  and  beliefs  of  sport 
supplements (e.g. caffeine, creatine and beetroot juice) and will take no longer than 10 
minutes. 
 
All information collected will be used for research purposes only. 
Note: This research is open to anyone who is over the age of 18. Pease do not complete if you 
are younger as your information  will not be use 
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Demographic information 
9. What is your gender 
□ Female  □ Male 
10. What is your age 
□ Under 18 
□ 18 to 24 
□ 25 to 34 
□ 35 to 44 
□ 45 to 54 
□ 55 to 64 
□ 65 to 74 
□ 75 or older 
11. What sport do you compete in? 
 
12. What event or position? 
 
13. What is your highest level of competition 
 
14. How many years have you been training? 
 
15. How many hours a week do you train? 
 
16. What is your highest level of education? 
□ High school 
□ College/A-level 
□ BSc University degree or equivalent  
□ MSc University degree or equivalent  
□ PhD
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Sport Supplement Use 
Sport supplements are substances used by athletes with the belief that they will improve or 
facilitate athletic performance (e.g. Lucozade, multi-vitamins, caffeine, and creatine). 
4. Do you use sport supplements?  
□ Yes   □ No 
5. If yes, please select which sport supplements you use 
□ Β-Alanine 
□ Beetroot juice 
□ Caffeine 
□ Creatine 
□ Electrolytes 
□ Energy gels 
□ Protein shakes 
□ Vitamins and minerals 
 
Other (please specify):  
 
 
6. On average, how often do you use sport supplements? 
□ Never  □ Monthly  □ Weekly  □ Daily 
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Beliefs about Sport Supplements  
 Please read each question carefully and specify your level of agreement (between “not 
relevant and “relevant”) with the following: 
1. Sport supplements improve my performance 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
2. Sports supplements are necessary for me to be competitive 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
3. Sports supplements improve my confidence 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
4. My chances of winning improve when I use sports supplements 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
5. Sport supplements help me realise my potential 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
6. Sports supplements allow me to improve the quality of my training 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
7. Athletes using sports supplements are usually the ones who medal at major 
championships 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
8. Sports supplements provide a greater improvement compared to a healthy diet 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
9. Sports supplements are the same as having the best equipment 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
10. Using supplements make me optimistic about my performance  
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
11. Training increases the need for sports supplements 
□ Strongly disagree   □ Disagree  □ Slightly agree  □Slightly agree  □ Agree   □Strongly agree 
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Thank you 
Thank you for completing the questionnaire. 
I am very grateful for your responses and taking the time to complete it.  
If you have any questions or queries about the research or questionnaire, please do not 
hesitate to contact me. 
Phil Hurst 
Canterbury Christ Church University 
philip.hurst@canterbury.ac.uk  
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Appendix 8 – Sports Supplements Beliefs Scale (SSBS) 
Sports Supplements Beliefs Scale 
 
 
  
Please read each statement carefully and specify your level of agreement (between 'strongly disagree' to 
'strongly agree') with the following: 
  Strongly 
Disagree Disagree  
Slightly 
Disagree 
Slightly 
Agree Agree 
Strongly 
Agree 
1 Supplements improve my performance 1 2 3 4 5 6 
2 Supplements are necessary for me to be competitive 1 2 3 4 5 6 
3 Supplements improve my confidence 1 2 3 4 5 6 
4 My chances of winning improve when I use supplements 1 2 3 4 5 6 
5 Supplements help me realise my potential 1 2 3 4 5 6 
6 Supplements improve the quality of my training 1 2 3 4 5 6 
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Appendix 9 – Information sheet and informed consent for Study 2 and 3 
 
 
 
 
Information sheet 
Attitudes and sport supplements 
 
Thank you for considering taking part in this research. Please read all the information 
carefully and decide whether you would like to take part in this study. 
 
What is the aim of the research? 
The main aim of this research is to determine the effectiveness of inorganic nitrate during 
repeat sprint performance. A secondary aim is to understand your attitudes towards sport 
supplements. This research is being undertaken as part of the requirements of a PhD in Sport 
and Exercise Science.  
What will happen during the research? 
You will then be asked to complete two questionnaires that aim to determine your beliefs and 
attitudes towards performance enhancing substances.  
After the presentation you will complete a standardised warm up and perform 5 x 20m repeat 
sprints. These sprints will be run at maximal intensity, with a 2 minute rest in between 
sprints. Following completion of the first set of sprints you will you receive the supplement, 
which has been shown to influence repeat sprint and endurance performance. Once you have 
received the supplement, a 20 minute ‘break’ will follow that will include light exercise 
before performing the final set of 5 x 20m sprints. 
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On completion of the second 20m sprints, you will be debriefed about the results of the study. 
To understand the variation of beliefs and attitudes about performance enhancing 
supplements, you will be asked to complete the same belief and attitude questionnaires that 
you completed earlier in the session. 
What are the benefits? 
For an athlete, this is a rare opportunity to benefit from involvement in a research project that 
is at the forefront of sports medicine. This is one of the first research studies investigating the 
effects this supplement has on repeat sprint performance. There is also the opportunity to 
determine your acceleration and speed over a 20m sprint and your endurance capabilities of 
repeating this over a short period of time. This could give you an understanding of the areas 
you may need to improve to allow you to perform to a higher standard. 
Are there any risks and discomforts? 
The supplement should pose no health risks or discomfort. It is important however that 
following ingestion, you continue to exercise to ensure that the supplement has been fully 
digested. Please do not take any other sport supplements (e.g. caffeine, sodium 
bicarbonate, and creatine) other than what is provided by the research team. If you have 
used any other sport supplements during the day of testing, please inform the lead researcher. 
As the protocol involves maximally sprinting, it is important that a full warm up is completed 
to limit any possibility of injury. You may have some discomfort within the next 48 hours 
caused through the sprinting protocol. Delayed onset of muscle soreness (DOMS) is 
commonly associated with this type of exercise. For this reason, please make sure that you 
have cooled down after the protocol and that you have adequate food and water to maximise 
your recovery following the session.  
You should experience no discomfort over and above the repeat sprint itself, however, your 
safety is a priority, so should you feel any pain or discomfort, please tell the researcher 
immediately.  
 
 
220 
 
What information is collected and how will it be used? 
Your beliefs and attitudes towards sport supplements will be measured using two validated 
questionnaires (Sports Supplements Beliefs Scale and the Performance Enhancement Attitude 
scale). You will be asked about your current use of sport supplements and how often you use 
these. Performance measures will include your 20m sprint times collected over 10 runs. The 
data collected will be used as part of a PhD thesis and may be published in an academic 
journal. Disclosure of your personal information (e.g. name, email address) will not be 
revealed to anyone outside of the research team, ensuring that the results cannot be traced 
back to you.  
Who will have access to my results? 
Your results will be kept in accordance with the Data Protection Act (1998) and Canterbury 
Christ Church University’s own data protection requirements (2008). All your data will be 
stored either on a password protected computer or locked filing cabinet. Information will only 
be accessed by the research team (Philip Hurst, Dr Abby Foad, Dr Damian Coleman and Dr 
Chris Beedie). All results will be kept secure from anyone outside of the research team.  
Can I withdraw? 
This research is completely voluntary and you have the right to withdraw at any time without 
reason. You will not be placed at any disadvantage whatsoever if you decide to withdraw. 
 
If you have any questions about the study or would like to know more about the research, 
please do not hesitate in contacting Phil Hurst in person, via email: 
philip.hurst@canterbury.ac.uk or phone: 01227 783130. 
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Informed Consent 
Attitudes and performance enhancing supplements 
Please read and sign the information below if you would like to participate in this study 
Statement by participant 
I understand that: 
• This research project is completely voluntary 
• I can withdraw at any time without reason 
• I am satisfied with the methods in which the data will be stored and distributed 
• I know that the results will not be able to be traced back to me 
• I am aware of the benefits of the research 
• I am aware of the possible risks and discomforts 
• I am aware the supplement may influence my repeat sprint performance 
 
I have read the information sheet and consent form and fully understand what is expected of 
me. I agree to take part in this research: 
 
Signed (Participant):      Date:  
 
Signed (Witness):       Date: 
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Appendix 10 – Example of questionnaire used in Study 2 and 3 
Demographic information 
1. What is your full name: ………………………………………… 
2. What is your email address: ………………………………………………………. 
3. What is your gender:  Male         Female 
4. What is your age:  Under 18    18 to 24    25 to 34    35 to 44      
     45 to 54      55 to 64      65 or older 
5. What sport do you compete in: ………………………………………… 
6. What event or position: ………………………………………………….. 
7. Do you compete for individual or team purposes:  Individual    Team    Both    
8. What is your highest level of competition:  club  county   regional   international 
9. How many years have you been training: ………………… 
10. How many hours a week do you train: …………….. 
Sport Supplement Use 
Sport supplements are substances used by athletes with the belief that they will improve or 
facilitate athletic performance (e.g. Lucozade, multi-vitamins, caffeine, and creatine). 
1. Do you use sport supplements?  
□ Yes   □ No 
2. If yes, please select which sport supplements you use 
□ Β-Alanine 
□ Beetroot juice 
□ Caffeine  
□ Creatine 
□ Electrolytes 
□ Energy gels 
□ Protein shakes 
□ Vitamins and minerals 
 
Other (please specify): 
  
3. On average, how often do you use sport supplements? 
□ Never  □ Monthly  □ Weekly  □ Daily 
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Appendix 11 – Performance Enhancement Attitude Scale (PEAS) 
Please read each question carefully and specify your level of agreement (between 'strongly disagree' to 'strongly 
agree') with the following: 
  Strongly 
Disagree Disagree  
Slightly 
Disagree 
Slightly 
Agree Agree 
Strongly 
Agree 
1 Doping is necessary to be competitive. 1 2 3 4 5 6 
2 Doping is not cheating since everyone does it. 1 2 3 4 5 6 
3 Athletes often lose time due to injuries and 
drugs can be used to help to make up the lost 
time. 
1 2 3 4 5 6 
4 Only the quality of performance should 
matter, not the way athletes achieve it. 1 2 3 4 5 6 
5 Athletes in my sport are pressured to take 
performance enhancing drugs. 1 2 3 4 5 6 
6 Athletes who take recreational drugs use them 
because they help them in sport situations. 1 2 3 4 5 6 
7 Athletes should not feel guilty about breaking 
the rules and taking performance enhancing 
drugs. 
1 2 3 4 5 6 
8 
The risks related to doping are exaggerated. 1 2 3 4 5 6 
9 Athletes have no alternative career choices, 
but sport. 1 2 3 4 5 6 
10 Recreational drugs give the motivation to train 
and compete at the highest level. 1 2 3 4 5 6 
11 Doping is an unavoidable part of competitive 
sport. 1 2 3 4 5 6 
12 Recreational drugs help to overcome boredom 
outside of competition 1 2 3 4 5 6 
13 There is no difference between drugs and the 
technical equipment that can be used to 
enhance performance (e.g. hypoxic altitude 
simulating environments) 
1 2 3 4 5 6 
14 
The media should talk less about doping 1 2 3 4 5 6 
15 The media blows the doping issue out of 
proportion. 1 2 3 4 5 6 
16 Health problems related to rigorous training 
and injuries are just as bad doping side effects. 1 2 3 4 5 6 
17 Legalizing performance enhancements would 
be beneficial for sports 1 2 3 4 5 6 
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Appendix 12 – Post Questionnaire used in Study 3  
 
 
1. What is your name? ……………………………………………….. 
2. Do you think that athletes may benefit from learning about the placebo effect? 
Yes   No  
3. Do you believe if other athletes knew about the placebo effect they may be less likely 
to use sport supplements? 
Yes   No  
5. On a scale of 1 to 10 (1 no influence and 10 high influence), how much did you believe the supplement 
would influence your performance 
1  2  3  4  5  6  7  8  9  10 
 
6. How has knowledge of the placebo effect influenced your beliefs towards sport 
supplements? 
 
7. In your opinion, how do you think other sport supplements (e.g. caffeine, creatine, protein 
shakes) are influenced by the placebo effect? 
 
 
8. How may knowledge of the placebo effect influence your decision to using sport 
supplements? 
 
 
9. Do you have any other comments about the study 
4. Over the next 3 months I think I will use sport supplements: 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Slightly 
Disagree 
4 
Slightly Agree 
5 
Agree 
6 
Strongly Agree 
